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 ABSTRACT 
Sporadic cancers comprise the vast majority of diagnosed cancer cases, many 
with a largely environmental etiology. The mechanisms by which specific 
environmental factors influence cancer risk, however, remain widely 
uncharacterized. Because sporadic cancers are diagnosed later in life, many 
incident cancer studies poorly quantify previous exposures or utilize 
methodologies that may not be appropriate for the study of cancer initiation or 
prevention. Developing novel methods of studying the role of nutrition and the 
environment in carcinogenesis will provide essential insight towards the 
prevention, early identification, and treatment of cancer. Incorporating novel 
culture methods, including primary tissue culture, will allow for the study of 
specific and relevant normal cell populations, including stem cells, that may be 
particularly sensitive to environmental and nutritional factors. 
 
The overarching goal of this dissertation was to develop and apply novel 
statistical and experimental methods to characterize the roles of nutrition and the 
environment in carcinogenesis and cancer prevention, with a focus on epigenetic 
change. In Chapter 2, comprehensive epidemiological and clinical information 
were paired with DNA methylation profiling of head and neck tumors to identify 
significant differences in tumor DNA methylation in chemically induced or human 
papillomavirus induced tumors. In Chapter 3, data on average dietary intake was 
paired with tumor epigenetic measurements to identify that a head and neck 
cancer patient’s diet in the year before diagnosis can significantly affect tumor 
epigenetic profiles, providing a potential mechanism by which diet affects disease 
prognosis. In Chapter 4, normal human breast stem cells from reduction 
mammoplasty tissue were treated with the putatively cancer prevention 
xii 
 
compounds curcumin and piperine, and a genome-wide screen was conducted to 
identify the stem cell specific changes induced by these compounds. The results 
and conclusions presented here reflect the utility of the application of these 
methods, from cancer molecular epidemiology to normal human in vitro stem cell 
culture, to understand the role of the environment in cancer.      
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CHAPTER 1. INTRODUCTION  
1.1 Background and Motivation 
Sporadic cancers comprise the vast majority of diagnosed breast and 
head and neck cancer cases, many with a largely environmental etiology 
(Lichtenstein et al. 2000). Smoking, alcohol consumption, and poor diet are 
estimated to be the leading risk factors for cancer worldwide (Danaei et al. 2005). 
The shifting epidemiological profile of these diseases provides additional 
evidence that the environment plays a significant role in cancer development. In 
the United States, the epidemiology of head and neck cancer has undergone a 
radical shift in the past decade. The traditional risk factors for the development of 
head and neck cancer are tobacco smoking, alcohol consumption, and poor diet 
(Lewin et al. 1998). Since 1999, however, there has been a significant increase 
in the incidence of oropharangeal cancer in non-smoking males under the age of 
50 (Marur et al. 2010).  In developing countries, including those of southeast and 
central Asia, the probability of developing breast cancer more than doubled 
between 1980 and 2010 (Forouzanfar et al. 2011). Some of the increased 
incidence can undoubtedly be attributed to lengthening lifespan and 
improvements in detection over this time period. However, these dramatic shifts 
in cancer rates, paired with the stable nature of the human genome over this time 
period, suggest a strong role of the environment in cancer.  
Despite the changing epidemiology of cancer worldwide, the mechanisms 
by which specific environmental factors influence cancer risk remain widely 
uncharacterized. Since cancer is diagnosed later in life and it takes decades for 
most cancers to progress from initiation to neoplasia, many cancer studies poorly 
quantify previous exposures or utilize methodologies that may not be appropriate 
for the study of cancer initiation or prevention. For example, cancer epigenetic 
epidemiology studies often either poorly characterize environmental exposures or 
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focus on a limited number of epigenetic target sites. In vitro studies of cancer 
have traditionally relied on the use of immortalized cells or cells derived from 
tumor tissue. These studies often do not account for interindividual variability in 
response and may be limited in their ability to produce physiologically relevant 
data about effects of environmental exposures. Developing novel methods for 
studying the role of nutrition and the environment in carcinogenesis will provide 
essential insight towards the prevention, early identification, and treatment of 
cancer. Incorporating novel culture methods, including primary tissue culture, will 
allow for the study of environmental and nutritional factors in specific normal cell 
populations that may be at increased risk for cancer development, including stem 
cells. 
1.2 Genetic and Epigenetic Causes of Tumor Heterogeneity 
The tumor is a complex microenvironment that forms from the interaction 
of cancer cells, tumor associated stroma, blood vasculature, and immune cells 
(Hanahan and Weinberg 2000, 2011). Cellular heterogeneity within a tumor, 
reflected as phenotypically distinct cellular subpopulations, has long been 
described in a range of tumor types. In colorectal cancer, for example, tumor 
heterogeneity has been well-characterized as the gradual sequential 
accumulation of genetic and epigenetic alterations throughout tumorigenesis. As 
normal colonic epithelium progresses to a carcinoma, mutations in APC, KRAS, 
DCC, and TP53 are accumulated, leading to a dramatic phenotypic change in 
cells that accumulate the range of mutations (Fearon and Vogelstein 1990). This 
serial acquisition of genetic mutations that confers increasing fitness can lead to 
expansion of clonal populations with phenotypes increasingly divergent from 
normal cells. This hypothesis has been elegantly illustrated in recent experiments 
sequencing the genomes of tumors at ultrahigh depths to understand their clonal 
evolution. These studies have identified that even within a tumor, there can be 
substantial genetic variation. For example, sequencing analyses of 21 individual 
breast cancers identified that tumors are comprised of a diverse number of 
genetic subclones, with individual mutations only found in subsets of cells (Nik-
Zainal et al. 2012). Tumors evolve to thrive from the selective pressure from their 
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surroundings, and the genomic instability in a tumor allows for hyper-accelerated 
evolution. Thus, within a tumor, individual cells can be more or less likely to 
survive therapy based on both their mutational profile and their interactions with 
the microenvironment.  
While the genetic contribution to cancer is undoubtedly a necessary part 
of tumorigenesis, the contribution of epigenetic factors to cancer is also 
becoming clear (Feinberg and Tycko 2004). Epigenetic modifications cause 
heritable changes in gene expression without changing the underlying genetic 
code. Since the hundreds of different cell types in the human body, from a liver 
cell to a skin cell, all share the same basic genetic code, epigenetic modifications 
control the gene expression required to establish and maintain each of these cell 
types (Reik 2007). Thus, epigenetic modifications are essential for establishing 
cellular identity during and throughout development, as cells progress from 
pluripotent, to multipotent, to fully differentiated. Epigenetic modifications are 
environmentally labile, varying over the lifetime and by tissue. They are also 
potentially reversible, representing a distinct mechanism for organisms to adapt 
to their environment (Feinberg and Irizarry 2010). The effect of environmental 
exposures on epigenetic regulation in human populations, however, remains 
poorly understood. 
There are a number of epigenetic mechanisms of gene regulation that 
have been identified, and all of these are dysregulated in cancer (Virani et al. 
2012). DNA methylation is by far the best characterized, and involves the 
covalent addition of a methyl group to a cytosine in a cytosine-guanine pair 
(CpG). The methyl group of 5-methylcytosine lies in the major groove of DNA 
and can directly interfere with binding of transcription factors, or can attract a 
class of proteins known as “methyl binding proteins” which can also block 
transcription factors (Fuks et al. 2003). A well-characterized role of DNA 
methylation takes place in the context of “CpG Islands”, dense stretches of CpGs 
typically found in promoter regions of genes. Methylation of CpG islands in gene 
promoters is usually associated with transcriptional silencing (Merlo et al. 1995). 
Besides the promoter region of genes, CpGs are distributed unevenly throughout 
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the genome, where they are overrepresented in repetitive regions and distal 
gene regulatory regions (Ponger et al. 2001). Tumors have distinct patterns of 
DNA methylation, where CpGs in repetitive regions, which are normally 
methylated, become hypomethylated, paired with aberrant methylation of 
promoter regions of genes, some of which are likely important drivers of 
carcinogenesis (Esteller and Herman 2002). 
Experimental evidence accumulating over the past two decades has 
shown that within many tumors, the cellular hierarchy imitates that found during 
the development of normal tissue. Early observations by pathologists identified 
gross similarities between embryonic tissues and tumors, leading to the original 
hypothesis that cancers arise from embryo-like cells (Récamier 1829; Virchow 
1855). Further work, particularly the seminal research of Becker, McCulloch, and 
Till in the 1960s, provided the first evidence for tissue-specific stem cells and led 
to the hypothesis that tumors may arise from dysregulation of this cell population 
(Becker et al. 1963; Till and McCulloch 1961). Advances in fluorescence 
activated cell sorting (FACS) have confirmed pathological observations of tumor 
heterogeneity, identifying that cancers are comprised of distinct cellular 
compartments that can be differentiated based on cell surface markers. These 
same techniques have allowed for these different tumor cell populations to be 
purified, assayed, and characterized. Cancer stem cells at the apex of the tumor 
hierarchy can differentiate to provide the complex cellular hierarchy found in a 
tumor (Wicha et al. 2006). Cancer stem cells are also defined by their ability to 
initiate a new tumor, suggesting an essential role in metastasis. These cells have 
become an intense subject of research (Kreso and Dick 2014). They have natural 
defense mechanisms, including increased adaptation to oxidative stress and 
drug resistance, which makes them resistant to traditional chemotherapeutics 
(Dean et al. 2005; Conley et al. 2012). In solid tumors, cancer stem cells, similar 
to normal stem cells, are rare cells that are often quiescent. As 
chemotherapeutics often target rapidly cycling cell populations, the stem cell 
population of the tumor can survive, despite reductions in tumor bulk. The 
identification of these rare cells that potentially drive tumorigenesis highlights the 
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need to better understand the role of epigenetics in cancer and cellular 
differentiation.  
1.3 Epigenetics of HPV(+) vs HPV(-) Head and Neck Cancers 
Head and neck squamous cell carcinomas (HNSCCs), the eighth most 
commonly diagnosed cancer in the U.S. population, have a complex etiology that 
includes life style behaviors, classical chemical carcinogenesis, and infection with 
high risk types of human papillomavirus (HPV). Traditionally, head and neck 
cancer is associated with a profound history of tobacco and alcohol use, and 
those with HNSCC experience poor survival compared to other cancers (Marur 
and Forastiere 2008). Over the last decade, high-risk HPV has emerged as a risk 
factor for head and neck cancer, particularly of the oropharynx (D'Souza et al. 
2007; Gillison et al. 2000).  Patients with HPV(+) head and neck cancer have a 
distinct risk profile, associated with a less remarkable history of tobacco and 
alcohol use (Gillison et al. 2008), a more beneficial micronutrient profile (Arthur et 
al. 2011), and improved survival compared to those with HPV(-) tumors (Fakhry 
et al. 2008). 
Both tobacco- and alcohol-related, as well as HPV-associated, head and 
neck cancers have a well-described multistep model of carcinogenesis (Califano 
et al. 1996). Broadly, mutations or loss of heterozygosity of major cell cycle 
regulator genes, such as p53, are frequently detected in tobacco and alcohol-
related head and neck cancers (Lee et al. 2011; Somers et al. 1992), although 
mutation at these genes has not consistently been associated with patient 
survival. Likewise, HPV(+) head and neck cancers are associated with functional 
inactivation of p53 and Rb, which is mediated by E6 and E7 viral oncoproteins, 
resulting in overexpression of p16 (Boyer et al. 1996; Hafkamp et al. 2003; 
Werness et al. 1990). HPV(+) head and neck cancers have a distinct clinical 
profile when compared to alcohol and tobacco-related HPV(-) tumors, the former 
of which are typically more responsive to treatment (Kumar et al. 2008).  
Epigenetic modifications are an important mechanism in carcinogenic 
progression (Hansen et al. 2011), but the epigenetic profiles between HPV(+) 
and HPV(-) tumors remain poorly characterized, with most studies focusing on 
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specific loci or global levels of DNA methylation (Marsit et al. 2006; Richards et 
al. 2009). A handful of epigenome-wide studies of head and neck cancer have 
focused on differences between normal and tumor tissue, associations with 
alcohol and tobacco exposure, and associations with global marks of DNA 
methylation (Marsit et al. 2009; Poage et al. 2011). We reported an epigenome-
wide analysis of concurrently measured DNA methylation and gene expression in 
HPV(+) and HPV(-) squamous cell carcinoma cell lines, noting that HPV(+) cell 
lines have higher amounts of genic methylation as well as increased expression 
of DNMT3A (Sartor et al. 2011). Information about the specific epigenomic 
differences in DNA methylation based on clinical characteristics, including HPV 
infection, remain unknown, and require a well-characterized cohort of patient 
samples. Because of the particular morbidity associated with treatment for head 
and neck cancer, epigenetic biomarkers of survival may allow for de-escalation of 
treatment for those most likely to respond. 
1.4 Epigenetics and Nutrition in Cancer 
Epidemiologic evidence also supports the hypothesis that diet modulates 
the risk, progression and prognosis of head and neck cancer (Duffy et al. 2009; 
Lucenteforte et al. 2009; Sandoval et al. 2009). However, the molecular 
mechanisms by which dietary compounds exert their effects are not entirely 
understood. Dietary intake, particularly of micronutrients involved in the one-
carbon metabolism pathway, has been widely hypothesized to influence 
epigenomic states by modifying the availability of functional groups required for 
DNA and histone protein modifications (Oommen et al. 2005). Early evidence 
from a clinical trial of 8 postmenopausal women fed a low folate diet for three 
months showed lymphocyte DNA hypomethylation, as quantified by the [3H]-
methyl acceptance assay, which was found to be reversible following high level 
folate supplementation for three weeks (Jacob et al. 1998). A similar study in 
elderly women also reported overall genomic hypomethylation following seven 
weeks of folate depletion, without the same recovery following dietary folate 
supplementation (Rampersaud et al. 2000). Restriction of another key factor in 
the one-carbon metabolism pathway, vitamin B12, was also found to significantly 
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decrease the DNA methylation of colonic epithelium in rats (Choi et al. 2004). 
These findings provide evidence that variation of intake of nutrients relevant to 
one-carbon metabolism can influence DNA methylation and potentially 
carcinogenesis. 
Epidemiology studies of the effects of diet on epigenetics have typically 
focused on lifestage specific effects in populations exposed to food scarcity. 
Individuals exposed prenatally to famine in the Dutch Hunger Winter, during a 
German-imposed food embargo at the end of World War II, have been studied 
extensively for epigenetic dysregulation that could be linked to nutrient 
deprivation in utero. Individuals who were exposed to famine during early 
gestation had significantly lower methylation at the IGF2 differentially methylated 
region in whole blood, as measured by quantitative mass spectrometry, than their 
unexposed same-sex siblings (Heijmans et al. 2008). A follow up study in the 
same population extended these findings to an additional 15 loci associated with 
cardiovascular and metabolic disease (Tobi et al. 2009). The proximal promoter 
region of INSIGF was found to be hypomethylated in famine exposed individuals 
compared to their unexposed sex-matched siblings, while IL10, LEP, ABCA1, 
MEG3, and GNASAS were all found to be hypermethylated in famine exposed 
individuals. These findings suggest that nutrient deprivation can lead to global 
DNA hypomethylation, but either loci-specific hyper- or hypomethylation based 
on both exposure timing and sex (Tobi et al. 2009). Interestingly, while nutrient 
deprivation in utero has been associated with an increased risk of developing 
chronic diseases ranging from Type 2 diabetes (Hales and Barker 1992) to renal 
disease (Hoy et al. 1999), individuals exposed to famine early in utero were 
found to be less likely to develop a CpG Island Methylator Phenotype (CIMP) 
colorectal tumor (Hughes et al. 2009). These examples suggest that once 
methylation and disease associations are established, the use of dietary 
interventions to modify the epigenome could have a large impact on how we 
influence human health. 
1.5 Epigenetics and Cellular Hierarchies 
Breast Development 
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Cancer can be thought of as a “hijacking” of the normal developmental 
machinery in a cell. Thus, understanding the role that stem cells play in breast 
cancer is aided by an understanding of normal breast development and tissue 
homeostasis throughout the life course. However, knowledge of the molecular 
mechanisms that govern human breast development is limited due to the 
difficulty in obtaining non-pathologic samples. Many inferences about human 
breast development are derived from research in model organisms, most 
commonly mice, although there have been a small number of studies that 
examine human fetal and infant breast structure (Anbazhagan et al. 1991; 
Anbazhagan et al. 1998; Jolicoeur et al. 2003; Jolicoeur 2005). Human breast 
development begins in utero typically around the fifth week of gestation with a 
thickening within the ectoderm of a 2 to 4 cell layer, termed the mammary band. 
During the sixth to seventh weeks, the thoracic region thickens to form the 
mammary crest, followed by involution of the mammary band. Soon after, the 
mammary crest forms into a nodule that sinks into the surrounding developing 
mesoderm defining the region that will become the developing nipple. Between 
18-21 weeks, epithelial outgrowths form from the breast bud and invade the 
mesenchyme. These outgrowths quickly form a lumen, characterized by two 
layers of cubiodal epithelial cells, which over the course of the next few weeks 
form the early side branches, which define the tree-like structure of the mammary 
ductwork.  
Interestingly, at birth, there is considerable, and currently unexplained, 
variation noted in breast structure between individuals (Anbazhagan et al. 1991). 
Some individuals are born with a full mammary ductwork, complete with terminal 
ductal lobular units and lobules, while other individuals are born with a simple 
series of dead-end tubes. Whether these differences can be attributed to 
gestational age at birth, in utero nutrition, the maternal hormonal environment, or 
other exogenous factors is currently unknown. Regardless of the developmental 
status of the mammary gland at birth, during the first few months of infancy, the 
glands undergo an involution similar to that observed during menopause, leading 
to mammary glands that are similar between the sexes. Leading up to puberty, 
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the breast tissue grows in proportion relative to other tissues, with an elongation 
of the rudimentary ducts proportionate to the growth of other organs. 
The temporality of the gross anatomical and molecular changes that occur 
in the developing human mammary gland during puberty are currently poorly 
understood. Throughout puberty, the ducts that were established in utero 
undergo side branching, invading through the surrounding mammary stroma. 
This invasion is driven first by estrogen and epidermal growth factor (EGF), 
which control ductal elongation and branching. As puberty progresses and 
menarche begins, the cyclical fluctuations in the levels of estrogen and 
progesterone begin to drive the development of mammary lobules and alveoli. 
Throughout menstruation, monthly cycling of progesterone induces the 
proliferation of the breast epithelium, with the highest rates of proliferation 
observed in the luteal phase (Söderqvist et al. 1997). Additionally, throughout the 
menstrual cycle, morphological changes of the breast can be observed, with the 
formation of double layered acini during menstrual days 6 -15, followed by an 
increase in terminal ductal lobule units at days 16-24, and increased vacuolation 
and apoptosis within lobules in days 25-28 (Ramakrishnan et al. 2002). 
During pregnancy, the breast undergoes dramatic remodeling in 
preparation for lactation, and following a successful term pregnancy, undergoes 
what amounts to the terminal differentiation of the organ. Early in pregnancy, 
increased secretion of progesterone from the ovaries leads to dramatic increases 
in the generation of alveoli, the structures which will secrete milk following birth 
(Macias and Hinck 2012). Prolactin, produced mainly in the pituitary gland but 
also in the mammary epithelium itself, is required for mammary ductal 
sidebranching, alveolar budding, and lobuloalveolar growth (Ormandy et al. 
1997). After weaning, the mammary architecture undergoes involution that 
involves epithelial apoptosis, detachment of alveolar cells, and eventually, 
collapse of alveolar structure over the course of approximately a week. The 
involution that occurs during menopause involves the replacement of the 
mammary glands with adipose, ultimately reducing the epithelial content of the 
breast substantially. 
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Stem cells are known to play key roles throughout mammary 
development. The massive structural changes that occur in the breast, 
particularly during puberty and pregnancy, require the existence of cells with 
great proliferative potential that can also differentiate into multiple cell types, 
including the myoepithelial, luminal, and alveolar lineages of the breast. Serial 
transplantation assays, where a small tissue fragment is serially transplanted into 
cleared murine mammary fat pads and allowed to form a full mammary tree, 
originally identified that there is likely a mammary stem cell population that can 
regenerate the mammary structure (Daniel et al. 1968). Early studies of 
mammary development in mice identified that the tip of the mammary terminal 
end bud contained cap cells that can produce new myoepithelial cells required 
for ductal branching and morphogenesis, suggesting that the tip of the terminal 
end buds may be a site of mammary stem cells (Williams and Daniel 1983). A 
major advance in mammary stem cell biology came in 2006, when a bipotent 
murine mammary stem cell was characterized by isolating discrete populations of 
mammary cells utilizing cell surface markers and reimplanting single cells into 
cleared mammary fat pads to reconstitute a mammary gland (Shackleton et al. 
2006). More recently, lineage tracing studies have identified that both the luminal 
and myoepithelial lineages have distinct populations of stem cells that 
demonstrate significant self-renewal capacity (Van Keymeulen et al. 2011). 
Further, an in vivo labeling study in mice provided evidence for the existence of 
long-lived bipotent stem cells in the basal portion of the mammary gland that 
drive proliferation throughout puberty and play important roles in mammary tissue 
homeostasis (Rios et al. 2014). These combined results provide strong evidence 
for the existence of a bipotent mammary stem cell that is essential for mammary 
development. The identification and isolation of these cells in the normal human 
breast is an area of great interest, and factors that influence their potential for 
self-renewal may identify not yet appreciated avenues for cancer prevention.     
Identification of Normal and Cancer Stem Cells 
A key feature of normal stem cells that has proven essential to isolate and 
characterize these cells in the breast is the expression of specific surface and 
10 
 
enzymatic markers of stemness. Early studies of the cellular hierarchy of the 
breast identified that the expression of the cell surface markers MUC-1- to ±/CD-
10 ± to +/ESA+ isolated cells with the ability to develop colonies with both luminal 
and myoepithelial features (Stingl et al. 1998). A follow-up study identified that 
normal bipotent mammary progenitors are enriched in a cellular subfraction 
expressing both CD49f (α6 integrin) and EpCAM (Stingl et al. 2001). Recent work 
has identified that normal bipotent mammary stem cells are further enriched in 
the CD44+/CD24- fraction of CD49f+/EpCAM+ cells (Ghebeh et al. 2013). In 
addition to stem cell enriching cell surface protein markers, enzymatic markers of 
breast stemness have also been identified. Normal breast stem and progenitor 
cells were found to express high levels of aldehyde dehydrogenase 1 (ALDH1) 
(Ginestier et al. 2007). ALDH1 expressing cells can be identified using the non-
immunological Aldefluor assay, where the substrate, Bodipy-aminoacetaldehyde, 
is converted intercellularly to fluorescent Bodipy-aminoacetate. Stem cells can 
also be isolated by exploiting their increased expression of ATP-binding cassette 
drug transporters (Bunting 2002). By staining cells with Hoechst, a DNA-binding 
dye that is effluxed by ATP-binding cassette transporters, one can discriminate 
populations of cells that are high and low Hoechst staining, with the low-Hoechst 
stained, stem cell enriched, fraction termed the “side population”.  
A number of functional assays for the identification and classification of 
both normal and cancer stem cells have been established. The first series of 
experiments to identify the presence of tumor initiating cells utilized a 
transplantation assay of human acute myeloid leukemia cells into severe 
combined immunodeficient (SCID) mice (Lapidot et al. 1994). The SCID mice 
were examined for the presence of human leukemia cells, with limiting dilution 
experiments identifying that approximately 1 in 250,000 cells have the ability to 
engraft, with the cells most likely to engraft possessing the CD34+CD38- 
hematopoetic progenitor signature. In the human breast, cancer stem cells were 
first identified by injecting single cell suspensions of dissociated human breast 
tumor tissue into non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice (Al-Hajj et al. 2003). Tumor cells were sorted based on cell 
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surface markers (CD44, CD24, EpCAM) and injected into the mammary fat pads 
of mice at limiting dilutions, revealing that as few as 200 ESA+/CD44+/CD24- 
cells were consistently able to form tumors, while injection with 20,000 
CD44+/CD24+ cells failed to grow tumors (Al-Hajj et al. 2003). Furthermore, the 
ESA+CD44+CD24- cell fractions were able to recapitulate the original tumor 
phenotype after serial transplantations, showing that these cells possess the 
ability to both proliferate and differentiate into the different cell types that 
comprised the original tumor.  
In addition to the transplantation assays described above, a number of 
other assays have been utilized to enrich and characterize normal and cancer 
stem cells. Neural stem cells were first discovered to grow in anchorage 
independent, serum free culture conditions forming free floating spheroids of 
neural cells termed neurospheres (Reynolds and Weiss 1996). These culture 
conditions were later adapted for mammary tissue, where both tumor and normal 
breast stem/progenitor cells were found to propagate under these conditions, 
termed mammosphere formation conditions (Dontu et al. 2003). The 
mammosphere formation assay is useful for characterizing three key aspects of 
stem cell biology: (1) Proliferation potential; (2) The ability to self-renew; and (3) 
the ability to differentiate into downstream progeny. Since each mammosphere is 
initiated by a single cell, proliferation capacity can be assessed by 
mammosphere size. Mammospheres can then be serially passaged to assess 
stem cell self-renewal capacity over time. Finally, mammospheres can be stained 
for known markers of luminal vs. myoepithelial differentiation, or plated into 
differentiating culture conditions to assay the bipotency of the stem cell 
population. 
Identifying the Source of Cancer Stem Cells 
While the evidence for a subpopulation of cancer cells with stem cell like 
properties is growing, the cell of origin for breast cancer stem cells has not been 
characterized. There are three competing theories for the origin of breast cancer 
stem cells. First, normal breast stem cells could acquire genetic and epigenetic 
changes that confer the ability to inappropriately undergo symmetric self-renewal 
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and initiate tumorigenesis. A second possibility is that cancer stem cells derive 
from lineage committed rapidly cycling progenitor cells that undergo mutations 
that reconfer stem-like properties. A final possibility is that a series of mutations 
in fully differentiated cells can lead to dedifferentiation to a tumorigenic stem 
state. As the body of research surrounding both normal and cancer stem cells 
grows, evidence for each of these potential pathways is accumulating.  
In vivo labeling of mammary stem cells revealed that bipotent stem cells 
are detectable in adult animals, and are essential for both tissue remodeling and 
homeostasis (Rios et al. 2014). These cells are activated during puberty and 
pregnancy, and a subpopulation of long lived luminal progenitor cells was found 
to contribute extensively to ductal remodeling. Importantly, these long lived stem 
cells have the potential to accumulate the genetic and epigenetic effects over a 
lifetime’s worth of environmental exposures, passing these mutations to their 
progeny. Additionally, recent evidence suggests that normal breast, as well as 
breast cancer, stem cells exist in two different states, luminal-like (ALDH+) and 
basal-like (CD44+/CD24-) (Liu et al. 2013; Van Keymeulen et al. 2011). Luminal 
stem cells have an epithelial phenotype and are proliferative, while basal stem 
cells have a mesenchymal phenotype and are invasive. As luminal stem cells 
have a greater proliferative capacity, their phenotype could therefore be more 
susceptible to the effects of environmental insult. Thus, the increased risk of 
breast cancer associated with exposures during windows of susceptibility, such 
as puberty or pregnancy, could reflect an increased vulnerability of cycling 
luminal stem cells to oxidative stress and DNA damage resulting from 
environmental stressors. Support for this hypothesis comes from recent studies 
of the role of breast stem cells in carcinogenesis. Despite a distinct basal-like 
tumor phenotype, BRCA1 mutant tumors were experimentally found to arise from 
a luminal progenitor compartment (Molyneux et al. 2010). Transformation of 
EpCAM+ luminal breast cells was able to give rise to a range of breast tumors 
that recapitulate many subtypes observed in humans, while transformation of 
basal CD10+ cells solely gave rise to rare subset of tumors that resemble the 
claudin-low subtype (Keller et al. 2012). Luminal breast progenitors are also 
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more prone to have shortened telomeres, and can induce a telomere specific 
DNA damage response (Kannan et al. 2013). These data point to the luminal 
stem/progenitor compartment as a major source of tumor initiating cells, 
however, there is also evidence to suggest that dedifferentiation of lineage-
committed may also play a role in the formation of cancer stem cells. In a 
landmark 2011 paper, Robert Weinberg’s laboratory reported that both normal 
and cancer nonstem cells can spontaneously dedifferentiate into stem-like cells 
(Chaffer et al. 2011). A floating population of hTERT-immortalized human 
mammary epithelial cells was isolated and found to be enriched in CD44+/CD24-
/EpCAM- and CD44-/CD24+/EpCAM- cells. When the CD44- fraction of these 
cells was isolated and plated into 2D culture, the cells were found to increasingly 
form CD44+ cells. Similar experiments conducted with primary cells found that 
after 12 days in culture, 6% of the CD44- cells had been stochastically converted 
to CD44+ cells (Chaffer et al. 2011). These striking results suggest that cell type, 
at least in culture, is very plastic, and that differentiated cells can convert to stem-
like cells with relative ease. These results, however, stand in contrast to the low 
conversion efficiency of induced pluripotent stem cells (iPSCs). Normal human 
fibroblasts exposed to the required transcription factors to induce pluripotency 
(Oct3/4, Sox2, Klf4, c-Myc) have very low dedifferentiation efficiency, less than 1 
in 1000 (Takahashi et al. 2007). The difference could potentially lie in the ease of 
transition from a differentiated breast cell to a breast stem cell, instead of a 
differentiated skin cell to a pluripotent stem cell. Additionally, there is the 
possibility that the different stem cell types in the breast (luminal-like vs. basal-
like) interconvert, and that the “dedifferentiation” observed is actually due to a 
state transition between two types of stem cell. Recently, computational modeling 
of the effect of dedifferentiation on cancer stem cell populations found that 
estimated rate of dedifferentiation was heavily dependent on stem cell 
homeostasis (Jilkine and Gutenkunst 2014). In a model where stem cell 
regulation is tightly conserved, with each stem cell undergoing asymmetric self-
renewal, dedifferentiation plays a minor role in the generation of cancer stem 
cells. If stem cell homeostasis is not tightly conserved, and stem cells are 
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allowed to symmetrically self-renew, dedifferentiation can lead to dramatic 
expansion of the stem cell population. These results point to key gaps in our 
understanding of normal stem cell homeostasis that are reflected in the currently 
unknown origin of cancer stem cells. 
1.6 Targeting Stem Cells with Curcumin for Cancer Prevention 
Curcumin is a dietary polyphenol derived from the rhizomes of turmeric 
(curcuma longa) which has been widely used in traditional Indian and Chinese 
medicine for treatment of  a range of diseases, including inflammatory conditions, 
diabetes, and rheumatoid arthritis (Noorafshan and Ashkani-Esfahani 2013). 
Preclinical models have implicated curcumin as a potential agent for both the 
prevention and treatment of cancers. The promise of curcumin as a preventive 
agent and as a potential adjuvant to traditional cancer chemotherapy has led to 
considerable interest in translating these preclinical findings to the clinic (Gupta 
et al. 2013). To this regard, there are a number of completed and ongoing clinical 
trials examining the safety and efficacy of curcumin for treatment of a number of 
cancer types, including breast. A dose-escalation study identified that 
glucoronidated and sulfated metabolites of curcumin were detectable in the 
plasma of advanced colorectal cancer patients receiving 3.6g curcumin/day, 
while the parent compound was rarely detected (Sharma et al. 2004). 
Additionally, 3.6g/day curcumin treatment was found to significantly reduce the 
concentrations of the inflammatory mediator PGE2 in isolated blood leukocytes 
treated with liposaccharide (LPS), although basal circulating PGE2 levels were 
unchanged. These findings suggest that curcumin treatment inhibits PGE2 
induction, which may represent a mechanism by which curcumin acts as an anti-
inflammatory compound. A trial examining the effects of treatment with a 
combination of curcumin (480 mg) and the dietary flavonol quercitin (20mg) 
orally, three times per day, in 5 patients with familial adenomatous polyposis 
(FAP) found a significant reduction in both the number and size of the polyps 
(Cruz–Correa et al. 2006). Oral curcumin (4g/day for 30 days) also significantly 
reduced the number of aberrant crypt foci in 41 smokers who had 8 or more 
aberrant crypt foci, as diagnosed by colonoscopy, at baseline (Carroll et al. 
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2011). These results suggest that curcumin is effective at inhibiting the growth of 
early cancer-related lesions in the colon. Whether these results can be extended 
to other organs, such as the breast, where orally ingested curcumin may not be 
as bioavailable is unknown. 
The wide range of diseases that can be treated with curcumin (Gupta et 
al. 2013) reflect the pleiotropic action of the compound. Relevant to 
tumorigenesis, curcumin has been shown to act as a potent anti-inflammatory 
and antioxidant compound. Curcumin downregulates the production of the pro-
inflammatory cytokines TNF-α and IL-1β at a range of doses (5 – 20 µM) (Chan 
1995; Cho et al. 2007), potentially through the inhibition of the binding of the AP-
1 and NF-κB transcription factors (Bierhaus et al. 1997; Xu et al. 1996). 
Curcumin treatment also induces expression of the antioxidant enzyme Heme 
Oxygenase 1 (HO-1), through the dissociation of NRF2 from the NRF2-KEAP1 
complex (Balogun et al. 2003). Curcumin is also a direct antioxidant, with the 
ability to scavenge hydroxyl radicals (Reddy and Lokesh 1994), nitrogen dioxide 
radicals (Rao 1994), and ferrous iron chelation (Ak and Gülçin 2008).  
Curcumin has also been previously shown to inhibit stem cell self-renewal, 
a potential mechanism by which curcumin may exert its cancer preventive 
effects. Curcumin was found to inhibit primary and secondary mammosphere 
formation of cells isolated from normal human mammoplasty reduction tissue in a 
dose dependent manner (Kakarala et al. 2010).  Increasing concentrations of 
curcumin were also shown to reduce the expression of the breast stem cell 
marker ALDH1A1, representing a functional readout of inhibition of stem cell self-
renewal (Kakarala et al. 2010). Kakarala et al. also found that curcumin 
decreased the number of cells with nuclear beta-catenein, suggesting that 
curcumin also inhibits the activation of the Wnt signaling pathway (Kakarala et al. 
2010). A number of studies in other cell types besides breast have also reported 
inhibition of Wnt signaling by curcumin, suggesting that this mechanism is 
conserved across tissues (Li and Zhang 2014). Curcumin was also found to 
reduce the size of the side population (Hoescht dye positive) in rat glioma cells in 
a dose dependent manner, with significant effects observed at 5uM treatment 
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(Fong et al. 2010). A study of the effects of curcumin on six esophageal 
squamous cell carcinoma cell lines found that cells which survived a 60uM 
curcumin treatment had significantly fewer ALDH1A1 cells, as quantified by 
immunocytochemistry (Almanaa et al. 2012). Additionally, curcumin treatment 
surviving cells were able to form tumorspheres at a much lower rate than the 
parental cell line, suggesting that curcumin treatment induced a change, 
potentially epigenetic, that limited the number of cancer stem cells in this 
population. Together, these results point to the efficacy in curcumin to limit stem 
cell self-renewal in both normal and cancer cells. The mechanism by which 
curcumin targets normal breast stem cells remains to be fully characterized, but 
likely involves modulation of Wnt signaling. 
A major hurdle in the use of curcumin as a chemopreventive agent in a 
breast cancer susceptible patient population is the limited bioavailability of orally 
ingested curcumin. Curcumin is rapidly metabolized and eliminated, leading to 
low serum levels and poor tissue distribution, which limits its use as a therapeutic 
agent (reviewed in (Anand et al. 2007)). A number of different strategies to 
enhance the bioavailability of curcumin have been studied, with one of the most 
promising approaches being the use of adjuvants in concurrent dosing with 
curcumin. Piperine, an alkaloid compound derived from black pepper, has been 
shown to increase the bioavailability of curcumin up to 2000% in a study of 
human volunteers (Shoba et al. 1998). The mode of action of piperine’s influence 
on the metabolism of curcumin likely involves inhibition of drug and nutrient 
metabolizing enzymes, including CYP3A4 and P-glycoprotein (Bhardwaj et al. 
2002).  Besides influencing the bioavailability of nutritive compounds such as 
curcumin, piperine also has anticarcinogenic activities, reducing cancer incidence 
in rodent models of lung carcinogenesis (Pradeep and Kuttan 2002; Selvendiran 
et al. 2004). Kakarala et al previously showed in a preclinical in vitro model that 
both curcumin and piperine, when given individually or in combination, can limit 
breast stem cell self renewal while remaining non-toxic to normal differentiated 
cells (Kakarala et al. 2010). The mechanisms by which both piperine and 
curcumin combine to affect influence breast self-renewal capacity are not known. 
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1.7 Research Objectives 
The overall goal of this dissertation is to apply novel genomic and 
epigenomic methods in the context of epidemiological and in vitro stem cell 
studies to understand epigenetic mechanisms of carcinogenesis and cancer 
prevention in two cancer types with strong environmental influences, breast and 
head and neck. The specific aim of the work presented in Chapter 2 was to 
quantify the epigenetic differences between HPV(+) and HPV(-) head and neck 
tumors. The working hypothesis for this aim was that HPV-induced head and 
neck tumors have a distinct epigenetic profile, which reflects the viral etiology of 
the disease. This work was published in PLOS ONE in 2013 (Colacino et al. 
2013). The specific aim of the work presented in Chapter 3 was to identify dietary 
factors associated with head and neck tumor DNA methylation, with the 
hypothesis for the aim being that increased intake of dietary nutrients involved in 
the one carbon metabolism pathway would influence the methylation profile of 
the tumor. The work in Chapter 3 was published in Epigenetics in 2012 (Colacino 
et al. 2012). Finally, the specific aim of the research summarized in Chapter 4 
was to comprehensively characterize the effects of the cancer preventive 
compounds curcumin and piperine on normal human breast stem cells. The 
hypothesis for this aim was that curcumin and piperine treatment of normal 
breast cells will induce molecular changes that are involved in regulating breast 
stem cell self-renewal. These studies provide insight into the etiology of head and 
neck and breast cancers and provide novel routes of prevention and treatment of 
these deadly diseases. 
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 CHAPTER 2. COMPREHENSIVE ANALYSIS OF DNA METHYLATION IN 
HEAD AND NECK SQUAMOUS CELL CARCINOMA INDICATES 
DIFFERENCES BY SURVIVAL AND CLINICOPATHOLOGIC 
CHARACTERISTICS 
2.1 Abstract 
Head and neck squamous cell carcinoma (HNSCC) is the eighth most 
commonly diagnosed cancer in the United States. The risk of developing HNSCC 
increases with exposure to tobacco, alcohol and infection with human papilloma 
virus (HPV). HPV-associated HNSCCs have a distinct risk profile and improved 
prognosis compared to cancers associated with tobacco and alcohol exposure. 
Epigenetic changes are an important mechanism in carcinogenic progression, 
but how these changes differ between viral- and chemical-induced cancers 
remains unknown. CpG methylation at 1505 CpG sites across 807 genes in 68 
well-annotated HNSCC tumor samples from the University of Michigan Head and 
Neck SPORE patient population were quantified using the Illumina Goldengate 
Methylation Cancer Panel. Unsupervised hierarchical clustering based on 
methylation identified 6 distinct tumor clusters, which significantly differed by age, 
HPV status, and three year survival. Weighted linear modeling was used to 
identify differentially methylated genes based on epidemiological characteristics. 
Consistent with previous in vitro findings by our group, methylation of sites in the 
CCNA1 promoter was found to be higher in HPV(+) tumors, which was validated 
in an additional sample set of 128 tumors. After adjusting for cancer site, stage, 
age, gender, alcohol consumption, and smoking status, HPV status was found to 
be a significant predictor for DNA methylation at an additional 11 genes, 
including CASP8 and SYBL1. These findings provide insight into the epigenetic 
regulation of viral vs. chemical carcinogenesis and could provide novel targets for 
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development of individualized therapeutic and prevention regimens based on 
environmental exposures.    
2.2 Introduction 
Head and neck squamous cell carcinomas (HNSCCs), the eighth most 
commonly diagnosed cancer in the U.S. population, have a complex etiology that 
includes life style behaviors, classical chemical carcinogenesis, and infection with 
high risk types of human papillomavirus (HPV). Traditionally, head and neck 
cancer is associated with a profound history of tobacco and alcohol use, and 
poor survival compared to other cancers (Marur and Forastiere 2008). Over the 
last decade, high-risk HPV has emerged as a risk factor for head and neck 
cancer, particularly of the oropharynx (D'Souza et al. 2007; Gillison et al. 2000).  
Patients with HPV(+) head and neck cancer have a distinct risk profile, 
associated with a less remarkable history of tobacco and alcohol use (Gillison et 
al. 2008), a more beneficial micronutrient profile (Arthur et al. 2011), and 
improved survival compared to those with HPV(-) tumors (Fakhry et al. 2008). 
Both tobacco- and alcohol-related, as well as HPV-associated, head and 
neck cancers have a well-described multistep model of carcinogenesis (Califano 
et al. 1996). Broadly, mutations or loss of heterozygosity of major cell cycle 
regulator genes, such as p53, are frequently detected in tobacco and alcohol-
related head and neck cancers (Lee et al. 2011; Somers et al. 1992), although 
mutation at these genes has not consistently been associated with patient 
survival. Likewise, HPV(+) head and neck cancers are associated with functional 
inactivation of p53 and Rb, which is mediated by E6 and E7 viral oncoproteins, 
resulting in overexpression of p16 (Boyer et al. 1996; Hafkamp et al. 2003; 
Werness et al. 1990). Conversely, HPV(+) head and neck cancers have a distinct 
clinical profile when compared to alcohol and tobacco-related HPV(-) tumors, the 
former of which are typically more responsive to treatment (Kumar et al. 2008b).  
Epigenetic modifications are an important mechanism in carcinogenic 
progression (Hansen et al. 2011), but the epigenetic profiles between HPV(+) 
and HPV(-) tumors remain poorly characterized, with most studies focusing on 
specific loci or global markers of DNA methylation (Marsit et al. 2006; Richards et 
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al. 2009). A handful of epigenome-wide studies of head and neck cancer have 
focused on differences between normal and tumor tissue, associations with 
alcohol and tobacco exposure, and associations with global marks of DNA 
methylation (Marsit et al. 2009; Poage et al. 2011). 
Recently, we reported an epigenome-wide analysis of concurrently 
measured DNA methylation and gene expression in HPV(+) and HPV(-) 
squamous cell carcinoma cell lines, noting that HPV(+) cell lines have higher 
amounts of genic methylation as well as increased expression of DNMT3A 
(Sartor et al. 2011). Information about the specific epigenome-wide differences in 
DNA methylation based on clinical characteristics, including HPV infection, 
remain unknown, and require a well-characterized cohort of patient samples. In 
this study, a comprehensive methylation bead array was used to measure DNA 
methylation at 1505 CpG sites across 807 genes in both HPV(-) and HPV(+) 
head and neck cancer in tumor samples collected from the ongoing patient 
cohort in the University of Michigan Head and Neck Specialized Program of 
Research Excellence (SPORE). In addition, important survival differences by 
epigenetic profiles are identified as described. Findings from this study provide 
insight into the epigenetic regulation of viral vs. chemical carcinogenesis and 
provide novel targets for development of individualized therapeutic regimens 
based on environmental exposures.    
2.3 Methods 
Design 
Subjects for this study were obtained from a prospective, cohort study of 
patients enrolled in the University of Michigan Head and Neck Cancer SPORE. 
Newly diagnosed patients were recruited, provided informed consent, and 
followed quarterly for 2 years and then yearly thereafter. In addition tumor 
samples were collected. Institutional Review Board approval was approved from 
all participating sites including the Institutional Review Boards of the University of 
Michigan Medical School and the Institutional Review Board for Human Subject 
Research at the Veterans Affairs Ann Arbor Healthcare System. 
Study Population  
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Individuals eligible for participation included patients diagnosed with first 
primary head and neck cancer between January 1, 2003 and December 31, 2005 
completed an epidemiologic questionnaire, and had paraffin-embedded tumors 
available for analysis with adequate residual tissue for microdissection (N=82). 
The epidemiologic questionnaire included questions about lifestyle behaviors, 
including smoking and drinking. Clinical characteristics included tumor site and 
stage, comorbidities, depression, quality of life, and recurrence status, as well as 
treatment modalities. Tumor blocks were re-cut for uniform histopathologic 
review and microdissection, with the first and last slides in a series of 12 
reviewed by a qualified pathologist (JM) to confirm the original diagnosis and to 
circle areas for DNA extraction. Percent cellularity was estimated for each tumor 
and areas with >70% cellularity of cancer were designated for use in the 
analyses.  
Laboratory Methods 
FFPE tissue, DNA isolation, bisulfite conversion 
Regions identified for DNA extraction were cored from the formalin fixed 
paraffin embedded (FFPE) tissue blocks using an 18 gauge needle. Isolation of 
DNA from cored tissue samples was performed using the QIAamp DNA FFPE 
Tissue Kit (Qiagen, Valencia, CA) modified to include overnight incubation at 
56oC in lysis buffer. DNA concentration and purity were confirmed via NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, MA). Sodium bisulfite 
modification was performed on 500ng to 1µg of extracted DNA using the EZ DNA 
Methylation kit (Zymo Research, Orange, CA) following the manufacturer’s 
recommended protocol. 
HPV testing  
HPV status was determined by an ultra-sensitive method using real-time 
competitive polymerase chain reaction and matrix-assisted laser 
desorption/ionization-time of flight mass spectroscopy with separation of products 
on a matrix-loaded silicon chip array, as described in Tang et al. (Tang et al. 
2012) . Multiplex PCR amplification of the E6 region of 15 discrete high-risk HPV 
types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 73), and 
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human GAPDH control was run to saturation followed by shrimp alkaline 
phosphatase quenching. Amplification reactions included a competitor oligo 
identical to each natural amplicon except for a single nucleotide difference. 
Probes that identify unique sequences in the oncogenic E6 region of each type 
were used in multiplex single base extension reactions extending at the single 
base difference between wild-type and competitor HPV so that each HPV type 
and its competitor were distinguished by mass when analyzed on the MALDI-
TOF mass spectrometer as described previously (Kumar et al. 2008a; Maxwell et 
al. 2010a; Maxwell et al. 2010b; Worden et al. 2008).  
Bead Array Methods 
The commercially available Illumina Goldengate® Methylation Cancer 
Panel was used to detect DNA methylation patterns in tumor samples. The 
Cancer Panel measure DNA methylation at 1505 CpG sites located in known 
CpG islands across 807 genes related to cancer, including oncogenes, tumor 
suppressor genes, imprinted genes, and genes involved in cell cycle regulation, 
DNA repair, apoptosis and metastasis. Bead arrays were processed at the 
University of Michigan DNA Sequencing Core Facility according to the 
manufacturer’s protocol. Briefly, bisulfite converted tumor DNA was hybridized to 
the bead array as described previously (Bibikova et al. 2006), and bead arrays 
were imaged using Illumina BeadArray Reader software. Raw bead array 
fluorescence data were initially analyzed using Illumina BeadStudio Methylation 
software, which converts fluorescence values of the methylated (Cy5) and 
unmethylated (Cy3) alleles into an average methylation value at a specific probe 
using the formula β = [Max(Cy5,0)]/[Max(Cy5,0) + Max(Cy3,0) + 100], ranging 
from completely unmethylated (β = 0) to completely methylated (β ≈ 1). For each 
probe, background fluorescence, as estimated from a set of negative controls, 
was subtracted. Fourteen of the 82 samples (17.1%) failed on the array were 
excluded from further analyses, resulting in a final sample size of 68 tumors. 
Methylation at specific CpG probes on the Goldengate BeadArray has been 
shown to be biased by probe thermodynamic properties (Kuan et al. 2010). 
Known biases include probe length and GC content, which can affect the melting 
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temperature of the probes as well as probe fluorescence intensities. Thus, we 
used the method proposed by Kuan et al. to normalize our average β values 
based on probe length and GC content (Kuan et al. 2010).  
Detection p-values on the Goldengate BeadArray are calculated based on 
fluorescence signal at a probe compared to background fluorescence and 
represent the (1-probability) that a signal is stronger than background 
fluorescence. The weighted methodology proposed by Kuan et al. was used to 
develop sample and site weights based on p-values of detection, with sites and 
samples with lower p-values of detection given higher weights. Both samples and 
sites with larger detection p-values are generally considered less reliable and 
were down-weighted in further gene specific analyses. 
Site Specific Validation 
DNA methylation of four CpG sites in the promoter region of CCNA1 was 
quantified in an additional sample of 128 pretreatment head and neck tumors 
using the Sequenom EpiTyper, a MALDI-TOF mass spectrometry based 
platform. DNA was extracted from FFPE tumors, HPV status was determined, 
and the DNA was bisulfite converted as described above. Bisulfite PCR 
amplification was performed using FastStart Taq Polymerase (Roche 
Diagnostics, Indiana, US) with a forward and reverse primer concentration of 0.2 
µM and an annealing temperature of 48C and 45 PCR cycles. The primer 
sequences, including the forward and T7 promoter tags required for Sequenom 
analysis were: 5’-AGGAAGAGAGATGTATTTTGGATTTTTTATTGGGG (forward 
primer) and 5’-
CAGTAATACGACTCACTATAGGGAGAAGGCTAAAAAAACATTCTAACAAACC
TCCA (reverse primer). Methylation analyses were performed at the University of 
Michigan Sequencing Core Facility following the manufacturer’s recommended 
protocol.    
Statistical Methods 
Unsupervised hierarchical clustering was performed using the Euclidean 
distance metric and the Ward clustering method in the hclust package in R 
version 2.10.1.(Wang and Zhu 2008). All 68 tumor samples were included in the 
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hierarchical clustering algorithm. To minimize sex-specific effects, we excluded 
CpG sites on the sex chromosomes. The cluster analysis was performed using 
three different cutoffs for inclusion of individual CpG sites; the 50%, 25%, and 
10% of CpG sites with the highest variance in methylation across samples.  
Clinical characteristics were evaluated across clusters based on cluster 
membership using non-parametric rank-based and exact statistics. For survival 
analyses, death was considered an “event”; survival time was censored at 3 
years (1095 days). The Kaplan-Meier method was used to estimate overall 
survival and the log-rank test was used to test differences in survival distributions 
amongst the subtypes using the R survival package. Differences in age were 
compared using analysis of variance (ANOVA). Fisher’s Exact test was 
performed to test differences in cancer site, stage, and HPV status. Cox 
proportional hazards models were constructed to test the association between 
methylation at each CpG site on the Goldengate BeadArray and survival, 
adjusting for HPV status, gender, age, disease stage, cancer site, smoking 
status, and problem drinking using the coxph function in the R survival package. 
Individuals with a tumor testing positive for any strain of HPV were considered 
HPV positive. Age was treated as a continuous variable, while disease stage and 
cancer site were treated as categorical variables. Smoking was categorized, as 
an ordinal variable, into never smoker, past former smoker (quit more than 12 
months ago), recent former smoker (quit in previous 12 months), and current 
smoker. Problem drinking was defined as a score of greater than 8 on the 
validated Alcohol Use Disorders Identification Test, as previously described 
(Duffy et al. 2009). Due to the simultaneous testing of multiple proportional 
hazard models, we controlled the false discovery rate by calculating the false 
discovery rate q-value (Storey and Tibshirani 2003). Q-values were calculated 
using the qvalue R package. 
Overall site specific methylation differences between HPV(+) and HPV(-) 
tumors were compared by calculating the difference in the mean methylation per 
CpG site in HPV(+) and HPV(-) tumors. The effects of clinical characteristics on 
DNA CpG methylation measured on the Goldengate array were examined using 
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Limma in R 2.10.1 (Smyth 2004). Sample weights generated with LumiWCluster 
based on detection p-values across samples were used in the lmFit function from 
the Limma package to downweight samples with higher detection p-values. CpG 
sites were identified as differentially methylated between HPV(+) and HPV(-
)tumors, adjusting for cancer site (oral cavity, nasopharynx, oropharynx, 
hypopharynx, larynx), cancer stage, sex and age. An empirical Bayes method 
(using the eBayes function in Limma) was used to rank CpG sites in order of 
significance of differential methylation. Additionally, Limma was used to examine 
methylation differences between the case cluster with significantly worse survival 
compared to the remaining cases by comparing methylation for individuals in the 
cluster with worst survival to all other individuals. For CCNA1 validation, mean 
methylation was calculated across the 4 sites measured by the EpiTyper and 
compared across HPV(+) and HPV(-) tumors using the Wilcoxon rank-sum test. 
Additionally, a multiple linear regression model was constructed with mean 
CCNA1 methylation as the independent variable and HPV status as the main 
predictor, adjusting for age, sex, tumor site, and tumor stage. Gene Set 
Enrichment Analysis (GSEA) was used to identify common pathways and 
chromosomal locations for genes identified as significant (p<0.05) in the Limma 
analysis (Subramanian et al. 2005). Statistically significant genes were ranked by 
t-value and input into GSEA as a ranked list. The full list of genes assayed on the 
Goldengate BeadArray were input into GSEA as a chip platform file, which 
provided the background for the enrichment analysis. Weighted enrichment 
statistics were calculated by the GSEA software, using a minimum analyzed 
gene set size of 5.  
2.4 Results 
Descriptive statistics: Study samples 
The mean age of the 68 subjects was 57 years (range: 28 - 82 years); 
75% of the subjects were male. The majority of the HNSCCs were from the 
oropharynx (47%), oral cavity (25%), and larynx (19%), with a large proportion of 
cancers diagnosed as late stage (22% stage III and 62% stage IV, Table 2.1). 
Approximately one-third of the tumors tested positive for HPV (20 HPV-16, 2 
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HPV-18, 1 HPV-35 and 1 HPV-59).  The majority of the patients were former 
(60%) or current (24%) cigarette smokers and 34% screen positive for problem 
drinking. All patients were treated in a standardized fashion with single modality 
treatment for patients with early stage tumors (Stage I/II) and combined 
chemotherapy and radiation and in some cases surgery for patients with 
advanced (Stage III/IV) cancers. Median follow up for the entire cohort was 60 
months (95% CI: 59.9, 60.0). 
General clustering: cluster characteristics 
Excluding CpG sites located on the sex chromosomes (n=84), and limiting 
the cluster analysis to the 50% of CpG sites with the most variance (n=711), six 
distinct clusters were identified (Figure 2.1). Clusters by epidemiological and 
clinical characteristics were assessed first. Individuals who grouped in Cluster 3 
tended to be older (mean age = 61.6 years, Table 2.2) and were significantly 
more likely to be HPV positive (62%, p = 0.02). There was no significant 
difference in the proportion of individuals who were problem drinkers in each of 
the clusters. Tumor samples from individuals grouped into Cluster 5 were more 
likely to have widespread DNA hypomethylation, while tumor tissue from 
individuals in Clusters 3 and 4 tended to have higher levels of methylation in the 
most differentially methylated genes. A similar distribution of epidemiological 
characteristics was observed across clusters when including only the 25% of 
CpG sites with the greatest variance, which revealed 3 distinct clusters, with HPV 
(p=0.004) and age (p=0.04) remaining statistically significantly different. These 
differences were not observed when restricting the analysis to only the top 10% 
most variable CpG sites, , where 4 distinct tumor clusters were observed, and 
neither age (p=0.41) nor HPV (p=0.07) were statistically significantly different 
across clusters. There was no clear clustering of the tumors from the HPV-18, 
HPV-35, or HPV-59 individuals. 
Next, cluster membership was characterized by survival. Three year 
survival was compared between the six clusters (Figure 2.2). Overall, individuals 
in Cluster 3 had the best three year survival (86%) while individuals in Cluster 5 
had the worst overall survival (25%). Cluster membership was found to be a 
36 
 
significant predictor of three year survival (p=0.02). HPV(+) cases were found to 
have statistically significant better three year survival than HPV(-) cases 
(p=0.03). Interestingly, Cluster 3 had the highest proportion of Stage IV disease, 
the highest proportion of HPV(+) tumors, and the best three-year survival, while 
Cluster 5 had the lowest proportion of Stage IV disease and the worst survival. 
This aligns with previous findings that HPV positive tumors have a better 
prognosis, leading to the increased survival rates observed for Cluster 3 (Kumar 
et al. 2008b). This also aligns with the observation that many HPV-positive 
patients present with advanced nodal disease. 
CpG Site-Specific Methylation Differences by HPV Status 
Plotting average differences in methylation at each site showed that 
HPV(+) tumors tended to be hypermethylated at more sites than HPV(-) tumors 
(Figure 2.3). In order to better understand how HPV infection affects the DNA 
methylation profile in head and neck cancer, associations between methylation at 
each of the 1505 CpG sites on the Goldengate array and HPV status were 
calculated. Thirteen individual CpG sites on the array were found to be 
significantly associated with the HPV status of the tumor with a q-value <0.05 
(Table 2.3). The top hit, a CpG site located slightly downstream of the 
transcription start site of CCNA1 in a CpG island, was found to be significantly 
more methylated in HPV(+) tumors (p = 1.8x10-6). This finding corroborates our 
recent analysis of epigenome-wide DNA methylation differences in HPV(+) and 
HPV(-) cell lines where CCNA1 was found to be a major interaction hub following 
bioinformatic analyses (Sartor et al. 2011). CpG sites in GRB7, CDH11, 
RUNX1T1, SYBL1, and TUSC3 were also found to be significantly more 
methylated in HPV(+) tumors. CpG sites in SPDEF, RASSF1, STAT5A, MGMT, 
ESR2, JAK3, and HSD17B12 were found to be significantly hypomethylated in 
HPV(+) tumors (Table 2.4).  
CCNA1 Site Specific Validation 
To validate our findings of increased CCNA1 methylation HPV(+) tumors, 
we quantified methylation at 4 CpG sites in the promoter region of CCNA1 in an 
additional 128 pretreatment head and neck tumors. Mean CCNA1 methylation 
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was significantly higher in HPV(+) tumors (p=0.0005). After adjusting for age, 
sex, tumor site, and tumor stage, HPV(+) tumors were found to be, on average, 
9.6% more methylated at the CCNA1 promoter compared to HPV(-) tumors 
(p=0.029). 
Gene Set Enrichment Analysis (GSEA) 
To analyze if specific gene sets or pathways display differential epigenetic 
regulation in HPV(+) versus HPV(-) tumors, a GSEA of the genes associated with 
HPV status was conducted. An analysis of Gene Ontology (GO) Biological 
Processes significantly enriched for differentially methylated genes implies that 
three gene sets associated with cell cycle regulation were hypomethylated in 
HPV(+) tumors (Table 2.5). Specific genes included in these gene sets that were 
significantly less methylated in HPV(+) (p < 0.05) include RASSF1, CDK10, 
CHFR, RUNX3, APC, and CDKN2A (p16). An analysis of enriched gene sets 
from the Kyoto Encyclopedia of Genes and Genomes (KEGG) found that genes 
associated with Neuroactive Ligand Receptor Interactions were hypermethylated 
in HPV(+) tumors (Table 2.5). The specific genes from this KEGG pathway 
include GRPR, MC2R, GABRA5, PRSS1, NTSR1, and F2R. Additionally, genes 
from the enriched KEGG set JAK-STAT Signaling Pathway were found to be 
hypomethylated in HPV(+) tumors, specifically STAT5A, JAK3, OSM, MPL, and 
EPO. None of these pathways were significantly enriched (q<0.05) after adjusting 
for multiple comparisons, however. 
CpG Sites Associated with Survival 
Cox Proportional Hazards Regression was used to determine whether 
methylation at individual CpG sites is associated with three year survival rates. 
Significantly associated genes (p-value<0.05) are listed in Table 2.6. While no 
individual CpG site was found to have a false discovery rate less than 0.15, 
methylation at a number of genes was found to be potentially associated with 
survival, including NOTCH1, UGT1A1, and IL-6.  
After comparing survival by cluster, where we noted that cases in Cluster 
5 had significantly worse survival as well as apparent widespread differences in 
methylation, we conducted a post hoc analysis to identify specific genes 
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differentially methylated in that cluster. After adjusting for other clinical 
covariates, including age, sex, cancer site, stage, smoking, problem drinking, and 
HPV status, a substantial number of genes were found to be differentially 
methylated in Cluster 5 compared to all other clusters (Table 2.7). Gene set 
enrichment analysis identified pathways, molecular functions, and a 
chromosomal region significantly differentially methylated in Cluster 5 cases 
(Table 2.8). Genes located in chromosome 7q21 were found to be significantly 
hypomethylated in Cluster 5 cases. Biological processes associated with 
negative regulation of cellular metabolism as well as homeostatic processes 
were found to be enriched with genes hypomethylated in this cluster. An analysis 
of molecular functions identified dysregulation of nucleotide binding, particularly 
purine and adenyl nucleotide binding as well as kinase and phosphorus 
transferase activity.  
2.5 Discussion 
Using an epidemiologically well characterized sample of head and neck 
cancer patients with a high proportion of HPV(+) cases, we confirmed a distinct 
epigenetic profile in HPV(+) head and neck cancers when compared to HPV(-) 
cancers. This has been previously noted by others for global methylation 
(Richards et al. 2009), candidate gene methylation (Weiss et al. 2011) and by 
Marsit et al. using the same platform as this study (Marsit et al. 2009). Other 
studies have described the association between methylation and traditional risk 
factors for HPV(-) head and neck cancer such as smoking and alcohol use 
(Smith et al. 2007).  
Our prior work has shown how epigenetic profiles and expression patterns 
correspond to these divergent mechanisms of carcinogenesis in HPV(+) and 
HPV(-) cell lines (Sartor et al. 2011). The findings of this study expand upon our 
prior cell line work, identifying  numerous loci in tumor samples that are 
differentially methylated between HPV(+) and HPV(-) tumors, particularly those 
involved in cell cycle regulation and JAK-STAT signaling.  The top differentially 
methylated site on the array between HPV(+) and HPV(-) tumors was seven 
bases downstream from the transcription start site of CCNA1 with an average 
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percent methylation level of 10% in HPV(-) tumors and 31% in HPV(+) tumors. 
This was also one of our top ranked genes in HNSCC cell lines (Sartor et al. 
2011), and was noted by other groups as differentially methylated (Weiss et al. 
2011) and differentially expressed (Weiss et al. 2012) in HPV (+) HNSCC, 
indicating that methylation and expression of this gene could likely be important 
both mechanistically and as a biomarker for HPV-associated HNSCC. CCNA1 is 
an important regulator of the cell cycle and is required for S phase and passage 
through G2 (Girard et al. 1991). Other genes involved in cell cycle regulation 
tended to be hypomethylated in HPV(+) compared to HPV(-) HNSCC, indicating 
that regulation of these pathways may be important for HPV(+) head and neck 
carcinogenesis. This hypomethylated set of genes included many genes that 
have previously been shown to be methylated in head and neck cancer, including 
RASSF1 (Paluszczak et al. 2011), CHFR (Toyota et al. 2003), RUNX3 
(Tsunematsu et al. 2009), APC (Uesugi et al. 2005), and CDKN2A (p16) (El-
Naggar et al. 1997).  These results are of particular importance to studies of 
biomarkers for head and neck cancer, which frequently do not take HPV status 
into account (Demokan et al. 2010; Guerrero-Preston et al. 2011; Viet and 
Schmidt 2008).  
These analyses represent essentially a sizeable candidate-gene study, 
and the large number of loci allowed for initial pathway and positional analyses of 
the methylated CpGs. This was particularly useful when evaluating the 
contribution of epigenetic modifications to the prediction of survival, where 
methylation at single genes or sites did not predict survival time in this cohort. 
Hierarchical cluster analysis identified one set of patients with particularly worse 
survival solely based on methylation. Notably, this cluster did not include any 
HPV(+) cases, and contained the lowest proportion of males of all clusters (63%). 
This cluster had significant hypomethylation of 7q21, a region amplified in 
multiple cancers (Holzmann et al. 2004; Takada et al. 2005). This region has 
been identified as containing a placental-specific imprinted gene region (Monk et 
al. 2008), which is epigenetically inactivated in prostate carcinoma (Ribarska et 
40 
 
al. 2010). Thus, epigenetic regulation of this region may also play a role in a 
subset of head and neck cancers.  
 These and other epigenetic studies have strong implications for head and 
neck cancer research, particularly in light of recent reports on the complex 
landscape of head and neck cancer research (Agrawal et al. 2011; Stransky et 
al. 2011). For example, the mutation rate of HPV-associated tumors was 
reported to be much lower than HPV(-) tumors by exome sequencing (from 2 to 5 
times less likely to harbor mutations). The results of this study indicate that HPV-
associated tumors are likely driven to a larger extent by methylation changes 
than HPV(-) tumors. Additionally, it is intriguing to hypothesize that methylation 
could serve as a complementary mechanism of inactivation in many known 
candidate tumor suppressor genes. For example, methylation of NOTCH1 was 
the strongest predictor of survival in this study (p=0.0002), and was also 
identified as frequently mutated in head and neck tumors in Stransky et al. and 
Agrawal et al.  Interestingly, truncating mutations in NOTCH1 indicate a tumor 
suppressor function as opposed to activating mutations seen in other cancers, 
and methylation of this gene also indicates a tumor suppressor function. Loss of 
heterozygosity (LOH) at the NOTCH1 locus has also been reported for a small 
number of tumors (Agrawal et al. 2011). The significance of the mechanism of 
inactivation remains to be clarified, but given the stable, yet potential reversible 
nature and variable levels of epigenetic modifications, this may have direct 
implications for treatment and therapy. Longitudinal epigenetic phenotyping of 
tumor methylation profiles during treatment could provide insight to the degree to 
which DNA methylation marks are labile to chemotherapy, radiation, or dietary 
intervention. These results also emphasize the importance of simultaneous 
evaluation of molecular mechanisms in tumors in conjunction with epidemiologic 
characteristics, and future studies will benefit from the careful existing 
comprehensive studies of molecular alterations in HNSCC. 
 This study has a number of limitations. The population size was relatively 
small, however, the technology used was able to detect differences in promoter 
methylation in a large number of genes associated with cancer. The Goldengate 
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cancer panel, however, does not provide a measurement of promoter 
methylation in other genes with less well characterized functions, nor does it 
measure methylation at other genomic features, such as intergenic regions, 
which could provide information about genomic structure and stability. While the 
sample was representative of the patients seem in the institutions from which 
participants were recruited, women and particularly minorities were under-
represented. Future planned studies will include a more diverse patient 
population and a more comprehensive view of the cancer epigenome, integrating 
epigenetic and transcriptional measures. 
2.6 Conclusions 
Clinically and pathologically relevant subsets of tumors defined by 
methylation status have been identified in many cancer types, most notably the 
CpG Island Methylator Phenotype (CIMP) in colorectal cancer (Toyota et al. 
1999). These CIMP tumors exhibit a distinct somatic profile of microsatellite 
instability and BRAF mutations, with divergent epidemiologic characteristics 
compared to non-CIMP tumors including a survival advantage (Samowitz et al. 
2005a; Samowitz et al. 2005b). Array-based profiling of acute myeloid leukemias 
using the GoldenGate panel identified clinically relevant subgroups defined by 
epigenetic modifications, although there was not a strong association between 
these clusters and survival (Wilop et al. 2011). In this study we investigated the 
likelihood of identifying a clinically relevant subset of head and neck tumors 
defined by CpG methylation, taking advantage of a well-established patient 
cohort at the University of Michigan with well-annotated survival and 
epidemiologic data. Our sample was representative of the overall cohort 
regarding age, gender, smoking history, and alcohol consumption. We examined 
the epigenetic differences between HPV(+) and HPV(-) tumors, following from 
our recent work in cell lines showing evidence for divergent pathways of 
carcinogenesis and the well-described epidemiologic differences between 
individuals with differential HPV tumor status (Sartor et al. 2011). Further, we 
were able to evaluate survival in this cohort in light of their epigenetic profile (as 
defined by cluster status), HPV status and other epidemiologic characteristics. 
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 Figure 2.1. DNA methylation heatmap constructed using unsupervised hierarchical Ward clustering of the 711 CpG sites 
with the greatest variance across the 68 tumor samples identified six distinct methylation clusters.   
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Figure 2.2. Kaplan-Meier survival curves depicting three year survival for each of the six clusters identified via 
unsupervised hierarchical cluster analysis. 
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Figure 2.3 Average differences in methylation per CpG site comparing HPV(+) and HPV(-) tumors. 
 
 
 
50 
 
Table 2.1. Clinical characteristics of the study participants (n=68) 
Patient Characteristic  N (%) Mean (SD), Median (range) 
Age    57.0(10.0), 55.0 (28-82) 
    
Gender Male 51 (75%) 
 
Female 17 (25%) 
Stage  I and II 11 (16%) 
 III 15 (22%) 
IV 42 (62%) 
Cancer Site of first 
Primary  
Oral Cavity 17 (25%) 
 
Oropharynx 32 (47%) 
Hypopharynx 4 (6%) 
Larynx 13 (19%) 
Other 2 (3%) 
Tumor Tissue HPV (+) 
Status  24 (35%)  
Smoking Status  Never 11 (16%) 
  Past 41 (60%) 
Current 16 (24%) 
Pack-years   33.3(37), 25 (0-220) 
Non-cigarette Tobacco (yes/no) ever 12 (18%)  
Alcohol Problem AUDIT >= 8 
and drank 
within 1 year. 
23 (34%)  
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Table 2.2. Clinical characteristics of the six clusters identified via unsupervised hierarchical cluster analysis of DNA 
methylation values. 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 
N 10 9 21 9 8 11 
Age*   
mean(sd) 
median, (min-max) 
 
50.7 (9.1) 
51.5, (28-61) 
 
55.4 (8.2) 
54, (42-68) 
 
61.6 (9.7) 
62 (41-82) 
 
51.8 (6.4)    
53 (43-64) 
 
57.9 (9.6)    
57.5 (46-
72) 
 
58.9 (11.9) 
64 (41-73) 
Male  n (%) 7 (70%) 9 (100%) 16 (76%) 6 (67%) 5 (63%) 8 (73%) 
Cancer Site n (%) 
OC 
OP 
HP 
LA  
OT 
 
2 (20%) 
6 (60%) 
1 (10%) 
1 (10%) 
0  
 
1 (11%) 
4 (44%) 
1 (11%) 
2 (22%) 
1 (11%) 
 
1 (5%) 
15 (71%) 
1 (5%) 
4 (19%) 
0  
 
3 (33%) 
4 (44%) 
0  
2 (22%) 
0  
 
5 (63%) 
0 
0 
3 (37%) 
0  
 
5 (45%) 
3 (27%) 
1 (9%) 
1 (9%) 
1 (9%) 
Primary Cancer Stage n (%) 
I and IIIII 
IV 
 
 
0  
4 (40%) 
6 (60%) 
 
 
0  
3 (33%) 
6 (67%) 
 
3 (14%) 
2 (10%) 
16 (76%) 
 
 
1 (11%) 
2 (22%) 
6 (67%) 
 
 
3 (38%) 
2 (25%) 
3 (38%) 
 
4 (36%) 
2 (18%) 
5 (45%) 
HPV status   n (%)* 
Pos  
Neg 
 
4 (40%) 
6 (60%) 
 
1 (11%) 
8 (89%) 
 
13 (62%) 
8 (38%) 
 
3 (33%) 
6 (67%) 
 
0 
8 (100%) 
 
2 (18%) 
9 (82%) 
Smoking Status n (%) 
    Currently smoke cigarettes 
    Past smoker, quit within last year 
    Past smoker, quit over a year 
ago 
    Never smoked cigarettes 
 
1 (10%) 
5 (50%) 
3 (30%) 
1 (10%) 
 
3 (33%) 
4 (44%) 
1 (11%) 
1 (11%) 
 
5 (24%) 
3 (14%) 
7 (33%) 
6 (29%) 
 
4 (44%) 
3 (33%) 
0  
2 (22%) 
 
0  
5 (63%) 
3 (38%) 
0  
 
3 (27%) 
4 (36%) 
3 (27%) 
1 (9%) 
Problem Drinking n (%)a 4 (40%) 5 (56%) 5 (24%) 3 (33%) 3 (38%) 3 (27%) 
3 year Overall Survival* 7 (70%) 6 (66%) 18 (86%) 3 (66%) 2 (25%) 9 (82%) 
Treatment       
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    Surgery Only 1 (10%) 0 4 (19%) 1 (11%) 2 (25%) 0 
    Radiation Only 0 1 (11%) 1 (5%) 0 0 1 (9%) 
    Surgery and Radiation 0 2 (22%) 3 (14%) 2 (22%) 0 2 (18%) 
   Radiation and Chemotherapy 4 (40%) 4 (44%) 8 (38%) 4 (44%) 4 (50%) 7 (64%) 
   Surgery, Radiation and 
Chemotherapy 
5 (50%) 2 (22%) 3 (14%) 2 (22%) 0 2 (18%) 
*p<0.05 for difference between clusters 
a) Problem drinking defined: AUDIT>8 and drank in past 1 year. Note: n=14 missing AUDIT score 
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Table 2.3. CpG sites with DNA methylation values significantly associated (Adjusted p<0.05) with HPV status of 
the tumor. Positive T-Values correspond with higher methylation in HPV(+) while negative T-Values correspond 
with higher methylation in HPV(-) tumors. 
Gene 
Symbol Chromosome 
CpG 
Coordinate 
Distance 
to TSS 
DNA Strand 
of 
Transcription 
T-Value 
Mean % 
Difference 
in 
Methylation 
P-Value Adjusted P-Value 
CCNA1 13 35904640 7 + 5.30 21.3 1.86E-06 0.0028 
GRB7 17 35147553 -160 - 4.58 8.0 2.46E-05 0.0161 
SPDEF 6 34631953 116 - -4.51 -3.7 3.20E-05 0.0161 
CDH11 16 63713774 -354 - 4.32 18.4 6.08E-05 0.0192 
RUNX1T1 8 93176474 145 - 4.31 13.7 6.37E-05 0.0192 
RASSF1 3 50353615 -244 + -4.22 -2.1 8.47E-05 0.0213 
STAT5A 17 37693133 42 + -4.05 -11.5 1.51E-04 0.0318 
MGMT 10 131155184 -272 - -4.01 -3.6 1.73E-04 0.0318 
ESR2 14 63830765 66 + -3.98 -6.4 1.90E-04 0.0318 
JAK3 19 17819736 64 + -3.92 -11.8 2.31E-04 0.0348 
SYBL1 X 154763858 -349 + 3.88 12.2 2.71E-04 0.0370 
HSD17B12 11 43659026 145 - -3.83 -0.9 3.14E-04 0.0394 
TUSC3 8 15442130 29 - 3.73 6.7 4.28E-04 0.0496 
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Table 2.4. All CpG sites with DNA methylation values significantly associated (p<0.05) with 
HPV status of the tumor. Positive T-values correspond with sites more highly methylated in 
HPV(+) while negative T-values correspond with sites more highly methylated in HPV(-) 
tumors. Adjusted p-values were calculated via the Benjamini-Hochberg Method. 
Gene Symbol Chromosome CpG Coordinate 
Distance 
to TSS 
DNA Strand of 
Transcription 
T-
Value P-Value 
Adjusted 
P-Value 
CCNA1 13 35904640 7 + 5.30 1.86E-06 0.0028 
GRB7 17 35147553 -160 - 4.58 2.46E-05 0.0161 
SPDEF 6 34631953 116 - -4.51 3.20E-05 0.0161 
CDH11 16 63713774 -354 - 4.32 6.08E-05 0.0192 
RUNX1T1 8 93176474 145 - 4.31 6.37E-05 0.0192 
RASSF1 3 50353615 -244 + -4.22 8.47E-05 0.0213 
STAT5A 17 37693133 42 + -4.05 1.51E-04 0.0318 
MGMT 10 131155184 -272 - -4.01 1.73E-04 0.0318 
ESR2 14 63830765 66 + -3.98 1.90E-04 0.0318 
JAK3 19 17819736 64 + -3.92 2.31E-04 0.0348 
SYBL1 X 154763858 -349 + 3.88 2.71E-04 0.0370 
HSD17B12 11 43659026 145 - -3.83 3.14E-04 0.0394 
TUSC3 8 15442130 29 - 3.73 4.28E-04 0.0496 
TNFRSF10C 8 23016372 -7 + -3.66 5.38E-04 0.0578 
OSM 22 28993028 -188 + -3.61 6.39E-04 0.0629 
CD1A 1 156490545 -6 + 3.59 6.69E-04 0.0629 
PTPRG 3 61522325 40 - -3.53 8.07E-04 0.0677 
CDK10 16 88280653 74 + -3.52 8.34E-04 0.0677 
NEFL 8 24870155 -209 - 3.52 8.55E-04 0.0677 
MPL 1 43575405 -657 + -3.44 0.0011 0.0806 
PLAT 8 42184431 -80 + 3.37 0.0013 0.0924 
TNFRSF10D 8 23077555 -70 + -3.37 0.0014 0.0924 
SEMA3F 3 50168185 333 - 3.32 0.0016 0.0993 
IGF2AS 11 2118120 -203 + 3.31 0.0016 0.0993 
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SMARCA4 19 10932244 -362 - -3.28 0.0018 0.1064 
CHFR 12 131974892 -635 - -3.22 0.0021 0.1205 
ZNF264 19 62394284 -397 + 3.21 0.0022 0.1206 
IRF7 11 605691 236 - -3.17 0.0024 0.1271 
MYLK 3 125085707 132 - 3.17 0.0024 0.1271 
MEG3 14 100362306 91 + 3.12 0.0028 0.1381 
THBS2 6 169395933 129 + -3.12 0.0028 0.1381 
BCL2L2 14 22845586 -280 + 3.10 0.0030 0.1388 
OSM 22 28992874 -34 + -3.06 0.0034 0.1491 
RASSF1 3 50353255 116 + -3.05 0.0034 0.1491 
SEMA3B 3 50280140 96 + -3.03 0.0036 0.1491 
DES 2 219991571 228 - -3.02 0.0037 0.1491 
GRPR X 16051145 -200 - 3.01 0.0038 0.1491 
SHB 9 38059683 -473 - -3.01 0.0038 0.1491 
SPI1 11 47356469 205 + -3.01 0.0039 0.1491 
IRF5 7 128365107 -123 + -2.97 0.0043 0.1609 
CREBBP 16 3871424 -712 - 2.96 0.0044 0.1614 
HPSE 4 84475422 -93 + -2.95 0.0045 0.1624 
ICAM1 19 10242393 -386 - -2.94 0.0046 0.1624 
EYA4 6 133603698 -508 + -2.86 0.0059 0.1984 
ADAMTS12 5 33927829 52 - -2.85 0.0060 0.1984 
PTPRO 12 15366383 -371 + -2.84 0.0061 0.1984 
S100A2 1 151804894 36 - 2.84 0.0063 0.1984 
CASP8 2 201806900 474 + -2.82 0.0065 0.1984 
CTGF 6 132314848 -693 - 2.82 0.0066 0.1984 
E2F5 8 86276358 -516 - -2.82 0.0066 0.1984 
CTSL 9 89530719 -81 + 2.80 0.0069 0.2002 
NDN 15 21483412 131 - 2.80 0.0069 0.2002 
SHH 7 155297400 328 + 2.79 0.0071 0.2021 
RIPK4 21 42060152 166 + 2.78 0.0073 0.2042 
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DSC2 18 26936285 90 + 2.76 0.0077 0.2073 
FRK 6 116488650 -36 + 2.76 0.0077 0.2073 
CCNA1 13 35904417 -216 + 2.75 0.0080 0.2107 
CSF3R 1 36721104 -8 + 2.72 0.0086 0.2141 
CHFR 12 131974758 -501 + -2.71 0.0087 0.2141 
EPHA7 6 94186198 -205 - -2.71 0.0087 0.2141 
RUNX3 1 25164455 -393 - -2.71 0.0088 0.2141 
AXL 19 46416440 -223 - 2.71 0.0089 0.2141 
HLA-DOB 6 32893119 -357 - -2.70 0.0091 0.2141 
FGF1 5 142046169 -357 - 2.70 0.0092 0.2141 
NOTCH4 6 32299818 4 + 2.69 0.0093 0.2141 
RAB32 6 146906835 314 - 2.69 0.0094 0.2141 
SMO 7 128616006 57 + -2.68 0.0096 0.2151 
CDKN2A 9 21964709 229 - -2.67 0.0098 0.2164 
MC2R 18 13906560 -1025 + 2.66 0.0101 0.2193 
MMP9 20 44070765 -189 + 2.62 0.0111 0.2354 
GABRA5 15 24742740 44 - 2.62 0.0112 0.2354 
SPI1 11 47357603 -929 + 2.62 0.0113 0.2354 
HSPA2 14 64072214 -162 - -2.60 0.0117 0.2405 
SOX2 3 182911870 -546 + -2.59 0.0121 0.2405 
GADD45A 1 67922734 -737 - 2.58 0.0124 0.2405 
TNK1 17 7225093 -41 - 2.58 0.0124 0.2405 
JAK3 19 17819956 -156 - -2.58 0.0124 0.2405 
CDH11 16 63713623 -203 - 2.58 0.0125 0.2405 
FASTK 7 150409141 -257 + 2.57 0.0128 0.2405 
MMP14 14 22375425 -208 - 2.57 0.0128 0.2405 
EPHB4 7 100263392 -313 - -2.55 0.0134 0.2487 
RHOH 4 39874876 -121 + -2.54 0.0139 0.2556 
COL18A1 21 45649031 -494 - -2.51 0.0147 0.2619 
IGFBP5 2 217268372 144 + -2.51 0.0149 0.2619 
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FGF7 15 47502707 -44 + 2.51 0.0150 0.2619 
PRSS1 7 142136949 45 - 2.51 0.0150 0.2619 
CSF2 5 131437632 248 - 2.50 0.0151 0.2619 
SMO 7 128615494 -455 - 2.50 0.0153 0.2619 
HDAC6 X 48545533 102 + 2.49 0.0155 0.2629 
SERPINE1 7 100556653 -519 + 2.49 0.0158 0.2641 
TGFA 2 70634996 -558 + -2.48 0.0161 0.2661 
HRASLS 3 194441259 -353 - 2.47 0.0164 0.2669 
TRIM29 11 119514334 -261 + 2.47 0.0165 0.2669 
SLIT2 4 19864125 -208 + 2.46 0.0167 0.2669 
CD40 20 44179941 -372 - -2.45 0.0172 0.2700 
GNMT 6 43036604 126 + -2.45 0.0172 0.2700 
HOXA11 7 27191320 35 + -2.44 0.0178 0.2726 
PLA2G2A 1 20179228 268 + -2.43 0.0182 0.2726 
PTPNS1 20 1823858 433 - -2.43 0.0182 0.2726 
NOTCH1 9 138559607 452 - -2.43 0.0182 0.2726 
YES1 18 802927 -600 + -2.43 0.0183 0.2726 
JAK3 19 17820875 -1075 - 2.42 0.0185 0.2727 
FLT3 13 27573007 -302 + -2.42 0.0188 0.2745 
MET 7 116100028 333 + 2.41 0.0191 0.2757 
CD9 12 6179231 -585 - 2.40 0.0194 0.2785 
GDF10 10 48059133 39 + -2.39 0.0200 0.2827 
MATK 19 3752874 -64 + -2.39 0.0201 0.2827 
FGFR2 10 123348367 -460 - 2.38 0.0207 0.2886 
KCNK4 11 63815280 -171 - -2.37 0.0209 0.2886 
RHOH 4 39874044 -953 - 2.35 0.0222 0.3036 
INS 11 2139248 -248 + 2.34 0.0229 0.3089 
PLS3 X 114701835 70 + 2.33 0.0230 0.3089 
APC 5 112101600 117 - -2.33 0.0232 0.3095 
APC 5 112101203 -280 - -2.32 0.0237 0.3124 
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ZNF264 19 62394729 48 - -2.32 0.0240 0.3144 
GUCY2D 17 7846665 -48 - -2.31 0.0243 0.3151 
CD40 20 44180371 58 - -2.31 0.0247 0.3170 
EPHA2 1 16355354 -203 + 2.30 0.0251 0.3170 
ETV1 7 13995804 -515 + -2.30 0.0251 0.3170 
MAPK10 4 87593281 26 + 2.30 0.0253 0.3170 
ACVR1 2 158404019 -983 + 2.29 0.0259 0.3221 
AATK 17 76710603 -709 - 2.27 0.0269 0.3318 
IMPACT 18 20260446 -234 - 2.26 0.0273 0.3319 
LOX 5 121442166 -313 - 2.26 0.0274 0.3319 
MGMT 10 131155175 -281 + -2.26 0.0276 0.3319 
BTK X 100527943 -105 + -2.25 0.0281 0.3361 
NTSR1 20 60810316 -318 + 2.25 0.0284 0.3361 
ASCL2 11 2249367 -609 - 2.24 0.0291 0.3424 
MKRN4 X 40578589 249 - 2.22 0.0306 0.3453 
ICAM1 19 10243021 242 + -2.21 0.0309 0.3453 
IGSF4C 19 48836364 -533 - -2.21 0.0311 0.3453 
CD9 12 6179312 -504 + 2.21 0.0312 0.3453 
TIE1 1 43539317 66 - 2.21 0.0312 0.3453 
RUNX3 1 25164035 27 - -2.20 0.0315 0.3453 
SPDEF 6 34632075 -6 - 2.20 0.0315 0.3453 
ETV6 12 11694485 430 + -2.20 0.0319 0.3453 
CD86 3 123256908 -3 + 2.20 0.0319 0.3453 
PAX6 11 31790576 -1121 + -2.20 0.0319 0.3453 
INHA 2 220144009 1252 + -2.20 0.0321 0.3453 
EPO 7 100156603 244 - -2.19 0.0323 0.3453 
DBC1 9 121171318 204 + 2.19 0.0325 0.3453 
FLT3 13 27572379 326 - -2.19 0.0326 0.3453 
KRT5 12 51200818 -308 + 2.19 0.0329 0.3458 
IL4 5 132037010 -262 - 2.17 0.0344 0.3592 
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SLIT2 4 19864444 111 - -2.16 0.0353 0.3660 
MMP10 11 102156418 136 - 2.15 0.0357 0.3680 
CDKN1C 11 2864177 -626 + -2.14 0.0362 0.3706 
UBA52 19 18543375 -293 - -2.14 0.0366 0.3706 
MMP14 14 22375620 -13 + 2.14 0.0367 0.3706 
EMR3 19 14646849 -39 - 2.13 0.0375 0.3739 
GSTM1 1 110031699 -266 + 2.13 0.0375 0.3739 
DSC2 18 26936782 -407 - 2.12 0.0378 0.3739 
ARHGAP9 12 56169124 -260 + 2.12 0.0383 0.3739 
COL1A2 7 93861402 -407 - 2.12 0.0383 0.3739 
APOC2 19 50140706 -377 + 2.11 0.0389 0.3746 
STK11 19 1156503 -295 - -2.11 0.0392 0.3746 
KIAA1804 1 231529448 -689 - 2.11 0.0392 0.3746 
F2R 5 76047454 -88 + 2.11 0.0393 0.3746 
IGSF4 11 114880779 -454 + 2.10 0.0398 0.3763 
CDH11 16 63713318 102 - 2.10 0.0400 0.3763 
RARB 3 25444698 -60 + 2.09 0.0410 0.3790 
HIC2 22 20101165 -528 - 2.09 0.0411 0.3790 
SEMA3A 7 83662191 -343 + -2.09 0.0414 0.3790 
ITK 5 156540651 166 - -2.08 0.0416 0.3790 
NRAS 1 115061141 -103 - 2.08 0.0421 0.3790 
PTGS2 1 184916703 -524 - 2.07 0.0425 0.3790 
RIPK2 8 90839296 123 + -2.07 0.0425 0.3790 
RUNX3 1 25164309 -247 + -2.07 0.0426 0.3790 
COL1A1 17 45633997 -5 + 2.07 0.0432 0.3790 
TCF4 18 51406615 -175 - -2.07 0.0432 0.3790 
SMAD4 18 46810137 -474 - -2.07 0.0432 0.3790 
THY1 11 118799110 -20 - -2.06 0.0434 0.3790 
COL18A1 21 45649160 -365 - 2.06 0.0436 0.3790 
FES 15 89228490 -223 - -2.06 0.0439 0.3799 
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GNAS 20 56848248 58 + 2.05 0.0451 0.3873 
PTHLH 12 28016940 -757 + 2.05 0.0453 0.3873 
PITX2 4 111777933 24 - 2.04 0.0457 0.3887 
MCM6 2 136350345 136 + -2.04 0.0461 0.3896 
EPHA8 1 22762135 -456 - -2.03 0.0470 0.3939 
MYCN 2 15998211 77 - -2.03 0.0471 0.3939 
MYOD1 11 17697891 156 + 2.02 0.0476 0.3960 
RYK 3 135452769 -493 + -2.02 0.0481 0.3974 
RRAS 19 54835312 -100 - -2.01 0.0487 0.4004 
SEPT9 17 72827370 -374 + 2.01 0.0490 0.4005 
MME 3 156280182 29 + 2.00 0.0496 0.4005 
GPR116 6 46991675 -850 + 2.00 0.0497 0.4005 
DSG1 18 27151891 -159 - 2.00 0.0498 0.4005 
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 Table 2.5. Candidate enriched gene sets for differentially methylated genes associated with HPV status. 
Name Size Enrichment Score (ES) 
Normalized 
Enrichment 
Score (NES) 
Nominal 
P-Value 
FDR  
Q-
Value 
GENE ONTOLOGY - BIOLOGICAL PROCESSES 
Regulation of Cell Cycle 11 -0.54 -1.96 0.007 0.41 
Cell Cycle (GO 0007049) 14 -0.43 -1.69 0.036 1.00 
Negative Regulation of Cellular Metabolic 
Process 6 -0.58 -1.63 0.041 1.00 
KEGG PATHWAYS 
Neuroactive Ligand Receptor Interaction 
(HSA04080) 6 0.60 1.72 0.020 0.27 
JAK-STAT Signaling Pathway (HSA04630) 9 -0.49 -1.62 0.047 0.40 
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Table 2.6. CpG sites identified as significantly associated (p<0.05) with three year survival by Cox Proportional 
Hazards Modeling.  
Gene Symbol Chromosome CpG Coordinate 
Distance 
to TSS 
DNA Strand 
of 
Transcription 
Hazard 
Coefficient 
Standard 
Error 
P-
Value 
Q-
Value 
NOTCH1 9 138559607 452 - 22.29 5.95 0.0002 0.172 
TEK 9 27098915 -526 + -5.66 1.63 0.0005 0.172 
UGT1A1 2 234333094 -564 - -6.63 1.92 0.0005 0.172 
IL6 7 22732734 -611 + 4.86 1.45 0.0008 0.172 
AHR 7 17304605 -166 - 12.36 3.82 0.0012 0.172 
RRAS 19 54835312 -100 - 11.86 3.69 0.0013 0.172 
NEO1 15 71130861 -1067 + 22.72 7.17 0.0015 0.172 
F2R 5 76046703 -839 + -4.45 1.41 0.0016 0.172 
IGFBP3 7 45928431 -1035 + 11.24 3.58 0.0017 0.172 
PLS3 X 114701671 -94 - 8.04 2.58 0.0019 0.172 
HS3ST2 16 22732815 -546 + -6.21 2.00 0.0019 0.172 
MST1R 3 49916466 -392 + 13.09 4.22 0.0019 0.172 
MYOD1 11 17697891 156 + -4.41 1.44 0.0021 0.175 
FER 5 108110841 -581 + -4.86 1.64 0.0030 0.215 
PLAT 8 42184431 -80 + 12.04 4.06 0.0030 0.215 
VAMP8 2 85657987 -241 + 6.68 2.29 0.0035 0.217 
ARHGAP9 12 56169124 -260 + -3.76 1.31 0.0039 0.217 
TMEFF1 9 102275718 180 - 7.56 2.63 0.0041 0.217 
CYP1B1 2 38157008 -212 + 4.89 1.71 0.0042 0.217 
JAG2 14 104706470 -264 + 15.37 5.38 0.0043 0.217 
TMEFF2 2 192767395 494 - -3.70 1.30 0.0043 0.217 
ROR1 1 64012296 -6 + 4.60 1.64 0.0049 0.240 
RUNX3 1 25164035 27 - -3.52 1.26 0.0053 0.246 
EVI2A 17 26672423 420 + -3.78 1.37 0.0058 0.246 
S100A4 1 151785100 -194 - -3.35 1.22 0.0059 0.246 
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BTK X 100527943 -105 + -6.03 2.19 0.0060 0.246 
CDC25B 20 3724375 -11 - 28.47 10.46 0.0065 0.258 
DSP 6 7486833 -36 + 9.05 3.35 0.0069 0.262 
CFTR 7 116906881 -372 - -4.54 1.70 0.0075 0.263 
NTSR1 20 60810743 109 + 6.76 2.54 0.0077 0.263 
MC2R 18 13906560 -1025 + 3.51 1.32 0.0080 0.263 
JAK2 9 4974473 -772 - 8.76 3.30 0.0080 0.263 
HTR1B 6 78229607 232 - -3.58 1.35 0.0081 0.263 
RIPK4 21 42060490 -172 + 4.01 1.53 0.0087 0.275 
IRAK1 X 152938848 -312 + 5.69 2.18 0.0091 0.278 
JAK3 19 17820875 -1075 - -3.22 1.24 0.0093 0.278 
BCL2A1 15 78051825 -1127 - -3.05 1.18 0.0098 0.279 
CPA4 7 129719269 -961 - -2.81 1.10 0.0105 0.279 
FANCA 16 88411572 -1006 - -2.97 1.16 0.0105 0.279 
LAMC1 1 181259642 466 - 35.82 14.07 0.0109 0.279 
PTK6 20 61639101 50 + 3.65 1.44 0.0111 0.279 
YES1 18 802927 -600 + 22.56 8.92 0.0114 0.279 
VAV2 9 135847168 58 + 31.29 12.40 0.0116 0.279 
JUNB 19 12762161 -1149 - 7.59 3.01 0.0118 0.279 
PCDH1 5 141238392 -264 + 7.53 3.01 0.0124 0.279 
SEMA3F 3 50168185 333 - 12.85 5.14 0.0125 0.279 
ZIM3 19 62348179 203 + -4.55 1.82 0.0125 0.279 
SNURF 15 22751226 -2 - -3.91 1.57 0.0127 0.279 
FES 15 89228490 -223 - -5.26 2.11 0.0129 0.279 
LYN 8 56955279 353 + 5.58 2.25 0.0131 0.279 
NPR2 9 35781788 -618 + 3.91 1.58 0.0133 0.279 
MLH1 3 37009602 197 + 20.70 8.43 0.0140 0.284 
ICAM1 19 10242393 -386 - 6.95 2.84 0.0142 0.284 
ALPL 1 21708178 -278 + 15.42 6.30 0.0143 0.284 
ITGA2 5 52321134 120 + 16.56 6.81 0.0151 0.284 
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RBP1 3 140741330 -150 + 10.78 4.45 0.0153 0.284 
EPHA8 1 22762135 -456 - -4.16 1.71 0.0153 0.284 
ATP10A 15 23660487 -524 - -3.81 1.57 0.0155 0.284 
TDGF1 3 46593789 -428 - -3.13 1.30 0.0161 0.284 
MYH11 16 15858391 -22 + -4.50 1.87 0.0162 0.284 
MFAP4 17 19231283 -197 + -3.45 1.44 0.0163 0.284 
MMP19 12 54522728 274 - -2.74 1.14 0.0167 0.284 
MAP3K1 5 56146015 -7 + 12.84 5.37 0.0168 0.284 
PRKCDBP 11 6298110 206 + 5.20 2.18 0.0170 0.284 
MFAP4 17 19231096 -10 - -3.96 1.67 0.0177 0.289 
SH3BP2 4 2789568 -771 - 10.49 4.44 0.0182 0.289 
LRP2 2 169927239 20 + 2.32 0.98 0.0184 0.289 
PHLDA2 11 2907848 -622 + 6.22 2.64 0.0184 0.289 
SEMA3A 7 83662506 -658 - -8.23 3.50 0.0187 0.289 
PLS3 X 114701835 70 + 2.54 1.08 0.0189 0.289 
DDR2 1 160869183 331 + -2.97 1.27 0.0192 0.289 
SMAD2 18 43712069 -848 - 12.81 5.50 0.0199 0.289 
PGF 14 74492011 33 + 8.42 3.62 0.0201 0.289 
INHA 2 220144009 1252 + 9.52 4.10 0.0203 0.289 
BCL3 19 49943942 71 + 4.88 2.11 0.0205 0.289 
CTLA4 2 204440932 176 - -2.54 1.10 0.0205 0.289 
IL3 5 131423690 -556 + -2.18 0.94 0.0208 0.290 
GAS7 17 10042445 148 + -2.54 1.10 0.0213 0.293 
MYCN 2 15997670 -464 - 16.94 7.47 0.0233 0.316 
EPHX1 1 224079751 152 + -2.69 1.19 0.0236 0.316 
SOD3 4 24404928 -225 + -2.31 1.03 0.0244 0.321 
SLC5A8 12 100128060 60 - -3.05 1.36 0.0248 0.321 
EGR4 2 73374048 70 + 3.77 1.68 0.0251 0.321 
LMO1 11 8241717 265 - -23.80 10.66 0.0255 0.321 
BLK 8 11388916 -14 + -3.08 1.38 0.0258 0.321 
65 
 
MUSK 9 112470652 -308 + -2.44 1.10 0.0261 0.321 
EYA4 6 133603412 -794 + -2.50 1.13 0.0266 0.321 
ZNF264 19 62394729 48 - 7.10 3.20 0.0267 0.321 
PPARG 3 12304537 178 - 4.19 1.89 0.0268 0.321 
EDN1 6 12398606 -39 - 20.69 9.35 0.0269 0.321 
BMPR2 2 202950351 435 + 41.33 18.84 0.0283 0.330 
MYLK 3 125086308 -469 - -5.43 2.48 0.0286 0.330 
GLI3 7 42241564 148 - -3.45 1.58 0.0286 0.330 
PWCR1 15 22846906 -811 + -2.38 1.09 0.0294 0.335 
MAF 16 78192938 -826 - 15.89 7.31 0.0297 0.335 
MYBL2 20 41728769 -354 + 9.32 4.31 0.0307 0.343 
EMR3 19 14646849 -39 - 5.10 2.37 0.0310 0.343 
HLA-DPA1 6 33149321 35 - -2.52 1.18 0.0323 0.353 
TNK1 17 7224913 -221 + -2.98 1.40 0.0327 0.354 
IL8 4 74825056 -83 + -4.95 2.32 0.0331 0.354 
XRCC1 19 48772236 -681 - -2.12 1.00 0.0342 0.362 
KIAA1804 1 231529448 -689 - 3.08 1.46 0.0345 0.362 
PROK2 3 71916902 0 + 2.16 1.02 0.0349 0.363 
GPX1 3 49370989 -194 + 9.52 4.53 0.0356 0.364 
EVI1 3 170346817 -30 - -19.54 9.32 0.0361 0.364 
KRAS 12 25295039 82 + -3.42 1.63 0.0361 0.364 
ACVR1 2 158402708 328 - -2.23 1.07 0.0363 0.364 
PLG 6 161043679 406 + -2.26 1.08 0.0370 0.366 
C4B 6 32057622 -191 + -2.72 1.30 0.0373 0.366 
ITGB4 17 71228594 -517 + -6.47 3.11 0.0375 0.366 
LMO1 11 8242151 -169 + 17.98 8.67 0.0380 0.367 
S100A4 1 151785793 -887 - -2.55 1.24 0.0389 0.372 
AXL 19 46416440 -223 - -4.67 2.27 0.0393 0.372 
TDGF1 3 46594270 53 - -1.97 0.96 0.0410 0.376 
SEPT9 17 72827686 -58 - -1.77 0.87 0.0413 0.376 
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RASA1 5 86600014 107 + 13.88 6.80 0.0413 0.376 
SOX1 13 111768896 -1018 - -6.54 3.21 0.0414 0.376 
GSTP1 11 67107788 -74 + -25.67 12.59 0.0415 0.376 
LTA 6 31647858 -214 - -2.09 1.03 0.0419 0.376 
BDNF 11 27700131 -259 - -2.10 1.03 0.0423 0.376 
SMAD2 18 43711929 -708 - -76.61 37.81 0.0427 0.376 
CD34 1 206152086 -780 - -2.56 1.27 0.0435 0.376 
RYK 3 135452769 -493 + 6.38 3.16 0.0435 0.376 
FVT1 18 59185663 -225 + 2.17 1.07 0.0436 0.376 
CD81 11 2354912 -211 + -2.66 1.32 0.0444 0.380 
RET 10 42892544 11 + -3.52 1.76 0.0451 0.380 
TSC2 16 2038740 140 + -8.57 4.28 0.0452 0.380 
SLC6A8 X 152606393 -193 - 2.76 1.38 0.0460 0.380 
MME 3 156279765 -388 + -3.47 1.74 0.0462 0.380 
HHIP 4 145786045 -578 - -5.15 2.58 0.0463 0.380 
CCKAR 4 26101061 79 + -1.94 0.98 0.0467 0.380 
CDK6 7 92300892 256 + 23.63 11.90 0.0471 0.380 
HOXA11 7 27191447 -92 - 3.00 1.52 0.0479 0.380 
TMEFF1 9 102274912 -626 - -4.52 2.29 0.0483 0.380 
TGFBR3 1 92124672 -429 + 7.68 3.89 0.0486 0.380 
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Table 2.7.  CpG sites identified as significantly differentially methylated between cluster 5 and all other clusters. 
Gene Symbol Chromosome 
CpG 
Coordinate 
Distance 
to TSS 
DNA Strand 
of 
Transcription 
T-
Value P-Value 
Adjusted 
P-Value 
FGR 1 27823199 -39 + -8.71 3.7E-12 5.6E-09 
ACTG2 2 73973255 -346 + -8.20 2.7E-11 2.0E-08 
MLF1 3 159771921 243 + -7.09 2.0E-09 9.8E-07 
GFAP 17 40349608 -1214 + -7.00 2.8E-09 1.1E-06 
TNFRSF10C 8 23015767 -612 - -6.67 1.0E-08 3.0E-06 
MMP1 11 102174501 -397 - -6.54 1.7E-08 4.3E-06 
PTHLH 12 28016940 -757 + -6.38 3.1E-08 6.6E-06 
ARHGAP9 12 56169382 -518 - -6.34 3.6E-08 6.8E-06 
MSH3 5 79986037 -13 - -6.16 7.2E-08 1.2E-05 
DNAJC15 13 42495297 -65 + -5.87 2.2E-07 3.3E-05 
NKX3-1 8 23597266 -871 - -5.78 3.1E-07 4.3E-05 
SRC 20 35406205 -297 + -5.58 6.4E-07 8.0E-05 
ZNFN1A1 7 50411546 -179 + -5.42 1.2E-06 1.4E-04 
CSF1R 5 149473102 26 + -5.33 1.6E-06 1.8E-04 
P2RX7 12 120054464 -597 + -5.19 2.8E-06 2.8E-04 
LCN2 9 129951398 -141 - -5.12 3.6E-06 3.4E-04 
CDH17 8 95289955 31 + -5.01 5.3E-06 4.6E-04 
IFNG 12 66840247 -459 - -5.00 5.5E-06 4.6E-04 
NAT2 8 18293024 -11 + -4.90 8.1E-06 6.4E-04 
PLAGL1 6 144371482 -236 - -4.73 1.5E-05 1.1E-03 
THPO 3 185578143 483 + -4.60 2.3E-05 1.6E-03 
FOLR1 11 71578618 368 - -4.58 2.5E-05 1.7E-03 
TNFSF8 9 116732775 -184 + -4.55 2.7E-05 1.8E-03 
CLDN4 7 72882009 -1120 - -4.49 3.4E-05 2.1E-03 
PARP1 1 224663024 -610 - -4.46 3.8E-05 2.3E-03 
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CTLA4 2 204439628 -1128 + -4.35 5.5E-05 3.1E-03 
FGF9 13 21143013 -862 - 4.34 5.7E-05 3.1E-03 
EPHA1 7 142816226 -119 - 4.34 5.8E-05 3.1E-03 
MCF2 X 138552324 195 + -4.33 5.9E-05 3.1E-03 
THPO 3 185579211 -585 - -4.18 9.8E-05 4.9E-03 
SNRPN 15 22619657 -230 - -4.17 1.0E-04 5.0E-03 
EPO 7 100156197 -162 - -4.16 1.1E-04 5.0E-03 
ITGA6 2 172999898 -718 - -4.12 1.2E-04 5.5E-03 
FOSL2 2 28469667 384 - -4.11 1.3E-04 5.6E-03 
SLC5A5 19 17843842 60 + -4.09 1.3E-04 5.7E-03 
SYK 9 92603307 -584 + -4.07 1.4E-04 5.7E-03 
PTHR1 3 46894070 -170 - -4.07 1.4E-04 5.7E-03 
PMP22 17 15110623 -1254 + -4.07 1.4E-04 5.7E-03 
PWCR1 15 22847798 81 - -4.06 1.5E-04 5.7E-03 
GSTM1 1 110031602 -363 + -4.03 1.6E-04 6.1E-03 
LIG3 17 30331029 -622 - -4.01 1.7E-04 6.3E-03 
GFAP 17 40348450 -56 - -3.99 1.9E-04 6.7E-03 
DNMT2 10 17283886 -199 + -3.98 1.9E-04 6.7E-03 
TIMP3 22 31525688 -1114 - -3.97 2.0E-04 6.7E-03 
PCTK1 X 46962653 77 - 3.97 2.0E-04 6.7E-03 
LMTK2 7 97573099 -1034 + -3.95 2.1E-04 6.7E-03 
WNT8B 10 102213275 487 + -3.95 2.1E-04 6.7E-03 
NRAS 1 115061050 -12 - 3.95 2.1E-04 6.7E-03 
RAD54B 8 95556713 -227 + -3.94 2.2E-04 6.7E-03 
DMP1 4 88790677 194 + -3.93 2.2E-04 6.7E-03 
BRCA1 17 38531829 -835 - -3.92 2.3E-04 6.8E-03 
MMP9 20 44071042 88 - -3.92 2.4E-04 6.8E-03 
LMO2 11 33871206 -794 - -3.91 2.4E-04 6.8E-03 
APOA1 11 116213809 -261 + -3.89 2.6E-04 7.1E-03 
BCR 22 21852206 -346 + -3.88 2.7E-04 7.2E-03 
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SPARC 5 151046905 -195 + -3.87 2.8E-04 7.2E-03 
SERPINE1 7 100557361 189 - -3.87 2.8E-04 7.2E-03 
FGF7 15 47502141 -610 + -3.87 2.8E-04 7.2E-03 
WNT1 12 47658660 157 + 3.86 2.8E-04 7.2E-03 
SLC22A2 6 160600058 -109 + -3.86 2.9E-04 7.2E-03 
ABCB4 7 86947735 -51 + -3.85 3.0E-04 7.2E-03 
HOXB2 17 43977879 -488 - -3.85 3.0E-04 7.2E-03 
OPCML 11 132907684 -71 + -3.82 3.3E-04 7.9E-03 
DHCR24 1 55126145 -652 - -3.81 3.4E-04 8.0E-03 
WNT1 12 47658424 -79 - 3.80 3.5E-04 8.0E-03 
IPF1 13 27391427 -750 + -3.80 3.5E-04 8.0E-03 
ZIM3 19 62349100 -718 - -3.78 3.7E-04 8.2E-03 
SERPINB2 18 59704983 -939 + -3.78 3.7E-04 8.2E-03 
CDH17 8 95290362 -376 + -3.77 3.9E-04 8.4E-03 
BMPR1A 10 88506464 88 + -3.76 3.9E-04 8.5E-03 
DDR2 1 160868109 -743 - -3.75 4.1E-04 8.7E-03 
PTHR1 3 46894276 36 - -3.74 4.2E-04 8.7E-03 
GNG7 19 2604493 -903 + -3.71 4.7E-04 9.6E-03 
ZIM3 19 62348833 -451 - -3.70 4.8E-04 9.7E-03 
ELK1 X 47394808 156 + -3.69 4.9E-04 9.7E-03 
IGF2AS 11 2118327 4 + 3.69 4.9E-04 9.7E-03 
EGF 4 111053257 -242 - -3.69 5.0E-04 9.7E-03 
CYP2E1 10 135190441 -416 + -3.65 5.6E-04 1.1E-02 
PDGFA 7 525644 -78 + -3.65 5.6E-04 1.1E-02 
LEFTY2 1 224196262 -719 + -3.64 5.9E-04 1.1E-02 
MMP2 16 54070610 21 - 3.62 6.2E-04 1.2E-02 
AGXT 2 241456655 -180 + -3.60 6.5E-04 1.2E-02 
EGFR 7 55053959 -260 - -3.60 6.5E-04 1.2E-02 
AATK 17 76709831 63 - -3.60 6.6E-04 1.2E-02 
TRIM29 11 119514208 -135 + -3.59 6.8E-04 1.2E-02 
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PYCARD 16 31121902 -150 + -3.58 6.9E-04 1.2E-02 
VAMP8 2 85658114 -114 + -3.57 7.2E-04 1.2E-02 
CREBBP 16 3871424 -712 - -3.57 7.2E-04 1.2E-02 
NPR2 9 35781313 -1093 + -3.56 7.6E-04 1.3E-02 
IL1A 2 113259329 113 - -3.55 7.7E-04 1.3E-02 
KLK11 19 56224392 -1290 + -3.53 8.1E-04 1.3E-02 
SLC22A18 11 2877055 -472 - -3.53 8.3E-04 1.3E-02 
MPL 1 43576000 -62 + -3.53 8.3E-04 1.3E-02 
TMPRSS4 11 117452424 -552 + -3.52 8.4E-04 1.3E-02 
LMO2 11 33870264 148 + -3.52 8.5E-04 1.3E-02 
TFF2 21 42644733 -557 - -3.50 8.8E-04 1.4E-02 
NDN 15 21483412 131 - -3.50 9.0E-04 1.4E-02 
RARA 17 35717896 -1076 - -3.50 9.1E-04 1.4E-02 
EPHA2 1 16355354 -203 + -3.49 9.1E-04 1.4E-02 
WNT8B 10 102212572 -216 - -3.49 9.4E-04 1.4E-02 
KRAS 12 25295039 82 + -3.47 9.8E-04 1.5E-02 
HIC1 17 1904448 -565 - 3.47 9.9E-04 1.5E-02 
TSG101 11 18505322 -257 - -3.45 1.0E-03 1.5E-02 
HIF1A 14 61231504 -488 + -3.45 1.1E-03 1.5E-02 
ABCB4 7 86947255 429 + -3.44 1.1E-03 1.5E-02 
S100A2 1 151806116 -1186 + -3.44 1.1E-03 1.5E-02 
ACTG2 2 73973146 -455 - -3.42 1.1E-03 1.6E-02 
PIK3R1 5 67557911 -307 + -3.42 1.1E-03 1.6E-02 
IRAK3 12 64869271 -13 + -3.42 1.1E-03 1.6E-02 
GDF10 10 48059133 39 + 3.42 1.2E-03 1.6E-02 
PTPRH 19 60412481 173 + -3.41 1.2E-03 1.6E-02 
JAK3 19 17820875 -1075 - -3.40 1.2E-03 1.6E-02 
GABRG3 15 25343690 -75 + -3.40 1.2E-03 1.6E-02 
KRT5 12 51200314 196 - -3.39 1.2E-03 1.6E-02 
SRC 20 35406602 100 - -3.39 1.3E-03 1.6E-02 
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BCAP31 X 152644153 . + -3.38 1.3E-03 1.7E-02 
ASB4 7 94953168 -52 - -3.37 1.3E-03 1.7E-02 
ZIM2 19 62043777 110 + -3.37 1.4E-03 1.7E-02 
IL12B 5 158690034 25 + -3.36 1.4E-03 1.7E-02 
RET 10 42892087 -446 + 3.35 1.4E-03 1.8E-02 
CPA4 7 129718965 -1265 - -3.34 1.5E-03 1.8E-02 
MCF2 X 138553543 -1024 - -3.34 1.5E-03 1.8E-02 
CDK10 16 88280653 74 + -3.33 1.5E-03 1.8E-02 
VAMP8 2 85657987 -241 + -3.33 1.5E-03 1.8E-02 
ZP3 7 75864584 -220 + -3.33 1.5E-03 1.8E-02 
MLH3 14 74587814 72 + -3.33 1.5E-03 1.8E-02 
DIO3 14 101097351 -90 + 3.33 1.5E-03 1.8E-02 
PSCA 8 143759274 359 + -3.31 1.6E-03 1.8E-02 
TES 7 115637635 -182 + 3.31 1.6E-03 1.8E-02 
CCR5 3 58097 -630 - -3.31 1.6E-03 1.8E-02 
KLF5 13 72531130 -13 + 3.31 1.6E-03 1.8E-02 
WRN 8 31009351 -969 + -3.31 1.6E-03 1.8E-02 
IAPP 12 21417365 280 + -3.30 1.6E-03 1.9E-02 
STK23 X 152699886 182 - -3.30 1.7E-03 1.9E-02 
GUCY2F X 108612196 -255 + -3.29 1.7E-03 1.9E-02 
THBS1 15 37660072 -500 + -3.27 1.8E-03 2.0E-02 
GLA X 100549950 -343 - -3.27 1.8E-03 2.0E-02 
EPHX1 1 224078241 -1358 - -3.27 1.8E-03 2.0E-02 
IFNG 12 66839976 -188 + -3.27 1.8E-03 2.0E-02 
LTA 6 31648100 28 - -3.26 1.9E-03 2.0E-02 
UNG 12 108019628 -170 + -3.24 2.0E-03 2.1E-02 
CXCL9 4 77147397 268 - -3.22 2.1E-03 2.2E-02 
TDGF1 3 46594270 53 - -3.22 2.1E-03 2.2E-02 
ETS1 11 127897118 253 - 3.22 2.1E-03 2.2E-02 
RUNX3 1 25164455 -393 - -3.22 2.1E-03 2.2E-02 
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EPHA2 1 16355491 -340 - -3.22 2.1E-03 2.2E-02 
SIN3B 19 16800611 -607 + -3.22 2.1E-03 2.2E-02 
SFTPB 2 85749512 -689 - -3.21 2.2E-03 2.2E-02 
ZIM2 19 62043909 -22 + -3.20 2.2E-03 2.2E-02 
JAK3 19 17819956 -156 - -3.20 2.2E-03 2.3E-02 
TMPRSS4 11 117453059 83 + -3.19 2.3E-03 2.3E-02 
KRAS 12 25295772 -651 + 3.18 2.4E-03 2.3E-02 
TMEFF2 2 192767395 494 - -3.17 2.4E-03 2.4E-02 
CHI3L2 1 111571578 -226 + -3.16 2.5E-03 2.4E-02 
PTK2 8 142081249 -735 - -3.16 2.5E-03 2.4E-02 
ODC1 2 10506328 -424 + 3.14 2.6E-03 2.5E-02 
CD34 1 206151645 -339 - -3.14 2.6E-03 2.5E-02 
MMP7 11 101906629 59 + -3.14 2.7E-03 2.6E-02 
KLK11 19 56223205 -103 - -3.13 2.7E-03 2.6E-02 
SFTPC 8 22075126 13 + -3.12 2.8E-03 2.6E-02 
GABRA5 15 24742740 44 - -3.12 2.8E-03 2.6E-02 
ACVR1 2 158404019 -983 + -3.10 2.9E-03 2.7E-02 
HDAC11 3 13496268 -556 + 3.10 3.0E-03 2.7E-02 
IL16 15 79262162 -93 - -3.10 3.0E-03 2.7E-02 
PI3 20 43235518 -1394 - -3.08 3.1E-03 2.9E-02 
GPATC3 1 27099954 -410 - -3.08 3.1E-03 2.9E-02 
ELK3 12 95111824 -514 + -3.07 3.3E-03 2.9E-02 
WNT5A 3 55496328 43 + 3.06 3.3E-03 3.0E-02 
DDR2 1 160869183 331 + -3.04 3.5E-03 3.1E-02 
TRIP6 7 100301891 -1090 + -3.03 3.7E-03 3.2E-02 
FGF7 15 47502707 -44 + -3.03 3.7E-03 3.2E-02 
TGFB3 14 75517184 58 - -3.02 3.7E-03 3.3E-02 
HBII-52 15 22966310 -659 + -3.01 3.8E-03 3.3E-02 
EPS8 12 15834038 -437 + -3.01 3.9E-03 3.3E-02 
TCF7L2 10 114700008 -193 - -3.01 3.9E-03 3.3E-02 
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ITGB4 17 71229255 144 + -3.00 4.0E-03 3.4E-02 
DLL1 6 170441784 -386 + 2.98 4.2E-03 3.6E-02 
MST1R 3 49916161 -87 - -2.98 4.2E-03 3.6E-02 
DSG1 18 27152342 292 + -2.97 4.3E-03 3.6E-02 
UGT1A7 2 234254572 -751 - -2.97 4.3E-03 3.6E-02 
B3GALT5 21 39950794 -330 + -2.97 4.4E-03 3.6E-02 
ACTG2 2 73973699 98 - -2.96 4.4E-03 3.6E-02 
CARD15 16 49288249 -302 - -2.95 4.6E-03 3.7E-02 
UGT1A1 2 234333094 -564 - -2.95 4.6E-03 3.7E-02 
ALK 2 29997753 183 - 2.93 4.8E-03 3.9E-02 
MMP9 20 44070765 -189 + -2.93 4.8E-03 3.9E-02 
ALOX12 17 6840213 85 - -2.93 4.8E-03 3.9E-02 
GABRG3 15 25343888 123 - -2.93 4.9E-03 3.9E-02 
MAS1 6 160247307 -657 - -2.92 5.0E-03 3.9E-02 
CHD2 15 91243972 -451 + -2.92 5.0E-03 3.9E-02 
TNFRSF10C 8 23016372 -7 + -2.92 5.0E-03 3.9E-02 
GNG7 19 2603280 310 - -2.91 5.1E-03 4.0E-02 
CDH17 8 95290518 -532 + -2.90 5.2E-03 4.1E-02 
CSF3 17 35425456 242 - -2.90 5.2E-03 4.1E-02 
DSG1 18 27151891 -159 - -2.90 5.3E-03 4.1E-02 
FZD9 7 72485870 -175 + -2.90 5.3E-03 4.1E-02 
HLA-DPA1 6 33149321 35 - -2.89 5.4E-03 4.1E-02 
ICAM1 19 10243021 242 + -2.89 5.4E-03 4.1E-02 
PLSCR3 17 7239318 -751 - -2.88 5.5E-03 4.2E-02 
NOS2A 17 23151970 -288 - -2.87 5.7E-03 4.3E-02 
DIRAS3 1 68288993 55 - -2.86 5.8E-03 4.3E-02 
DSC2 18 26936285 90 + -2.86 5.9E-03 4.4E-02 
DIRAS3 1 68289793 -745 + -2.85 6.1E-03 4.5E-02 
SFN 1 27062338 118 + -2.85 6.1E-03 4.5E-02 
OSM 22 28993028 -188 + -2.84 6.2E-03 4.5E-02 
74 
 
HOXA9 7 27171422 252 - -2.84 6.2E-03 4.5E-02 
STK23 X 152699680 -24 + -2.84 6.3E-03 4.5E-02 
APOC1 19 50109355 -406 - -2.83 6.3E-03 4.6E-02 
TAL1 1 47468847 -817 + -2.83 6.4E-03 4.6E-02 
KRT1 12 51361244 -798 - -2.82 6.5E-03 4.6E-02 
BCAM 19 50004278 100 - -2.82 6.5E-03 4.6E-02 
SYBL1 X 154764230 23 - -2.82 6.5E-03 4.6E-02 
MMP8 11 102100779 89 - -2.81 6.7E-03 4.7E-02 
TESK2 1 45729672 -252 - -2.81 6.7E-03 4.7E-02 
ATP10A 15 23660110 -147 + -2.81 6.7E-03 4.7E-02 
TNFSF8 9 116732333 258 - -2.81 6.8E-03 4.7E-02 
MSH3 5 79986053 3 + -2.80 6.9E-03 4.8E-02 
GNAS 20 56848104 -86 + -2.80 6.9E-03 4.8E-02 
ERBB2 17 35097860 -59 - -2.80 6.9E-03 4.8E-02 
PTGS1 9 124173130 80 + -2.79 7.0E-03 4.8E-02 
TNFSF10 3 173723965 -2 - -2.79 7.1E-03 4.8E-02 
TRIM29 11 119513884 189 + -2.79 7.2E-03 4.9E-02 
ITGA2 5 52321134 120 + -2.78 7.4E-03 5.0E-02 
EDNRB 13 77447813 -148 - -2.77 7.4E-03 5.0E-02 
KRT13 17 36916067 -676 + -2.77 7.5E-03 5.0E-02 
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Table 2.8. Significantly enriched gene sets for genes identified as differentially methylated in cases from the cluster identified with 
worst survival (Cluster 5) compared to all other cases. 
Name Size 
Enrichment 
Score (ES) 
Normalized 
Enrichment 
Score (NES) 
Nominal P-
Value 
FDR Q-
Value 
POSITIONAL GENE SETS 
CHR 7q21 5 -0.68 -1.70 0.015 0.148 
GENE ONTOLOGY - BIOLOGICAL PROCESSES 
Negative Regulation of Cellular Metabolic Process 12 0.51 2.29 0.000 0.043 
Negative Regulation of Metabolic Process 12 0.51 2.21 0.000 0.046 
Homeostatic Process 10 0.56 2.20 0.004 0.032 
Chemical Homeostasis 7 0.56 1.89 0.018 0.154 
Interphase 5 0.67 1.88 0.006 0.129 
Interphase of Mitotic Cell Cycle 5 0.67 1.87 0.024 0.121 
Regulation of Biological Quality 21 0.32 1.78 0.032 0.166 
Cell Fate Commitment 5 0.62 1.73 0.037 0.184 
GENE ONTOLOGY - MOLECULAR FUNCTION 
Purine Ribonucleotide Binding 11 0.48 1.98 0.000 0.192 
Purine Nucleotide Binding 11 0.48 1.97 0.013 0.098 
Nucleotide Binding 11 0.48 1.96 0.012 0.071 
ATP Binding 10 0.47 1.83 0.007 0.122 
Adenyl Nucleotide Binding 10 0.47 1.83 0.011 0.098 
Adenyl Ribonucleotide Binding 10 0.47 1.82 0.012 0.082 
Kinase Activity 29 0.27 1.81 0.028 0.073 
Transferase Activity - Transferring Phosphorus Containing 
Groups 29 0.27 1.72 0.030 0.098 
Protein Kinase Activity 28 0.26 1.71 0.027 0.095 
Magnesium Ion Binding 5 0.62 1.69 0.024 0.090 
Phosphotransferase Activity - Alcohol Group as Acceptor 28 0.26 1.62 0.036 0.114 
Protein Serine Threonine Kinase Activity 14 0.34 1.59 0.034 0.122 
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CHAPTER 3. PRETREATMENT DIETARY INTAKE IS ASSOCIATED WITH 
TUMOR SUPPRESSOR DNA METHYLATION IN HEAD AND NECK 
SQUAMOUS CELL CARCINOMAS 
3.1 Abstract 
Background: Diet is associated with cancer prognosis, including head and neck 
cancer (HNC), and has been hypothesized to influence epigenetic state by 
determining the availability of functional groups involved in the modification of 
DNA and histone proteins.  
Objective: To describe the association between pretreatment diet and HNC 
tumor DNA methylation. 
Methods: Information on usual pretreatment food and nutrient intake was 
estimated via food frequency questionnaire (FFQ) on 49 HNC cases. Tumor DNA 
methylation patterns were assessed using the Illumina Goldengate Methylation 
Cancer Panel. First, a methylation score, the sum of individual hypermethylated 
tumor suppressor associated CpG sites, was calculated and associated with 
dietary intake of micronutrients involved in one-carbon metabolism and 
antioxidant activity, and food groups abundant in these nutrients. Second, gene 
specific analyses using linear modeling with empirical Bayesian variance 
estimation were conducted to identify if methylation at individual CpG sites was 
associated with diet. All models were controlled for age, sex, smoking, alcohol, 
and HPV status. 
Results: Individuals reporting in the highest quartile of folate, vitamin B12, and 
vitamin A intake, compared to those in the lowest quartile, had significantly less 
tumor suppressor gene methylation (p=0.04, 0.04, and p=0.01, respectively), as 
did patients reporting the highest cruciferous vegetable intake (p=0.04). Gene 
specific analyses, identified differential associations between DNA methylation 
and vitamin B12 and vitamin A intake when stratifying by HPV status. 
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Conclusions: These preliminary results suggest that intake of folate, vitamin A, 
and vitamin B12 may be associated with the tumor DNA methylation profile in 
HNC, and enhance tumor suppression.  
3.2 Introduction 
Head and neck cancer (HNC) is the sixth most common type of cancer 
and accounts for approximately 5% of all new cancer diagnoses worldwide each 
year (Argiris et al. 2008; Ferlay et al. 2010). These malignancies develop from 
the epithelial tissue of the oral cavity, nasopharynx, oropharynx or larynx, and 
more than 90% are of squamous cell histologic type. HNC is most often 
associated with extensive lifetime exposure to tobacco and alcohol consumption, 
although high-risk human papillomavirus (HPV) has recently emerged as the 
primary etiologic factor responsible for an increasing number of oropharyngeal 
tumors (Chaturvedi et al. 2011; Maxwell et al. 2010).  
Epidemiologic evidence also supports the hypothesis that diet modulates 
risk, progression and prognosis of head and neck cancer (Duffy et al. 2009; 
Lucenteforte et al. 2009; Sandoval et al. 2009). However, the molecular 
mechanisms by which dietary compounds exert their effects are not entirely 
understood. Epigenetic dysregulation is a key mechanism in tumorigenesis that 
may be influenced by dietary intake. Aberrant DNA methylation in cancer is 
typically characterized by gene promoter specific hypermethylation, leading to 
gene silencing, and hypomethylation of intergenic regions, leading to overall 
genomic instability (Ehrlich 2002; McKay and Mathers 2011).  
Dietary intake has been widely hypothesized to influence epigenetic state 
by determining the availability of functional groups involved in the covalent 
modification of DNA and histone proteins (Burdge et al. 2007; Oommen et al. 
2005). Specifically, nutrients that act as methyl donors, such as methionine and 
folate, or nutrients that act as cofactors in one carbon metabolism pathway, such 
as betaine, vitamin B12, and choline, are required for establishment and 
maintenance of methylation marks both on DNA and histone protein tails 
(Cooney et al. 2002; Dobosy et al. 2008; Keyes et al. 2007; Waterland and Jirtle 
2003; Waterland et al. 2006). A deficiency or excess of any of the nutrients 
involved in one-carbon metabolism can potentially alter the availability of S-
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adenosylmethione (SAM), the universal donor involved in DNA methylation, and 
ultimately alter epigenetic state (McKay and Mathers 2011). In addition to diet, it 
has been shown that in smokers, chronic DNA damage coupled with reduced 
DNA repair capacity may induce gene promoter methylation (Leng et al. 2008). 
Given these findings we hypothesize that, in addition to micronutrients involved in 
one-carbon metabolism, micronutrients involved in cell growth and differentiation, 
such as vitamin A, or with antioxidant activity such as vitamin C, vitamin E and β-
carotene may indirectly influence DNA methylation by reducing DNA damage 
(Stidley et al. 2010). 
The objective of this study was to test the hypothesis that pretreatment 
dietary intake of methyl donors, antioxidants, and foods abundant in these 
micronutrients is associated with tumor DNA methylation in head and neck 
cancer. A better understanding of how dietary intake is associated with tumor 
DNA methylation in head and neck cancer will enhance our knowledge of 
disease pathogenesis and may allow for the development of individualized 
medical nutrition therapy regimens.  
3.3 Methods 
Design 
This was a cross-sectional study of patients enrolled in the University of 
Michigan Head and Neck Cancer Specialized Program of Research Excellence 
(SPORE). The independent variables were micronutrients involved in one-carbon 
metabolism, antioxidant nutrients, and food groups abundant in these 
micronutrients.  Confounding variables included age, sex, smoking, alcohol 
problem and HPV-status.  The outcome variable was DNA methylation. Our 
analyses were limited to foods and nutrients we hypothesized are associated 
with DNA methylation—namely those involved in one-carbon metabolism or with 
antioxidant activity.  A two-tiered analysis was conducted; first we observed 
whether dietary intake is associated with methylation at CpG sites in tumor 
suppressor genes overall and second, we observed whether DNA methylation at 
specific CpG sites is associated with dietary intake.   
Study Population  
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Sixty-eight newly diagnosed cases of head and neck cancer were 
identified and recruited at two sites participating in the University of Michigan 
Head and Neck SPORE: the University of Michigan Health System and the Ann 
Arbor Veterans Administration (VA) Medical Center. Individuals eligible for 
participation included patients diagnosed with first primary head and neck cancer 
between January 1, 2003 and December 31, 2005 who signed written, informed 
consent, completed an epidemiologic questionnaire that includes questions on 
demographic and behavioral data, and had a paraffin-embedded tumor available 
for analysis with adequate residual tissue for microdissection. Exclusion criteria 
included: 1) < 18 years of age; 2) pregnant; 3) non-English speaking; 4) 
diagnosed as mentally unstable; or 5) a diagnosis of another non-upper 
aerodigestive tract cancers (such as thyroid or skin cancer). For the purposes of 
the current analysis, patients were excluded if they had not completed a baseline 
FFQ (n = 19), yielding a final sample size of 49 participants. Excluded patients 
did not differ significantly from included patients in respect to age, sex, tumor 
site, cancer stage or smoking status. This study was approved as being within 
the ethical standards of the Institutional Review Boards of the University of 
Michigan and the Ann Arbor VA Medical Center.  
Tumor blocks were recut for uniform histopathologic review and 
microdissection, with the first and last slides of a series of 12 reviewed by a 
qualified pathologist (JM and ND) to confirm the original diagnosis and to circle 
areas for DNA extraction. Percent cellularity was estimated for each tumor, and 
areas with >70% cancer cellularity were designated for use in the analyses.  
Measures 
FFPE tissue, DNA isolation, and bisulfite conversion  
Regions that were identified for DNA extraction were cored from the 
formalin fixed paraffin embedded (FFPE) tissue blocks using an 18 gauge 
needle. Isolation of DNA from the cored tissue samples was performed using the 
QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA) with a modification to the 
manufacturer’s recommended lysis protocol (incubation overnight at 56oC in lysis 
buffer). DNA concentration and purity was confirmed via NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, MA). We performed sodium 
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bisulfite modification on 500ng to 1µg of DNA using the EZ DNA Methylation kit 
(Zymo Research, Orange, CA) following the manufacturer’s recommended 
protocol. 
Bead Array Methods 
The commercially available Illumina Goldengate® Methylation Cancer 
Panel was utilized to detect DNA methylation patterns in tumor samples. The 
Cancer Panel interrogates 1505 CpG sites located in known CpG islands across 
807 genes related to cancer, including oncogenes, tumor suppressor genes, 
imprinted genes, and genes involved in cell cycle regulation, DNA repair, 
apoptosis and metastasis. Bead arrays were run at the University of Michigan 
DNA Sequencing Core Facility according to the manufacturer’s protocol. Briefly, 
bisulfite converted tumor DNA was hybridized to the bead array as described 
previously(Bibikova et al. 2006), and bead arrays were imaged using Illumina 
Cancer Panel Reader software. Raw bead array fluorescence data was initially 
analyzed using Illumina BeadStudio Methylation software, which converts 
fluorescence values of the methylated (Cy5) and unmethylated (Cy3) alleles into 
an average methylation value at a specific probe using the formula β =[Max(Cy5,0)]/[Max(Cy5,0) + Max(Cy3,0) + 100] with β ϵ (0,1). 
Methylation at specific CpG probes on the Goldengate Cancer Panel has 
been shown to be biased by probe thermodynamic properties (Kuan et al. 2010). 
Known biases include probe length and GC content, which can affect the melting 
temperature of the probes as well as probe fluorescence intensities. Thus, we 
used the method proposed by Kuan et al. to normalize our average β values 
based on probe length and GC content (Kuan et al. 2010). 
Detection p-values on the Goldengate Cancer Panel are calculated based 
on fluorescence signal at a probe compared to background fluorescence and 
represent one minus the probability) that a signal is stronger than background 
fluorescence. The weighted methodology proposed by Kuan et al. was used to 
develop sample and site weights based on p-values of detection. Both samples 
and sites with larger detection p-values are generally considered less reliable 
and were down-weighted in further gene specific analyses. 
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Dietary Intake Estimation 
Dietary components of interest in this study included antioxidant 
micronutrients, micronutrients involved in one-carbon metabolism, and food 
groups serving as rich sources of these micronutrients including cruciferous 
vegetables, green leafy vegetables, dark yellow vegetables, refined grains, whole 
grains, red meat, and legumes. Pre-treatment dietary intake was collected using 
a self-administered, semi-quantitative FFQ, designed to assess respondents’ 
usual dietary intake from food and supplements over the year prior to diagnosis. 
The reproducibility and validity of this 131-item questionnaire has been reported 
previously (Rimm et al. 1992; Willett 1998; Willett et al. 1985).  The FFQ includes 
given standard portion sizes for each item (i.e. 1 orange or 3-5 oz chicken) which 
allowed participants to choose their average frequency of consumption over the 
past year from a list of 1-9 choices ranging from “almost never” to “≥6 times per 
day”. Daily energy and nutrient intake was estimated by summing intakes from 
each food based on the given standard portion size, reported frequency of 
consumption, and nutrient content of each food item (Willett 1998). Daily food 
group servings were estimated by summing the frequency weights of each food 
item based on reported daily frequencies of consumption.  
Covariates 
Each participant completed a self-administered health questionnaire at 
baseline. This questionnaire was designed to collect demographic data as well 
as data on smoking, alcohol use, physical activity, sleep, comorbidities, 
depression and quality of life. Age, sex, smoking and alcohol data were collected 
from the health questionnaire. Smoking data permitted analysis by “current-past-
never” smoking. Alcohol consumption was measured using the previously 
validated Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al. 
1993). An AUDIT score ≥8 was considered problem drinking. Tumor site and 
stage was recorded from operative notes and surgical pathology forms at 
baseline. As we have previously shown HPV status to be associated with both 
tumor DNA methylation profiles at specific gene promoter regions (Sartor et al. 
2011b) and micronutrient intake (Arthur et al. 2011), we considered HPV status 
as a potential confounder in statistical analyses. 
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HPV status was determined by an ultra-sensitive method using real-time 
competitive polymerase chain reaction and matrix-assisted laser 
desorption/ionization-time of flight mass spectroscopy with separation of products 
on a matrix-loaded silicon chip array. Multiplex PCR amplification of the E6 
region of 15 discrete high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68 and 73), and human GAPDH control was run to saturation 
followed by shrimp alkaline phosphatase quenching. Amplification reactions 
included a competitor oligo identical to each natural amplicon except for a single 
nucleotide difference. Probes that identify unique sequences in the oncogenic E6 
region of each type were used in multiplex single base extension reactions 
extending at the single base difference between wild-type and competitor HPV so 
that each HPV type and its competitor were distinguished by mass when 
analyzed on the MALDI-TOF mass spectrometer. 
Statistical Methods 
Methylation Score 
To create a measurement of stochastic methylation across genes that 
could be associated with dietary intake, we developed a novel method of 
calculating a methylation score based on methylation of genes associated with 
specific cellular functions. Since the Goldengate Cancer Panel quantifies 
methylation of cancer-related genes with various functions, we first subsetted 
genes associated with our main cellular function of interest, tumor suppression. 
To identify genes associated with tumor suppression, we conducted a simply 
query of the National Center for Biotechnology Information (NCBI) Gene 
database for “tumor suppressor” and extracted Gene IDs. A total of 444 
individual CpG sites across 237 genes on the Goldengate Cancer Panel were 
linked to tumor suppression. Next, for each study participant, the methylation 
score was defined as the number of tumor suppressor gene-associated CpG 
sites with normalized average β values above 0.5. A β value cutoff of 0.5 was 
established as a methylation level likely to result in decreased expression of 
tumor suppressor genes. Thus, the methylation score ranged from 0 to 444. We 
infer that a higher methylation score is associated with higher levels of DNA 
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methylation of promoter regions of genes associated with tumor suppression and 
cell cycle regulation. 
Micronutrients were adjusted for total energy intake using the residual 
method (Willett et al. 1997). Descriptive statistics, including means, medians, 
maxima and minima were calculated for both the energy adjusted nutrients and 
the methylation score. Associations between energy-adjusted micronutrient 
intake, food group intake, and methylation score were assessed with Spearman 
rank correlation due to the typical non-normal distribution of micronutrient and 
food group intake. Additionally, we used linear regression models with 
methylation score as the outcome and energy-adjusted micronutrient or food 
group intake as the main predictor, categorizing dietary variables into quartiles, 
and adjusting for age, sex, smoking status, problem alcohol drinking, and HPV 
status, as well as analyzing for trend by treating the quartiles as a continuous 
variable in regression analysis. To examine the robustness of our findings, we 
performed a sensitivity analysis in which we categorized micronutrient intake into 
tertiles as opposed to quartiles and adjusted for the same covariates. Regression 
diagnostic plots were examined to ensure that associations observed were not 
being driven by influential points. All analyses were performed in SAS software, 
Version 9.2 or R Version 2.13.0.   
Site Specific Analyses 
To determine whether methylation at specific sites of the genome may be 
labile to effects due to dietary intake, we calculated associations between DNA 
methylation at specific CpG sites and dietary intake, stratifying by HPV status. To 
limit the number of multiple comparisons conducted, we restricted our analysis to 
micronutrients identified as significant in the tumor suppressor gene methylation 
score analysis following sensitivity analysis, vitamin B12 and vitamin A, and 
compared site specific DNA methylation between highest and lowest quartile of 
intake. 
The association between micronutrient intakes and individual CpG site 
DNA methylation at the 1505 CpG sites measured on the Goldengate Cancer 
Panel were examined using the Limma package in R 2.10.1 (Smyth 2004). 
Sample weights based on detection p-values across samples were used in the 
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lmFit function from the Limma package to downweight samples with higher 
detection p-values. An empirical Bayes method (using the eBayes function in 
Limma) was used to shrink standard errors to a common value and to rank CpG 
sites in order of differential methylation. Multiple comparisons were accounted for 
using the q-value method previously described (Storey and Tibshirani 2003). 
Micronutrient intakes were categorized into quartiles, and differences in individual 
CpG site methylation between the highest and lowest quartile of intake were 
calculated, adjusting for age, sex, smoking status, and problem drinking.  
Based on the site specific analyses, we used Gene Set Enrichment 
Analysis (GSEA) to identify common pathways and chromosomal locations for 
genes identified as differentially methylated by micronutrient intake 
(Subramanian et al. 2005). All sites were ranked by t-value and input into GSEA 
as a ranked list. The full list of genes assayed on the Goldengate Cancer Panel 
was input into GSEA as a chip platform file, which provided the background for 
the enrichment analysis. Weighted enrichment statistics were calculated by the 
GSEA software, using a minimum gene set size of 5 to account for the limited 
number of genes assayed by the Goldengate Cancer Panel. Enrichment at the 
nominal p-value of 0.05 and an adjusted q-value of 0.25 was considered 
statistically significant. 
3.4 Results 
Descriptive Statistics: Study Sample 
The mean age of the 49 study participants with both dietary intake and 
methylation data was 57.3 years (range 41-75 years); 80% of the participants 
were male. The majority of the cancer sites were oropharynx (53%), evidenced 
by the relatively high proportion of HPV(+) cases (43%). Approximately 85% of 
the study participants reported being current or former smokers, with an 
estimated one-third reporting an alcohol problem. Clinical characteristics are 
displayed in Table 3.1.  
Dietary Intake Associations with Tumor Suppressor Methylation 
Reported average daily intakes of micronutrients and food group servings 
reported by study participants are presented in Table 3.2. The distribution of the 
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tumor suppressor methylation score for all subjects is shown in Figure 3.1. Table 
3.3 shows associations across quartiles of micronutrient and food group intake 
and tumor suppressor DNA methylation. Higher antioxidant, methyl donor and 
food group intake tended to be negatively associated with tumor suppressor 
methylation score, the sum of individual hypermethylated tumor suppressor 
associated CpG sites, suggesting an inverse relationship between DNA 
methylation at promoter regions of these genes and micronutrient intake. The 
regression coefficients in Table 3.3 can be interpreted as the number of CpG 
sites of genes associated with tumor suppression activity that are methylated 
more than 50% compared to individuals in the lowest quartile of intake. 
Specifically, individuals in the lowest quartiles of dietary folate, vitamin B12, and 
vitamin A intake were found to have significantly higher tumor suppressor 
methylation scores compared to individuals in the highest quartiles of intake. 
Additionally, tests for trend across quartiles of intake for dietary folate, vitamin 
B12, and vitamin A intake indicated statistically significantly higher methylation 
score with each decreasing quartile (Table 3.3). Individuals in the lowest quartile 
of cruciferous vegetable intake had a significantly higher tumor suppressor 
methylation score than individuals in the highest quartile of intake, and the test 
for trend across quartiles was also statistically significant (p=0.013). Interestingly, 
individuals consuming the highest servings per day of refined grains had 
significantly higher tumor suppressor methylation score than individuals 
consuming the lowest servings per day of refined grains. However the test for 
trend across quartiles of intake for refined grains was not statistically significant. 
In a sensitivity analysis, in which we categorized micronutrient intake into 
tertiles as opposed to quartiles and adjusted for the same covariates, our findings 
were similar to the findings reported above in that individuals in the lowest tertile 
of vitamin B12, vitamin A, and cruciferous vegetable intake had significantly 
higher tumor suppressor methylation score than those in the highest tertile of 
intake (β = 18.4, β = -18.2, and β = 18.2, respectively; data not shown). The tests 
for trend across tertiles of intake for the relationship between vitamin B12, 
vitamin A, and cruciferous vegetables and tumor suppressor methylation score 
were also significant (Ptrend = 0.015, Ptrend = 0.034, and Ptrend= 0.022, 
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respectively). The inverse association between tumor suppressor methylation 
score and food folate was no longer statistically significant (β = -14.7 for tertile 3 
versus tertile 1, Ptrend = 0.074).  
CpG Site Specific Associations with Vitamin A and Vitamin B12 Intake 
With respect to vitamin A intake, there were no significant associations 
with site-specific DNA methylation for HPV(+) individuals (all adjusted p-values 
>0.15). In contrast, a number of CpG sites were differentially methylated for 
HPV(-) individuals with the highest levels of both vitamin A and vitamin B12 
intake compared to those with the lowest levels of intake. Interestingly, vitamin 
B12 intake was also associated with hypomethylation of a CpG site associated 
with RARB (retinoic acid receptor beta) in HPV(+) individuals after adjusting for 
multiple comparisons (adjusted p-value <0.05).  The ten sites identified as the 
most significantly differentially methylated by both vitamin A and vitamin B12 
intake in HPV(-) individuals, as well as the one site differentially methylated by 
vitamin B12 intake in HPV(+) individuals are shown in Table 3.4. Consistent with 
the findings of the methylation score analysis, the most differentially methylated 
CpG sites were, by and large, hypomethylated in tumors from individuals in the 
highest quartile of vitamin A and vitamin B12 intake compared to tumors from 
individuals in the lowest quartiles of intake. There was one exception, CHGA 
(Chromogranin A), which was hypermethylated in tumors from HPV(-) negative 
individuals who consumed the largest amounts of vitamin B12. CpG sites 
associated with C4B (Complement Component 4B), GML 
(Glycosylphosphatidylinositol anchored molecule like protein), MLF1 (Myeloid 
Leukemia Factor 1), and THPO (Thrombopoietin) were significantly associated 
with methylation in tumors from HPV(-) individuals based on both vitamin A and 
vitamin B12 intake. 
Table 3.5 presents the results of the ranked Gene Set Enrichment 
Analysis (GSEA). An enrichment analysis, by genomic location, of genes 
differentially methylated by vitamin B12 intake in HPV(+) cancers revealed a 
trend towards hypomethylation of chromosome 12p12 with increased vitamin 
B12 intake. The same chromosomal region was identified as hypomethylated in 
tumors from HPV(-) individuals with the highest levels of vitamin A intake, as was 
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chromosome 8p21. While there was no consistent enrichment of Gene Ontology 
Biological Processes or Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways based on dietary intake for HPV(-) tumors, for HPV(+) tumors there 
was a significant enrichment of processes involved in immune function based on 
vitamin B12 intake.  
3.5 Discussion 
To our knowledge, this is the first study to comprehensively examine the 
association between dietary intake and promoter methylation of genes related to 
head and neck cancer. These novel findings suggest diet is significantly 
associated with epigenetic events that occur in head and neck cancer. While 
previous studies have indicated deficiencies of folate, vitamin B12 and vitamin A 
are associated with increased risk of developing head and neck cancer (Almadori 
et al. 2005; Lucenteforte et al. 2009; Nacci et al. 2008; Pelucchi et al. 2003) as 
well as with poorer prognosis in patients diagnosed with the disease (Kawakita et 
al. 2011), our study has shown a decrease in tumor suppressor methylation in 
the highest quartile of vitamin B12 and vitamin A intake. Epigenetic 
dysregulation, such as the silencing of tumor suppressor genes via promoter 
hypermethylation, is a major event in malignant disease. 
 Though the underlying biological mechanism related to how folate and 
vitamin B12 deficiencies may be associated with DNA hypermethylation has not 
been elucidated, we have two suggested hypotheses. First, folate and vitamin 
B12 play important roles in the synthesis of DNA and DNA damage repair (Blount 
et al. 1997; Choi and Mason 2000; Metz et al. 1968). Increases in DNA 
methylation have been observed in an experimental model inducing in vitro DNA 
damage, in the form of DNA strand breaks, and homology directed DNA repair 
(Cuozzo et al. 2007). An increased rate of DNA strand breaks was also observed 
in both animal models and cell culture models of folate deficiency (Branda and 
Blickensderfer 1993; Pogribny et al. 1995), potentially providing a mechanism 
that links folate deficiency, DNA strand breaks, and DNA methylation. Second, 
while the DNA methylation changes that occur in cancer have been well 
characterized, there is also interest in describing the DNA methylation changes 
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that occur with aging, as these changes could reflect what occurs in the early 
stages of carcinogenesis. A recent study has described that DNA methylation of 
two genes, ERα and SFRP1, in colon tissue increases with age and also with 
folic acid supplementation status (Wallace et al. 2010). In our study, we not only 
observed a decrease in tumor suppressor methylation in the highest quartile of 
vitamin A, vitamin B12 and food folate intake, but also a trend towards increased 
tumor suppressor methylation in the individuals who consumed the highest levels 
of refined grains. During the refinement process these grains are fortified with 
folic acid, niacin, riboflavin, thiamin and iron. It is unclear how these nutrients 
may be associated with increased DNA methylation and more research is 
necessary. The relative bioavailability of these nutrients could modulate the 
normal stochastic changes in methylation that occur due to aging and may be 
reflected in tumor DNA methylation.  
Other studies support our finding that increased consumption of folate and 
folate-rich foods are associated with decreased methylation of genes associated 
with tumor suppression. Another study conducted in head and neck cancer 
patients reported increased methylation of p16INK4a, a gene involved in cell cycle 
regulation that is commonly lost or silenced in head and neck cancer via 
epigenetic mechanisms, in those consuming the lowest levels of folate compared 
to the highest levels (Kraunz et al. 2006).  
Based on our findings that folate intake was inversely associated with 
tumor suppressor DNA methylation, it is not surprising that high cruciferous 
vegetable consumption was associated with lower methylation levels, given this 
food group is a rich source of folate. However, it is interesting to note that 
cruciferous vegetables are also rich sources of glucosinolates such as 
sulforphane and indole-3-carbinol, both of which are believed to exhibit anti-
cancer activities. Though there is little evidence suggesting involvement of 
sulforaphane in DNA methylation, this compound has been shown to act as a 
histone deacetylase (HDAC) inhibitor. HDACs have been shown to be widely 
overexpressed in a number of cancers and are involved in gene silencing by 
inducing a more condensed chromatin state, leaving DNA less accessible for 
transcription (Ropero and Esteller 2007). HDAC inhibitors, such as sulforaphane, 
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have been shown to be promising cancer therapies because of their ability to 
induce expression of epigenetically silenced genes (Marks et al. 2004).  
The finding that vitamin A intake is significantly associated with decreased 
DNA methylation in HPV(-) tumors is unexpected, considering vitamin A does not 
play a direct role in the one-carbon metabolism pathway. However, it is possible 
vitamin A can alter DNA methylation by influencing the availability and activity of 
methyltransferases. Two studies have reported rats treated with all-trans-retinoic 
acid (ATRA), a vitamin A metabolite, displayed increased levels and activity of 
glycine N-methyltransferase (GNMT), the enzyme involved in the conversion of 
S-adenosyl methionine (SAM) to S-adenosylhomocysteine (SAH) (Ozias and 
Schalinske 2003; Rowling et al. 2002). Increased GNMT activity led to a 
reduction of SAM, thus potentially resulting in a reduction of methylation. 
Similarly, Das et al reported demethylation of 402 gene promoters in 
neuroblastoma cells treated with ATRA. These cells also exhibited down-
regulation of the methyltransferases, DNMT1 and DNMT3B, which the authors 
proposed as the potential mechanism by which ATRA exerts its’ effect on DNA 
methylation(Das et al. 2010).  
The GSEA findings of this study confirm the previous work of our group 
and others describing the differences in tumor biology between HPV(+) and 
HPV(-) HNCs (Arthur et al. 2011; Sartor et al. 2011a). In this study, we identified 
that gene sets involved in immune function, including cytokine production and 
antigen processing and presentation, were significantly enriched based on DNA 
methylation differences in HPV(+) tumors from individuals with high and low 
levels of vitamin B12 intake. There was no consistent KEGG or Gene Ontology 
Biological Processes enriched in HPV(-) tumors, based on either vitamin A or 
vitamin B12 intake. A positional enrichment analysis identified the same 
chromosomal region, chromosome 12p12, as differentially methylated in HPV(+) 
tumors based on vitamin B12 intake as HPV(-) tumors based on vitamin A intake. 
This region has previously been identified as a candidate tumor suppressor 
region in head and neck and other cancers (Gunduz et al. 2005), and may 
represent a region of the genome that is more labile to the epigenetic influences 
of dietary intake. 
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 Results of this preliminary study should be interpreted in light of several 
limitations. Our small sample size poses analytic limitations in detecting 
associations of interest and the complexity of statistical tests used. Although we 
have adjusted for several covariates, there are no doubt other unmeasured 
sources of confounding we were not able to consider. The FFQ is susceptible to 
measurement error and potential unquantified systematic biases that may have 
led to misclassification of dietary intake. The FFQ was designed to assess usual 
dietary intake over the course of the year prior to diagnosis with HNC. Thus we 
cannot make any conclusions about the association between lifetime dietary 
exposures and tumor DNA methylation. While the Goldengate Cancer Panel 
provides a comprehensive measurement of methylation across 1505 CpG sites 
in promoter regions of genes with known roles in cancer, this technology does 
not provide an unbiased assessment of the epigenome. Finally, due to these 
limitations, the findings of this study should be validated in another set of tumors 
from similar individuals.  
  In conclusion, dietary intake of micronutrients involved in one-carbon 
metabolism such as folate and vitamin B12, as well as other micronutrients such 
as vitamin A, may be significant regulators of epigenetic events occurring in head 
and neck cancer. These findings have potential clinical implications for the 
treatment of head and neck cancer. The idea that dietary interventions could 
potentially reprogram the epigenome in such a way as to optimize the likelihood 
of positive disease outcomes is appealing. Further research is necessary to 
better understand the complex role these micronutrients play in regulating the 
epigenetic process, as well as how nutrients may differentially regulate this 
process according to HPV-status. Such studies could give rise to highly specific 
randomized controlled trials and ultimately to the development of individualized 
medical nutrition therapy regimens that may improve prognosis in the head and 
neck cancer population.  
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Figure 3.1. Histogram of the tumor suppressor methylation score, the sum of 
CpG sites with β values greater than 0.5.  
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Table 3.1. Clinical characteristics of the study participants (n=49) 
Patient Characteristic  N (%) Mean (SD), Median (range) 
Age    57.3(8.6), 55.0 (41-75) 
    
Gender Male 39 (80%)  Female 10 (20%) 
Stage  1 1 (2%) 
 
2 6 (12%) 
3 12 (24%) 
4 30 (61%) 
Cancer Site of first 
Primary  
Oral Cavity 9 (18%) 
 
Oropharynx 26 (53%) 
Hypopharynx 2 (4%) 
Larynx 10 (20%) 
Other 2 (4%) 
Tumor Tissue HPV (+) 
Status  21 (43%)  
Smoking Status  Never 9  (18%) 
  Past 32  (65%) 
Current 8  (16%) 
Alcohol Problem AUDIT >= 8 
and drank 
within 1 year. 
16 (32%)  
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Table 3.2. Summary of mean daily micronutrient and food group servings by quartile of consumption 
Dietary Component Quartile 1 Quartile 2 Quartile 3 Quartile 4 
  n = 12 n = 12 n = 13 n=12 
Micronutrients (energy-adjusted)     
    Total Folate (μg/d) 325 441 706 1294 
    Food Folate (μg/d) 202 269 330 422 
    Vitamin A (IU/d) 3869 6705 10594 222111 
    Vitamin B6 (mg/d) 1.8 2.5 3.8 10.5 
    Vitamin B12 (μg/d) 4.7 8.5 13.1 32.2 
    Vitamin C mg/day 64 114 243 1086 
    Vitamin D (IU/d) 77 183 462 835 
    Vitamin E (mg/d) 5.4 8.9 24.6 288 
    β-carotene (μg/d) 1022 1913 3353 9178 
    Methionine (g/d) 1.4 1.8 2.3 2.8 
Food Groups (servings/d)     
    Cruciferous Vegetables 0.02 0.1 0.22 0.62 
    Green leafy Vegetables 0.07 0.15 0.3 0.94 
    Dark Yellow & Orange 
Vegetables 0.03 0.09 0.19 0.45 
    Refined Grains 0.32 0.67 1.17 2.9 
    Whole Grains 0.07 0.36 0.86 2.11 
    Red Meat 0.18 0.4 0.66 1.43 
    Legumes 0.07 0.27 0.27 0.71 
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Table 3.3. Results of unadjusted and adjusted linear regression showing associations between tumor suppressor 
methylation score and quartile of energy adjusted micronutrient intake or intake of food group, setting Quartile 1 (lowest 
intake) as the reference category 
Unadjusted 
Micronutrient 
Quartile 2 β 
(S.E) 
Quartile 3 β 
(S.E) 
Quartile 4 β 
(S.E) 
P-Value for 
Trend 
Dietary Folate -4.3 (8.6) -7.0 (8.6) -16.8 (8.4) 0.047 
Total Folate 1.3 (8.7) -1.0 (8.7) -6.2 (8.7) 0.450 
Vitamin A -8.6 (8.6) -7.9 (8.6) -13.3 (8.6) 0.146 
Vitamin B6 -7.1 (8.6) -1.0 (8.6) -11.4 (8.6) 0.301 
Vitamin B12 -7.2 (8.0) -6.6 (8.2) -23.9 (8.2) 0.008 
Vitamin C 0.8 (8.6) 2.0 (8.6) -8.4 (8.6) 0.389 
Vitamin D -8.8 (8.6) -11.2 (8.6) -10.2 (8.6) 0.218 
Vitamin E -1.8 (8.8) -3.9 (8.8) -2.4 (8.8) 0.727 
Beta Carotene -3.3 (8.6) -7.5 (8.6) -13.1 (8.6) 0.111 
Methionine 1.5 (8.5) 11.7 (8.5) -4.4 (8.5) 0.932 
Cruciferous 
Vegetables -4.7 (8.0) -16.5  (8.0) -18.1 (8.5) 0.014 
Green Leafy 
Vegetables 0.7 (8.5) -6.1 (8.9) -6.6 (8.9) 0.343 
Dark Yellow 
Vegetables -5.3 (9.3) -5. 3 (9.0) -10.1 (8.4) 0.245 
Refined Grains 12.3 (8.5) 9.3 (8.8) 14.3 (8.7) 0.150 
Whole Grains 9.1 (8.7) 8.0 (9.3) -1.5 (8.8) 0.808 
Red Meat -17.8 (8.2) -11.3 (8.5) -12.4 (8.0) 0.185 
Legumes -5.6 (8.3) -5.4 (9.6) -9.8 (9.0) 0.307 
Adjusted* 
Dietary Folate -3.1 (8.9) -4.0 (9.5) -18.7 (8.9) 0.043 
Total Folate 4.6 (9.1) -3.2 (9.6) -9.1 (9.2) 0.258 
Vitamin A -13.3 (9.8) -15.1 (9.9) -21.1 (9.7) 0.040 
Vitamin B6 -5.5 (9.6) -2.2 (9.3) -12.9 (9.2) 0.219 
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Vitamin B12 -7.6 (8.8) -11.0 (8.7) -27.6 (8.8) 0.003 
Vitamin C 0.2 (8.9) -1.9 (9.4) -16.6 (9.3) 0.089 
Vitamin D -11.4 (9.3) -15.6 (9.5) -18.1 (9.8) 0.059 
Vitamin E -4.3 (9.2) -11.4 (9.8) -12.2 (9.9) 0.175 
Beta Carotene -3.4 (9.2) -12.5 (9.0) -15.6 (9.4) 0.055 
Methionine 3.9 (9.1) 9.6 (9.1) -7.9 (9.7) 0.687 
Cruciferous 
Vegetables -6.8 (8.5) -16.2 (8.5) -20.4 (9.2) 0.013 
Green Leafy 
Vegetables 4.8 (9.0) -8.7 (9.4) -10.9 (9.5) 0.183 
Dark Yellow 
Vegetables -6.8 (9.6) -15.4 (10.8) -15.4 (9.8) 0.098 
Refined Grains 15.3 (9.7) 13.5 (10.3) 22.6 (10.7) 0.069 
Whole Grains 10.2 (9.7) 0.8 (10.7) -3.8 (10.9) 0.542 
Red Meat -14.8 (10.3) -12.8 (10.5) -14.9 (11.8) 0.189 
Legumes -6.2 (8.9) -4.5 (10.6) -14.2 (10.6) 0.227 
* Adjusted for age, sex, smoking status, HPV status, and problem drinking. Food group 
analyses also adjusted for total calorie consumption. 
Bold text indicates p<0.05 
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Table 3.4. CpG sites with tumor DNA methylation values significantly different 
between highest (4th quartile) and lowest (1st quartile) of vitamin B12 and vitamin 
A intake, stratified by HPV status. 
Gene 
Symbol 
Chromosom
e 
CpG 
Coordinate 
Distanc
e to 
TSS 
T-
Valu
e 
P-Value 
Adjuste
d P-
Value 
HPV Positive Cases - Methylation by Vitamin B12 Intake 
RARB 3 25444872 114 -5.72 3.18E-05 0.0479 
HPV Negative Cases - Methylation by Vitamin B12 Intake 
C4B 6 32057984 171 -5.39 1.79E-05 0.0178 
GML 8 
14391293
8 -281 -5.23 2.64E-05 0.0178 
PTHR1 3 46893982 -258 -5.11 3.55E-05 0.0178 
MLF1 3 
15977192
1 243 -4.78 8.14E-05 0.0306 
THPO 3 
18557814
3 483 -4.58 0.0001 0.0341 
CHGA 14 92459297 52 4.57 0.0001 0.0341 
XIST X 72989344 -31 -4.44 0.0002 0.0350 
LCN2 9 
12995139
8 -141 -4.41 0.0002 0.0350 
SRC 20 35406338 -164 -4.40 0.0002 0.0350 
SFN 1 27062338 118 -4.26 0.0003 0.0442 
HPV Negative Cases - Methylation by Vitamin A Intake 
PTHLH 12 28016940 -757 -6.55 1.11E-06 0.0017 
LMO2 11 33870264 148 -5.80 6.64E-06 0.0050 
SIN3B 19 16800704 -514 -5.26 2.48E-05 0.0092 
TNFSF8 9 
11673277
5 -184 -5.19 2.91E-05 0.0092 
C4B 6 32057984 171 -5.17 3.06E-05 0.0092 
GML 8 
14391293
8 -281 -4.66 0.0001 0.0241 
HGF 7 81238681 -1293 -4.65 0.0001 0.0241 
MLF1 3 
15977192
1 243 -4.59 0.0001 0.0244 
THPO 3 
18557814
3 483 -4.51 0.0002 0.0244 
HOXA1
1 7 27191320 35 -4.44 0.0002 0.0244 
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Table 3.5. Significantly enriched gene sets for CpG sites identified as differentially methylated in tumors, stratified by HPV 
status, from individuals with the highest compared to the lowest quartile of vitamin A and vitamin B12 intake. 
Name Size 
Enrichment 
Score (ES) 
Normalized 
Enrichment 
Score (NES) 
Nominal 
P-Value 
FDR Q-
Value 
POSITIONAL ENRICHMENT - HPV(+) by Vitamin B12 
Chromosome 12p12 5 -0.87 -1.68 0.003 0.122 
KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG) PATHWAYS - HPV (+) by Vitamin B12 
Type I Diabetes Mellitus 19 -0.63 -1.71 0.001 0.076 
Antigen Processing and Presentation 9 -0.71 -1.62 0.016 0.164 
Pathogenic Escherichia Coli Infection EHEC 8 0.67 1.87 0.017 0.158 
Pathogenic Escherichia Coli Infection EPEC 8 0.67 1.86 0.009 0.081 
Adherens Junction 23 0.43 1.71 0.01 0.124 
Huntingtons Disease 7 0.61 1.66 0.033 0.121 
Epithelial Cell Signaling in Helicobacter Pylori Infection 15 0.43 1.58 0.025 0.139 
GENE ONTOLOGY - BIOLOGICAL PROCESSES - HPV(+) by Vitamin B12 
Regulation of Cytokine Production 8 -0.81 -1.82 0.000 0.080 
Negative Regulation of Multicellular Organismal Process 6 -0.84 -1.72 0.001 0.233 
Regulation of Multicellular Organismal Process 24 -0.60 -1.70 0.002 0.232 
Positive Regulation of Cytokine Production 5 -0.87 -1.68 0.000 0.229 
Cytokine Production 17 -0.63 -1.67 0.005 0.205 
POSITIONAL ENRICHMENT - HPV(-) by Vitamin B12 
Chromosome 17q11 8 -0.68 -1.55 0.024 0.214 
Chromosome 7q31 7 0.65 1.85 0.008 0.03 
POSITIONAL ENRICHMENT - HPV(-) by Vitamin A 
Chromosome 12p12 5 -0.82 -1.67 0.004 0.192 
Chromosome 8p21 8 -0.69 -1.59 0.020 0.218 
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CHAPTER 4. TRANSCRIPTOMIC EFFECTS OF CURCUMIN AND PIPERINE IN 
NORMAL HUMAN BREAST STEM CELLS 
4.1 Abstract 
Curcumin is a dietary polyphenol derived from the rhizomes of turmeric (curcuma 
longa) and a potential agent for both the prevention and treatment of cancers. Recently, 
curcumin treatment alone, or in combination with piperine, was shown to limit breast 
stem cell self-renewal while remaining non-toxic to normal differentiated cells. Here, we 
paired fluorescence activated cell sorting (FACS) with low input high throughput RNA 
sequencing (RNA-seq) to characterize the genome-wide changes induced specifically in 
normal breast stem cells following treatment with these compounds. We generated 
genome-wide maps of the transcriptional changes that occur in luminal (ALDH+) and 
basal (ALDH+/CD44+/CD24-) normal breast stem cells following treatment with 
curcumin and piperine. This transcriptome analyses confirm that these compounds 
target breast stem cell self-renewal in both stem cell populations by down-regulating 
expression of breast “stemness” genes. We also identified novel genes and pathways 
targeted by curcumin in these cells, including previously undescribed mechanisms by 
which curcumin may target Wnt signaling in breast stem cells, including downregulation 
of SCD and upregulation of CACYBP. These findings help clarify the mechanisms by 
which curcumin and piperine target breast stem cell self-renewal, providing insight into 
pathways involved in stem cell regulation in the normal human breast and novel targets 
for cancer chemoprevention and treatment efforts. 
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4.2 Introduction 
While there has been a significant reduction in the number of deaths due to 
breast cancer since 1990, breast cancer remains the second most deadly cancer in 
U.S. women, with an estimated 39,840 deaths in 2010 (Jemal et al. 2010). The large 
number of newly diagnosed cases and deaths from breast cancer are indicative of the 
necessity for the development of novel strategies for the prevention of this deadly 
disease. The current strategies for prevention of breast cancer in susceptible 
populations are associated with toxicity or short and long term risks from surgery 
(Brandberg et al. 2008) or antiestrogen therapy (Fisher et al. 1998; Vogel et al. 2010). 
Antiestrogen therapy has also been shown to be only effective at preventing estrogen 
receptor positive (ER+) disease, and ineffective at prevention or treatment of estrogen 
receptor negative (ER-) disease (Howell 2008). There is a need, therefore, for the 
identification and development of novel cancer prevention strategies that are non-toxic, 
safe, and prevent both ER+ and ER- disease.  
Curcumin is a dietary polyphenol derived from the rhizomes of turmeric (curcuma 
longa) which has been widely used in traditional Indian and Chinese medicine for 
treatment of a range of diseases, including inflammatory conditions, diabetes, and 
rheumatoid arthritis (Noorafshan and Ashkani-Esfahani 2013). Preclinical models have 
implicated curcumin as a potential agent for both the prevention and treatment of 
cancers. A major issue with the use of curcumin clinically is the limited bioavailability 
following ingestion. A number of strategies to increase the bioavailability of curcumin 
have been attempted, with the use of piperine as an adjuvant treatment showing up to a 
20-fold increase in curcumin bioavailability in a clinical trial (Shoba et al. 1998). 
Recently, the mammosphere model, an in vitro, anchorage independent primary breast 
tissue culture method that enriches for a population of stem and early progenitor cells 
(Dontu et al. 2003), was used to show that the dietary compounds piperine and 
curcumin combined limit breast stem cell self-renewal while remaining non-toxic to 
normal differentiated cells (Kakarala et al. 2010). 
Since breast tumors potentially arise from, and are sustained by, a population of 
progenitor or stem-like cells that harbor dysregulated self-renewal capacity, it is 
essential to characterize the effects of cancer preventive compounds specifically in 
104 
 
stem and progenitor cells (Al-Hajj et al. 2003; Molyneux et al. 2010). Evidence suggests 
that normal breast, as well as breast cancer, stem cells exist in two different states, 
luminal-like and basal-like (Liu et al. 2013; Van Keymeulen et al. 2011). Luminal stem 
cells have an epithelial phenotype, are proliferative, and express aldehyde 
dehydrogenase (ALDH+). Basal stem cells have a mesenchymal phenotype, are 
invasive, and are characterized by CD44+/CD24- surface expression (Liu et al. 2013). 
How these distinct populations of breast stem/progenitor cells in normal tissue respond 
to cancer preventive agents has not been comprehensively characterized. 
The goal of this study was to extend previous findings that curcumin and piperine 
targeting normal breast stem cell self-renewal (Kakarala et al. 2010) by 
comprehensively characterizing the genomic changes that occur specifically in normal 
breast stem cells following treatment with these compounds. By pairing fluorescence 
activated cell sorting (FACS) with low input high throughput RNA sequencing (RNA-
seq), we generated genome-wide maps of the transcriptional changes that occur in 
luminal (ALDH+) and basal (ALDH-/CD44+/CD24-) normal breast stem cells following 
treatment with curcumin and piperine. Our results confirm that these compounds target 
breast stem cell self-renewal in both stem cell populations by down-regulating 
expression of breast “stemness” genes. Additionally, we identify novel genes and 
pathways targeted by curcumin in these cells. These results help clarify the 
mechanisms by which curcumin and piperine target breast stem cell self-renewal and 
provide insight into pathways involved in stem cell regulation in the normal human 
breast. 
4.3 Materials and Methods 
Materials 
Curcumin (98% pure) and piperine (BioPerine; 95% pure piperine) were donated 
by Sabinsa Corporation (Piscataway, NJ). Curcumin and piperine were diluted in DMSO 
to form a stock solution for dissolution in cell culture media. MCF7 cells were obtained 
from American Type Culture Collection (ATCC). SUM149 cells were obtained from 
Asterland. 
Human Normal Breast Tissue Dissociation 
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Normal (non-pathogenic) breast tissue was isolated from women undergoing voluntary 
reduction mammoplasty at the University of Michigan hospital. The study protocol was 
approved by the University of Michigan Institutional Review Board. Breast tissue was 
mechanically and enzymatically digested as previously described (Dontu et al. 2003; 
Kakarala et al. 2010). 
Mammosphere Formation 
Single cells were plated in ultralow attachment plates (Corning) at a density of 
100,000 viable cells/mL for primary cells and a density of 20,000 viable cells/mL for 
SUM149, MCF7, and T47D cells. Primary mammospheres were allowed to form for 7-
10 days in serum-free mammary epithelial basal medium (MEBM) supplemented with 1 
ug/mL hydrocortisone, 50ug/mL insulin, 20 ng/mL EGF, B27, 20 ug/mL gentamycin, and 
1x antibiotic-antimytotic in the presence of either curcumin, piperine, or vehicle (DMSO) 
control.  Each experiment was performed in triplicate and sphere number quantified 
manually. Previous work had established that 5uM curcumin, individually or in co-
treatment with 5uM piperine, was sufficient to significantly inhibit primary and secondary 
mammosphere formation (Kakarala et al. 2010). To characterize interindividual variation 
in response to curcumin and piperine, we treated cells isolated from 13 mammoplasty 
reduction patients and quantified primary sphere formation. 
Flow Cytometry and Curcumin Treated Sorted Cell Populations 
Primary breast cells from 3 individuals were sorted on a MoFlo Astrios. Cells 
were first stained for a hematopoetic, fibroblast, and endothelial cell lineage depletion 
cocktail that consisted of biotinylated antibodies targeted against CD45, HLA-DR, 
CD14, CD31, CD41, CD19, CD235a, CD56, CD3, CD16, and CD140b (all from 
eBioscience, except for CD140b (Biolegend) and CD41 (Acris). Next, cells were stained 
with Alexafluor750-streptavidin, Alexafluor750 LIVE/DEAD Fixable Dead Cell Stain 
(Invitrogen), Brilliant Violet 421 – CD24 (Biolegend), APC-CD44 (BD), and Aldefluor 
(Stem Cell Technology). Single color and isotype controls were included for 
compensation and gating purposes. Aldefluor-positive gating was based on DEAB 
controls. Viability of cells post sorting was confirmed via trypan blue exclusion. Sorted 
cell populations were plated in mammosphere formation conditions as described above 
treated with either 5 µM  curcumin, 5 µM  piperine, 5 µM  curcumin and 5 µM piperine, 
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or vehicle control. After 24 hours, total RNA was isolated from each treated cell 
population using the RNEasy Micro Kit (Qiagen) with on column DNase treatment. 
High Throughput RNA Sequencing 
RNA concentration and quality was determined using a Nanodrop (Thermo) and 
Bioanalyzer (Agilent). Due to the low level of input RNA due to a small number of input 
cells following FACS sorting and treatment, we depleted ribosomal RNAs with 
Ribominus (Life) and prepared sequencing libraries utilizing the SMARTer Stranded 
RNA-Seq kit (Clontech) following the manufacturer’s recommended protocol. Libraries 
were multiplexed (4 per lane) and sequenced using paired end 50 cycle reads on a 
HiSeq 2500 (Illumina) at the University of Michigan DNA Sequencing Core Facility. Due 
to the high redundancy introduced at the beginning of the read by the SMARTer library 
preparation kit, one lane of PhiX control was included. 
RNA-Seq Data Analysis 
Raw sequencing read quality was assessed utilizing FastQC. Sequencing reads 
were concatenated by sample and read in pair using SeqTK. The first three nucleotides 
of the first read in each read pair were trimmed, as recommended by Clontech, using 
Prinseq 0.20.3. A splice junction aware build of the human genome (GRCh37) was built 
using the genomeGenerate function from STAR 2.3.0 (Dobin et al. 2013). Read pairs 
were aligned to the genome using STAR, using the options “outFilterMultimapNmax 10” 
and “sjdbScore 2”. The aligned reads were assigned to genomic features (GRCh37 
genes) using HTSeq-count, with the set mode “union”. We conducted differential 
expression testing on the assigned read counts per gene utilizing edgeR (Robinson et 
al. 2010). Separate analysis were conducted for each stem/progenitor cell type (luminal 
and basal), adjusting for study subject as a covariate using the glmLRT. To reduce the 
dispersion of the dataset due to lowly expressed genes, genes with a mean count less 
than five across samples were excluded from analysis. Normalized counts per million 
were estimated utilizing the “cpm” function in edgeR (Robinson et al. 2010). Genes 
were considered differentially expressed between conditions at a false discovery rate 
adjusted p-value < 0.05 (Benjamini and Hochberg 1995).  
Pathway analyses 
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Differentially expressed pathways were identified utilizing LRPath (Sartor et al. 
2009; Kim et al. 2012). A directional analysis was conducted on all genes by including 
p-value of the differential expression test as a measure of effect size and log2 fold 
difference in expression as a measure of effect direction. Input biological pathways 
included in analysis were Gene Ontology Biological Processes, KEGG pathways, 
Panther pathways, miRBase, and Transcription Factors. Biological pathways were 
considered differentially expressed at a false discovery rate adjusted p-value <0.05.  
4.4 Results 
Curcumin and piperine inhibit mammosphere formation 
To confirm and extend previous findings of the inhibitory effect of curcumin 
treatment on mammosphere formation (Kakarala et al. 2010), we exposed MCF7 cells, 
SUM149 cells, and primary human breast cells to curcumin and piperine in vitro. 
Curcumin inhibited mammosphere formation in both MCF7 and SUM149 in a dose 
dependent manner (Figure 4.1, panels A and B), as well as decreasing mammosphere 
size (representative images, Figure 4.1 panel C). Piperine alone was not found to affect 
mammosphere formation. Treatment with curcumin and piperine in combination was 
found to decrease primary mammosphere formation at a greater rate than curcumin 
treatment alone. In cell lines assayed here, and based on previous results (Kakarala et 
al. 2010), 5 µM curcumin treatment was found to significantly inhibit mammosphere 
formation without inducing acute cytotoxicity, as assayed by trypan blue exclusion. We 
found significantly inhibited primary mammosphere formation in primary breast cells 
isolated from voluntary mammoplasty patients (n=13) treated with 5 µM  curcumin, 5 µM  
piperine, and both agents simultaneously (Figure 4.1 panel D).  
Transcriptome-wide analysis of curcumin’s effects in ALDH+ and ALDH-
CD44+CD24- breast cells 
Differential expression in ALDH+ and ALDH-/CD44+/CD24- cells 
We isolated two distinct populations enriched for breast stem and progenitor 
cells, ALDH+ (epithelial-like) and ALDH-/CD44+/CD24- (mesenchymal-like), from 
normal reduction mammoplasty tissue via FACS (Figure 4.2). To characterize the 
baseline transcriptional differences in the two sorted normal breast cell populations, we 
compared expression between the vehicle control treated cell fractions after 24 hours of 
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culture. Figure 4.3 presents a multidimensional scaling plot based on the 500 most 
differentially expressed genes across the 6 samples (ALDH+ and ALDH-/CD44+/CD24- 
fractions from 3 subjects), with the two different cell fractions clearly clustering on the 
first dimension of the leading log fold change. A differential expression analysis 
identified 1369 genes upregulated in the ALDH-/CD44+/CD24- fraction and 1573 genes 
upregulated in the ALDH+ fraction (Figure 4.4). Amongst the 10 most differentially 
expressed genes, TNFRSF11B, S100A9, PIGR, SERPINB7, KRT23, KRT80, TCN1, 
and EHF were overexpressed in ALDH+ cells, while CCND2 and TP63 were 
overexpressed in ALDH-/CD44+/CD24- cells. Epithelial-mesenchymal transition (EMT) 
associated genes, such as BMP4 (FDR = 5.7E-4), FGF2 (FDR=9.2E-19), IGFBP4 
(FDR=1.6E-3), SERPINE1 (FDR=1.1E-8), and SNAI2 (FDR=3.6E-4) were significantly 
upregulated in ALDH-/CD44+/CD24- cells. Conversely, epithelial-phenotype associated 
genes, including CDH1 (FDR=2.7E-17), EPCAM (FDR=1.0E-7), CLDN1 (FDR=3.1E-
23), CLDN3 (FDR=4.4E-20), and KRT18 (FDR=1.3E-27) were overexpressed in the 
ALDH+ cells. Pathway analyses identified that previously identified biological processes 
involved in cell adhesion, mesenchymal cell proliferation, epithelial bud morphogenesis, 
and Notch signaling were differentially expressed between the two cell types (Table 
4.1). Other significantly enriched pathways not typically associated with cell stemness or 
epithelial/mesenchymal phenotype included transition metal ion transport (FDR=8.4E-
3), defense response (FDR=1.4E-3), and response to organic cyclic substance (FDR= 
3.3E-3).   
Transcriptomic changes in ALDH+ and ALDH-/CD44+/CD24- cells induced by curcumin 
To characterize the effects of curcumin in ALDH+ cells, we compared the 
transcriptional profiles of the sorted ALDH+ cells cultured for 24 hours with 5 µM  
curcumin or DMSO. Unlike when comparing the expression profiles of the ALDH+ and 
ALDH-/CD44+/CD24- cells, there was no clear separation by treatment using MDS for 2 
of the 3 samples tested (Figure 4.5). One hundred and ninety genes were identified as 
differentially expressed with curcumin treatment (FDR p-value < 0.05), with 97 genes 
upregulated and 93 genes downregulated (Figure 4.6). The most significantly 
upregulated genes with curcumin treatment included HMOX1, SRXN1, HSPA1A, 
HSPA7, HSPA6, HSPA1B, and UBB, while KRT15, KRT6A, and SCD were 
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downregulated. The list of all of the genes identified as differentially expressed by 
curcumin treatment in the ALDH+ cells, along with the estimated counts per million in 
each of the curcumin or DMSO treated samples, is shown in Table 4.2. LRPath 
pathway enrichment analysis revealed that curcumin treatment changed expression of 
genes in pathways involved in response to unfolded protein, protein ligase activity, and 
development (Table 4.3). Additionally, genes involved in sterol metabolism (FDR=5.6E-
5), response to calcium ion (FDR=5.6E-5), cell adhesion (FDR=1E-6), cell junction 
organization (FDR=9.7E-7), and biosynthesis of unsaturated fatty acids (FDR=1.3E-4) 
were also differentially expressed with curcumin treatment. 
  In ALDH-/CD44+/CD24- cells, curcumin treatment was found to induce a similar 
pattern of overall change as in the ALDH+ cells, with 2 of the 3 samples having no clear 
separation when visualized utilizing MDS (Figure 4.7). Interestingly, in contrast to 
ALDH+ cells, approximately two times more genes were significantly upregulated with 
curcumin treatment (164) than downregulated (83) in ALDH-/CD44+/CD24- cells 
(Figure 4.8; Table 4.4). The most upregulated genes following curcumin treatment 
included HSPA6, UBC, HSPA7, DNAJB1, HSPA1B, BAG3, HSPA1A, HMOX1, FBXL14, 
and TAOK3. Biological pathways involved in response to protein stimulus, protein 
folding, ribosome biogenesis, non-coding RNA metabolism, and heat response were the 
most enriched for differentially expressed genes following curcumin treatment (Table 
4.5). Additional pathways identified as enriched included MAPK signaling (FDR=2.3E-
5), bone morphogenesis (FDR=1.2E-4), regulation of cytokine production involved in 
immune response (FDR=3.2E-4), endocrine system development (FDR=3.0E-4), and 
regulation of Notch signaling (FDR=1.8E-3). 
 Between the curcumin and DMSO treated ALDH+ and ALDH-/CD44+/CD24- 
cells, there were 46 genes differentially expressed in both cell populations. These genes 
were enriched in biological processes involved in unfolded protein response 
(FDR=2.1E-16), response to protein stimulus (FDR=1.9E-14), response to organic 
substance (FDR=5.5E-8), and response to heat (FDR=6.1E-5). This overlap group 
included a number of genes previously reported as differentially expressed following 
curcumin treatment, including HMOX1, MIR22HG, IGFBP3, SOD1, and FOSB. 
CACYBP (calcyclin binding protein), a gene involved in calcium homeostasis was 
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upregulated in both cell populations, while S100A6 (calcyclin) was downregulated in the 
curcumin treated ALDH-CD44+CD24- population, while S100A8 (S100 calcium binding 
protein A8) was upregulated in the curcumin treated ALDH+ cells. A number of genes 
associated with normal or breast cancer “stemness” were also significantly 
downregulated in the curcumin treated cells. In the ALDH+ cell fraction, ALDH1A3, VIM, 
and PROM1 were downregulated with curcumin treatment, while TP63, ITGA6 (CD49f), 
NFKB1, and JAG1 were downregulated in the ALDH-/CD44+/CD24- cells following 
curcumin treatment. 
Transcriptomic changes in ALDH+ and ALDH-/CD44+/CD24- cells by piperine treatment 
Despite a significant reduction in primary mammosphere formation observed in 
the normal breast cells following 5 µM  piperine treatment (Figure 4.1), no genes were 
identified as differentially expressed (FDR < 0.05) in the piperine treated ALDH+ or 
ALDH-CD44+CD24- cells. LRPath analyses identified that in ALDH+ cells, the most 
enriched pathways in differentially expressed genes with piperine treatment involved 
DNA repair, transcription, development, and RNA metabolic processes (Table 4.6). 
Additionally, genes targeted by the micro-RNA mir-543 (FDR=0.025), or involved in non-
homologous end-joining (FDR=0.008) or MAPK signaling (FDR=0.024) were enriched 
following piperine treatment. In ALDH-CD44+CD24- cells, pathways involved in 
translational elongation, non-coding RNA processing, response to amino acid stimulus, 
and energy generation were enriched following piperine treatment (Table 4.6).    
Combined effects of curcumin and piperine in breast stem/progenitor cells 
Treatment of the ALDH+ cells with curcumin and piperine in tandem revealed many of 
the same genes to be differentially expressed as with curcumin only treatment. A total of 
191 genes were differentially expressed in ALDH+ cells, 82 upregulated and 109 
downregulated, with curcumin and piperine co-treatment (Figure 4.9; Tables 4.7 and 
4.8). Most of the same pathways that were identified as differentially enriched in 
curcumin treated vs control cells were also enriched in curcumin and piperine co-treated 
vs DMSO cells (data not shown). To specifically identify differentially expressed genes 
and pathways induced by curcumin and piperine co-treatment, we compared the 
genome-wide expression levels in curcumin and piperine treated ALDH+ or ALDH-
CD44+CD24- cells compared to curcumin treatment alone. A number of genes were 
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identified as differentially expressed in the curcumin and piperine cotreated ALDH+ cells 
(Table 4.9), including the ribosomal protein RPL26, ubquitin B (UBB), and the calcium 
homeostasis regulator CALHM2. In ALDH-CD44+CD24- cells, all of the significantly 
differentially expressed genes identified in the curcumin and piperine cotreated cells 
compared to curcumin only treated cells were genes involved in heat shock response 
(Table 4.9). The addition of piperine to the curcumin treatment affected pathways 
involved in translation, ribosomal biogenesis, and oxidative phosphorylation in the 
ALDH+ cell (Table 4.10). In ALDH-CD44+CD24- cells, pathways involved in protein 
folding, calcium ion transport, cytokine signaling, and growth regulation were enriched in 
the curcumin and piperine co-treated cells compared to the curcumin only treated cells 
(Table 4.10).  
4.5 Discussion 
Curcumin has shown great promise as a cancer preventive compound in 
preclinical models, particularly when paired with piperine as an adjuvant to increase 
bioavailability. Here, we confirm and extend previous findings of curcumin targeting self-
renewal of both normal and cancer stem cell populations. Here, we reported, for the first 
time, genome-wide expression profiles of FACS sorted ALDH+ and ALDH-CD44+CD24- 
normal breast cells treated with curcumin and piperine. These results highlight the 
efficacy of pairing flow cytometry sorting of normal stem and progenitor cell populations 
with low input high throughput RNA-sequencing methods to identify mechanisms of 
action of cancer preventive compounds in normal cells. 
  Mounting evidence from the past decade shows that breast tumors likely arise 
from, and are sustained by, a population of stem-like cells that harbor dysregulated self-
renewal capacity (Al-Hajj et al. 2003). Additionally, it was recently shown that cancer 
stem cells exist in two distinct phenotypic states, an epithelial-like, proliferative state, 
and a mesenchymal-like state that is quiescent and invasive, with cancer stem cells 
being able to interconvert between the two states (Liu et al. 2013). These results are 
consistent with findings from lineage tracing studies in the mouse mammary gland, 
where distinct stem cell populations were identified that are typically lineage restricted to 
generating either a luminal or basal progeny (Van Keymeulen et al. 2011), but either 
can recapitulate a full mammary gland when transplanted into a cleared mammary fat 
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pad (Keller et al. 2012). Here, we show that the widely used breast stem cell markers 
ALDH+ and ALDH-/CD44+/CD24- identify distinct epithelial-like and basal-like cell 
populations, respectively, based on comprehensive gene expression analyses.  
The findings that normal breast stem and breast cancer stem cells exist in 
multiple, interconvertable states has important implications for breast cancer prevention. 
It has been previously reported that ALDH+ cancer stem cells typically localize in the 
tumor interior, while CD44+/CD24- stem cells localize at the invasive edge of the tumor 
(Liu et al. 2013). Thus, ALDH+ stem cells may be responsible for maintaining the growth 
of the bulk of the tumor, while EMT-like CD44+/CD24- stem cells are responsible for 
invasion and metastasis. With respect to cancer prevention efforts, recent pathologic 
evidence suggests that population expansion of ALDH+ cells may be an important early 
step in carcinogenesis. In histologically normal tissue isolated from BRCA1/BRCA2 
mutation carriers, or women with a family history of breast cancer, increased numbers 
of ALDH positive cells were observed in the breast ductules compared to control 
patients (Isfoss et al. 2013). A comparison of benign breast biopsy tissues isolated from 
women who went on to develop breast cancer, or not, found increased ALDH-1 staining 
in both epithelial and stromal breast cells isolated from women who later went on to 
develop breast cancer (Kunju et al. 2011). Additionally, ALDH1A1 tumor staining was 
strongly associated with early recurrence and metastasis of breast cancer, regardless of 
ER, PR, or HER2 status (Zhong et al. 2013). CD44+/CD24- breast cancer cells were 
originally identified as the cells that contained the tumor initiating fraction in breast 
cancers (Al-Hajj et al. 2003). Further work identified that these cells have a basal 
phenotype and increased invasive capacity in tumors (Sheridan et al. 2006), and that 
these cells can be generated through an EMT in immortalized human mammary 
epithelial cells (Mani et al. 2008). The most efficacious cancer preventive compounds, 
therefore, should inhibit self-renewal in both of these stem cell phenotypes, particularly 
if the two phenotypes can interconvert. Here, we show that curcumin downregulated 
genes associated with breast “stemness”, including ALDH1A3 and PROM1 (CD133) in 
ALDH+ cells, and TP63 and ITGA6 (CD49f) in ALDH-/CD44+/CD24- cells. These 
results, paired with the functional results from the mammosphere formation assay, show 
that curcumin likely inhibits stem cell self-renewal of both of these stem cell populations. 
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In addition to downregulating genes involved in stem cell self-renewal, 24-hour 
curcumin treatment induced significant expression changes in a large number of genes 
and pathways in both ALDH+ and ALDH-/CD44+/CD24- cells that have been previously 
reported in other cell types. Induction of HMOX1 by curcumin treatment, which we 
observed in both stem cell fractions following curcumin treatment, has been previously 
identified in a number of model systems, and is likely mediated through NRF2 induction 
(McNally et al. 2007; Motterlini et al. 2000; Yang et al. 2009). Pathways involved in 
unfolded protein response, ligase activity, and response to heat were upregulated 
following curcumin treatment, corroborating previous findings of curcumin activating a 
heat shock and proteasome response (Dunsmore et al. 2001; Shen et al. 2007). These 
results may also point to a novel mechanism by which curcumin could inhibit breast 
stem cell self-renewal in light of recent findings in hematopoetic stem cells. Specifically, 
misfolded protein accumulation was shown to strongly induce apoptosis in 
hematopoetic stem cells, while lineage committed progenitor cells had an adapted 
response that allowed for their survival (van Galen et al. 2014). These results point to a 
mechanism by which tissue-wide damage due to the accumulation of unfolded protein in 
stem cells is limited due to stem cells preferentially undergoing apoptosis in these stress 
conditions.  
Curcumin treatment also modified Notch signaling in ALDH-/CD44+/CD24- cells, 
potentially through downregulation of JAG1, which has previously been reported in 
curcumin treated esophageal cancer cell lines (Subramaniam et al. 2012). Curcumin 
also decreased mammosphere formation as well as the CD44+/CD24- fraction of BT-
474 cells, in addition to decreasing the number of tubulin microtentacles, which are 
involved in the reattachment of suspended cells (Charpentier et al. 2014). Microtentacle 
formation has been shown to be dependent on vimentin and tubulin (Whipple et al. 
2008), both of which we identified as downregulated in ALDH+ curcumin treated cells, 
suggesting these processes may also be important in inhibition of mammosphere 
formation in normal breast cells. 
Due to our cell type specific, genome-wide approach, I was able to identify a 
number of novel genes and pathways differentially expressed in normal breast stem 
cells following curcumin treatment. In both ALDH+ and ALDH-/CD44+/CD24- cells, 
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curcumin treatment significantly downregulated expression of SCD (stearoyl-CoA 
desaturase), an enzyme involved in the synthesis of monounsaturated fatty acids. SCD 
has recently been implicated in carcinogenesis, as fatty acid synthesis is essential for 
the formation of plasma membranes as well as regulating glycolysis (Igal 2010). 
Relevant to stem cell function, downregulation of SCD has been associated with 
inhibition of beta-catenin and Wnt signaling in MCF7 and MDA-MB231 cells (Mauvoisin 
et al. 2013) and has been identified as required for lung cancer initiating cell spheroid 
production (Noto et al. 2013). We also observed a significant increase in expression of 
CACYBP (calcyclin binding protein) in both stem cell fractions treated with curcumin, 
with a concurrent decrease in the expression of S100A6 (calcyclin) in ALDH-
/CD44+/CD24- cells. CACYBP plays a role in the ubquitination and degradation of beta-
catenin (Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin 
degradation linked to p53 responses), and CACYBP expression has recently been 
shown to be regulated by S100A6 (Ning et al. 2012). Through our whole genome 
transcriptomic approach, we identified novel targets of curcumin that likely play a role in 
the downregulation of Wnt signaling previously reported by us (Kakarala et al., 2010) 
and others (reviewed in Li and Zhang 2014). Understanding the roles that SCD and 
CACYBP play in the regulation of normal breast stem cell self-renewal and 
differentiation could provide novel insight into mechanisms of carcinogenesis and 
provide new avenues for targeting cancer stem cells. 
Despite observing a modest, but statistically significant, decrease in primary 
mammosphere formation following 5 µM  piperine treatment, we did not observe any 
genes as significantly differentially expressed in either normal breast stem cell fraction. 
Pathway analyses showed, however, that piperine treatment affected pathways 
associated with non-recombinational DNA repair, RNA translation, and ribosome 
biogenesis. Co-treatment of curcumin and piperine led to differential expression of many 
of the same genes identified as differentially expressed with curcumin treatment. 
Comparison of the curcumin-treated and curcumin and piperine co-treated cells 
identified differences in expression of pathways associated with translational elongation, 
protein folding, and calcium transport, among others. Calcium homeostasis has recently 
been implicated in EMT of breast cancer cells, where intracellular chelation of calcium 
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was found to inhibit the expression of the EMT markers vimentin, Twist, and N-cadherin 
(Davis et al. 2014).These findings, paired with the interesting findings about CACYBP 
and S100A6 above, likely point to a role of calcium homeostasis in the regulation of 
normal breast stem cells that is modulated by both curcumin and piperine treatment.  
A weakness of this study is the lack of comprehensive characterization of 
molecular markers for normal human breast stem cells, which still remain to be fully 
characterized. Thus, our sorted cell fractions are enriched for progenitor and stem 
populations, but are not comprised entirely of stem cells. Here, we utilized two 
commonly used markers to isolate live normal human breast stem cells, ALDH and 
CD44+/CD24-, which we have previously shown to isolate distinct populations of breast 
cancer stem cells. Recent research, however, shows that the ALDH+ fraction of breast 
cells may represent two distinct populations as well. Two major aldehyde 
dehydrogenase enzymes have activity detected by Aldefluor, ALDH1A3 and ALDH1A1. 
A recent study identified that expression of these two enzymes is exclusive in normal 
human mammary tissue, with ALDH1A3 positive cells localizing in larger ducts, while 
ALDH1A1 cells typically localizing in branching points (Honeth et al. 2014). In our study, 
expression of ALDH1A3, but not ALDH1A1, was identified as significantly different 
between ALDH+ and ALDH-CD44+CD24- cells, suggesting an enrichment of the 
ALDH1A3+ cellular population in these experiments. Future research will be necessary 
to better clarify the roles of both the ALDH1A1 and ALDH1A3 populations in breast 
development and the role of either of these luminal stem cell populations in breast 
carcinogenesis in order to target these specific breast stem cell populations for cancer 
prevention efforts. 
4.6 Conclusion 
The results from this study confirm our previous findings of the effects of 
curcumin and piperine on normal and cancer stem cell self-renewal. We extended these 
findings using an experimental paradigm that combines FACS sorting of live, normal 
human breast cells into stem-enriched fractions, treatment in vitro, and whole genome 
RNA sequencing from these sorted cell populations utilizing low input methods. The use 
of primary tissues provides novel information about stem cell regulation in the normal 
human breast that may not be available from studies utilizing cell lines or model 
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animals. This experimental technique can thus be applied to understand the effects of 
carcinogens or cancer preventive compounds in specific cell populations. Here, we 
identify the pathways and individual genes differentially expressed by curcumin 
treatment, pointing to novel mechanisms of inhibiting stem cell self-renewal and 
potential biomarkers of curcumin efficacy in clinical trials. 
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Figure 4.1. The effects of curcumin and piperine treatment on primary mammosphere 
number and size in cancer cell lines and normal breast cells. Curcumin and piperine 
were tested at multiple concentrations in cell lines (5C = 5 µM  curcumin, 5P = 5 µM  
piperine, 5C5P = 5 µM  curcumin and 5 µM  piperine, for example). (A) and (B) The 
effects of curcumin and piperine on primary mammosphere formation in MCF7 and 
SUM149 cells, respectively (NT= Not treated). (C) The effects of curcumin on 
mammosphere size in MCF7 cells. (D) Curcumin and piperine significantly inhibited 
primary mammosphere formation in normal breast cells (N=13). 
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Figure 4.2. FACS gating scheme to isolate live, lineage negative, ALDH(+) and                         
ALDH(-)/CD44(+)/CD24(-) normal breast cells. 
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Figure 4.3. Multidimensional scaling plot of the vehicle control treated ALDH+ and 
ALDH-/CD44+/CD24- cells, based on the top 500 most variable genes. 
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Figure 4.4. False discovery rate (FDR) volcano plot of the log(2) ratio of gene 
expression between the vehicle control treated ALDH(+) and ALDH(-)CD44(+)CD24(-) 
cells. 
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Figure 4.5. Multidimensional scaling plot 5 µM  curcumin and DMSO treated ALDH+ 
cells, by the top 500 most differentially expressed genes. 
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Figure 4.6. FDR volcano plot of the log(2) ratio of gene expression between the 5 µM  
curcumin and DMSO treated ALDH+ cells. 
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Figure 4.7. Multidimensional scaling plot of the 5 µM  curcumin and DMSO 
treated ALDH-/CD44+/CD24- cells by the top 500 most differentially expressed 
genes. 
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Figure 4.8. FDR volcano plot of the log(2) ratio of gene expression between the 5 µM  
curcumin and DMSO treated ALDH-/CD44+/CD24- cells. 
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 Figure 4.9. FDR volcano plot of the log(2) ratio of gene expression between the 5 µM  
curcumin and 5 µM  piperine co-treated vs. DMSO treated ALDH+ cells. 
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Table 4.1. The 10 most differentially expressed Gene Ontology biological processes identified between the vehicle control 
treated ALDH+ and ALDH-/CD44+/CD24- cells. 
Name #Genes OddsRatio P-Value FDR 
calcium-independent cell-cell adhesion 11 1.33 2.11E-10 5.71E-07 
organ formation 21 0.77 1.18E-07 1.60E-04 
development of primary female sexual 
characteristics 61 0.81 6.53E-07 4.73E-04 
positive regulation of mesenchymal cell 
proliferation 20 0.78 8.86E-07 4.73E-04 
female sex differentiation 66 0.81 9.43E-07 4.73E-04 
morphogenesis of an epithelial bud 11 0.77 1.05E-06 4.73E-04 
regulation of mesenchymal cell proliferation 22 0.79 1.59E-06 5.02E-04 
regulation of Notch signaling pathway 11 0.77 1.60E-06 5.02E-04 
pattern specification process 199 0.85 1.87E-06 5.02E-04 
regulation of nervous system development 179 0.85 2.37E-06 5.02E-04 
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Table 4.2. The 190 genes identified as differentially expressed by curcumin treatment, 
with the estimated counts per million (CPMs) in each sample tested, in ALDH+ normal 
breast cells. 
Gene logFC P Value Sample 1 CPMs Sample 2 CPMs Sample 3 CPMs 
      Curcumin DMSO Curcumin DMSO Curcumin DMSO 
ABCA3 1.51 1.3E-04 5.31 20.98 10.23 24.05 8.66 22.7 
ABHD3 -0.99 2.9E-04 75.91 30.31 41.12 30.42 41.51 17.54 
ACAT2 0.91 3.7E-06 33.44 77.24 49.17 72.86 90.69 178.36 
ACOT13 -1.26 9.5E-06 29.9 9.91 38.33 21.26 75.15 28.28 
ACSL1 0.63 5.1E-05 74.85 141.94 249.07 314.75 315.74 498.39 
ACTN1 0.60 1.9E-05 155.89 270.76 437.4 598.69 400.33 587.16 
AGRN 1.04 1.4E-05 28.31 49.26 24.9 62.35 36.39 71.24 
AHSA1 -0.57 9.8E-05 1651.28 891.56 572.62 440.96 356.66 260.48 
AIF1L 0.92 4.4E-04 11.68 22.73 31.71 47.93 35.61 82.52 
AKR1C1 -0.86 6.3E-04 126.34 136.11 240.29 113.46 545.7 185.16 
ALDH1A3 0.59 1.3E-05 405.39 579.41 869.11 1219.8 2372.65 4008.56 
ANKRD11 0.59 1.6E-04 103.16 173.12 183.06 290.15 103.67 133.23 
ASNS 0.74 3.2E-04 50.96 91.81 68.29 89.74 40.52 81.57 
ATP6V1A -0.63 4.1E-05 225.08 130.28 150.93 105.1 184.92 123.85 
AZI2 -0.65 5.2E-04 129.7 80.73 77.07 49.13 63.74 41.6 
BAG3 -0.86 1.6E-06 894.83 390.55 290.6 234.65 203.21 95.71 
C20orf194 1.73 3.7E-04 3.54 27.98 11.98 19.83 6.49 20.26 
C5orf46 2.41 2.7E-04 0.18 8.74 9.09 17.12 4.13 21.75 
CACYBP -0.51 4.8E-04 1512.91 892.43 565.91 489.61 449.11 301.53 
CALD1 0.62 8.6E-05 149.7 285.62 641.12 762.48 334.82 538.35 
CBR3 -1.09 1.3E-05 121.92 69.95 34.81 18.71 36.98 11.96 
CBS 1.78 9.0E-06 10.97 20.4 9.5 30.97 7.08 47.99 
CCDC59 -0.61 2.7E-04 414.06 203.43 193.6 143.8 125.31 95.98 
CD24 0.75 4.2E-07 216.94 447.67 827.27 1138.8 1189.97 2020.73 
CD9 0.59 9.0E-05 148.64 285.62 385.85 535.87 633.44 822.49 
CDH1 0.73 3.2E-04 122.09 344.5 525.41 652.52 651.15 878.09 
CDK2AP1 0.70 6.4E-04 28.84 60.62 100.62 113.86 110.16 203.92 
CDK6 0.64 2.1E-04 51.85 95.89 162.81 195.24 141.44 246.88 
CEP85 -1.22 9.2E-06 94.31 26.23 33.57 19.67 48.59 22.98 
CHORDC1 -0.68 2.7E-05 623.04 308.94 386.16 313.96 208.52 125.21 
CLDN1 1.30 1.4E-05 13.27 77.82 85.95 150.81 67.08 110.12 
CLDN7 0.66 2.3E-04 67.59 148.64 145.04 216.58 206.16 253 
CLSTN1 0.76 6.6E-06 57.51 106.09 129.96 178.52 111.15 216.97 
CLU -0.60 1.6E-05 1475.93 842.88 919.73 688.27 1001.51 676.21 
CNN2 0.87 6.7E-05 32.2 95.89 81.61 123.58 102.69 146.55 
COPS4 -0.80 1.2E-04 96.61 48.38 64.15 41.72 62.16 35.48 
CRYAB -0.81 6.2E-08 1185.38 561.05 480.27 273.67 318.88 222.41 
CSRP2 -0.85 7.2E-05 364.87 128.82 67.36 46.1 48.39 34.53 
CTSL2 0.52 5.7E-04 100.15 153.01 282.44 349.15 128.66 204.6 
CYFIP1 0.67 1.2E-04 44.94 88.89 95.76 145.71 122.16 168.17 
131 
 
CYP51A1 0.71 4.7E-07 92.72 169.92 192.98 281.79 504.59 837.44 
DAG1 1.12 8.4E-05 12.39 57.42 50.83 89.34 85.97 121.81 
DDAH1 0.94 2.2E-04 15.04 56.25 103.51 139.58 84 129.97 
DDX42 0.71 6.9E-05 52.02 100.26 90.5 135.52 75.15 114.88 
DHCR7 1.55 4.4E-04 2.65 15.45 19.32 23.25 13.97 58.05 
DMD -0.83 4.6E-04 82.63 33.81 57.75 39.17 58.62 36.98 
DNAJA4 -0.80 1.2E-04 265.25 102.01 117.46 93 74.75 46.36 
DNAJB1 -0.99 1.5E-08 4078.31 1401.6 1294.73 807.54 893.31 528.29 
DNAJB4 -0.95 8.7E-10 1637.83 682.59 468.18 308.14 356.46 178.91 
DNAJC10 0.66 2.6E-04 63.88 135.53 146.69 171.51 152.66 250.42 
EDN1 0.57 1.9E-04 120.32 208.97 209.3 283.54 128.85 180.13 
ELF5 1.13 8.7E-05 10.62 21.86 16.43 41.72 28.92 57.1 
EMC4 -0.65 3.6E-04 99.27 75.49 109.71 68.56 123.34 67.57 
EPHA4 -1.53 4.4E-04 39.46 8.74 16.12 10.03 14.36 4.08 
ERBB3 0.71 1.6E-04 34.15 76.36 112.5 143.64 137.31 217.79 
ESRP1 0.62 5.0E-04 40.88 64.41 76.96 122.54 90.89 131.05 
FADS2 1.44 4.5E-06 2.65 10.49 16.53 33.92 29.31 84.56 
FAM53C -0.76 3.1E-04 122.27 56.25 64.67 45.86 68.66 43.1 
FBXO30 -0.86 7.6E-06 197.47 140.19 180.68 111.55 131.02 49.08 
FDFT1 0.54 1.5E-04 84.94 112.21 228.93 334.02 337.77 533.32 
FOSB -0.55 2.2E-04 478.29 337.8 137.91 102.63 120.2 72.46 
FTL -0.84 8.2E-08 678.95 498.09 522.93 268.97 1214.16 567.04 
FXR1 -0.50 4.7E-04 461.84 293.49 259.3 202.8 253.57 181.49 
GABARAPL1 -0.76 6.7E-05 242.6 214.8 223.97 117.13 247.48 110.8 
GABRP 0.93 4.2E-05 17.69 27.98 81.3 118.48 72 209.22 
GALNT3 0.59 1.6E-04 94.84 185.36 277.07 357.75 387.74 535.09 
GARS 0.69 1.8E-04 86.53 204.6 176.34 253.2 159.93 202.83 
GCLM -0.80 7.8E-05 178.54 153.3 212.19 123.02 300 114.47 
GLA -1.01 3.3E-05 65.65 27.69 40.5 24.44 67.48 32.22 
GLIPR1 0.85 6.7E-06 76.44 199.94 297.31 377.81 172.33 308.74 
GLRX -1.05 4.5E-07 38.75 11.37 84.09 55.42 351.74 175.92 
GPRC5A 0.69 4.0E-04 25.83 51 45.56 71.1 112.92 158.65 
GSR -1.09 4.3E-09 115.9 67.62 120.25 44.59 182.56 88.37 
GUCY1A3 0.78 2.5E-04 29.37 50.42 58.57 79.38 61.38 133.64 
HMGA2 1.26 4.1E-04 12.21 24.19 16.12 30.73 8.07 30.04 
HMOX1 -2.22 1.7E-21 1658.54 612.05 981.82 203.52 1418.56 184.48 
HSP90AA1 -0.76 2.2E-05 10902.15 4549.6 5881.1 4902.4 5422.03 3238.82 
HSP90AB1 -0.59 2.3E-04 24201.24 12006.74 8668.8 7316.5 7860.38 5500.05 
HSPA1A -1.36 2.5E-15 3483.76 1018.92 975.21 524.24 593.51 223.77 
HSPA1B -1.31 4.8E-13 5437.45 1475.92 1819.83 946.96 1172.85 546.37 
HSPA1L -1.57 1.1E-08 151.82 35.27 23.04 11.15 30.89 10.6 
HSPA2 -0.70 4.9E-05 255.51 138.44 101.14 73.49 67.67 39.83 
HSPA4 -0.59 3.9E-04 1646.15 818.99 638.84 563.66 756.98 509.26 
HSPA4L -0.87 2.7E-06 493.86 186.53 233.26 160.44 97.38 61.86 
HSPA6 -1.40 2.9E-14 10180.37 2545.27 2828.72 1357.7 1871.41 847.5 
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HSPA7 -1.28 7.2E-15 3024.76 930.32 248.24 130.74 325.57 140.43 
HSPB8 -0.90 4.7E-04 115.72 43.14 39.36 26.67 30.69 18.76 
HSPD1 -0.71 3.2E-05 4368.33 1880.17 1378.72 1101.7 874.03 575.2 
HSPH1 -0.73 4.1E-06 3030.24 1387.61 1277.79 974.67 703.67 439.25 
HTATIP2 -0.76 5.1E-06 129.53 78.11 140.6 91.17 162.29 85.65 
HYOU1 0.48 4.4E-04 583.4 939.94 725.62 947.36 547.28 708.02 
IER5 -0.78 1.0E-06 2094.54 909.63 890.29 637.47 730.03 461.14 
IGFBP3 1.04 2.6E-05 102.81 428.44 395.14 565.65 1678.23 2542.77 
ITGB4 0.70 4.1E-05 26.01 34.68 67.98 116.65 175.08 314.72 
ITGB8 0.67 1.3E-05 79.27 158.26 285.43 381.72 444.79 681.1 
ITPR3 0.57 6.0E-04 62.64 96.18 132.33 195.24 70.62 101.28 
KCNN4 0.75 2.5E-05 31.14 63.54 77.89 121.66 113.51 176.19 
KDM2A -0.50 5.0E-04 375.66 232.58 294.01 225.89 234.49 173.61 
KIF1B -0.55 1.3E-04 254.63 169.04 267.25 195.16 241.57 158.11 
KLK10 0.65 1.3E-04 16.63 22.15 76.86 122.38 198.69 340.41 
KLK7 1.00 3.1E-07 12.21 29.15 83.57 149.14 65.11 130.1 
KRT15 1.22 1.1E-15 175.71 463.99 733.06 1337.4 1084.13 2855.18 
KRT16 0.82 1.6E-07 139.44 186.82 360.54 704.83 403.08 826.84 
KRT17 0.77 3.9E-06 482.36 616.13 1504.96 2528.9 420.98 966.05 
KRT5 0.96 1.3E-09 209.15 434.56 503.82 752.84 265.38 631.34 
KRT6A 1.43 4.6E-15 12.03 43.43 133.88 304.88 68.85 179.86 
KRT7 0.66 7.9E-05 924.2 2008.99 3145.35 3772.7 5244.98 7956.76 
LAYN -3.19 6.1E-04 11.86 2.04 9.19 0.88 0.79 0 
LDLR 0.63 5.3E-06 176.59 304.57 313.02 458 357.05 524.22 
LOC344887 -1.59 8.7E-05 11.68 4.08 22.93 8.52 29.31 8.29 
LPIN1 0.58 4.0E-04 69.89 121.54 166.94 201.61 157.77 255.58 
LPP 1.06 4.5E-05 8.49 35.27 114.36 148.1 73.97 147.5 
LRP2BP -2.15 2.6E-04 31.5 4.95 6.3 2.63 5.31 0.82 
MACC1 0.60 4.0E-05 149.34 266.1 564.98 873.23 375.74 475.68 
MARS 0.53 5.3E-04 141.2 241.32 186.47 254.16 139.87 181.49 
MET 0.56 3.5E-04 273.03 528.7 677.58 933.99 841.38 1013.63 
MIR22HG -0.51 6.2E-04 667.63 494.6 316.32 258.94 265.18 150.77 
MRPL18 -0.61 9.6E-06 491.03 301.65 323.24 221.75 189.64 125.21 
MSMO1 0.87 5.0E-05 25.13 73.45 84.09 113.15 133.57 218.6 
MTHFD1L 0.87 2.6E-04 29.37 58.58 32.02 65.85 34.03 50.44 
MTHFD2 0.85 4.3E-09 152.71 284.46 170.14 291.02 111.93 207.46 
NGDN -0.51 5.2E-04 475.46 293.2 206.4 157.18 163.08 121.54 
NKTR 0.64 2.7E-04 68.48 138.44 126.45 188.23 98.75 126.57 
NUDC -0.66 2.9E-04 458.83 219.76 217.87 197.55 185.51 107.81 
OSGIN1 -1.02 1.7E-04 59.1 24.19 44.32 26.04 32.46 15.77 
PAIP2 -0.64 2.2E-05 216.76 147.77 180.68 119.99 184.92 107.4 
PARP6 0.95 6.2E-04 20.88 59.46 31.61 49.45 20.85 34.8 
PASK 3.70 2.1E-04 1.77 8.45 0.1 3.26 0.39 10.06 
PDIA4 0.64 4.2E-04 206.32 484.98 529.86 714.46 617.31 745.81 
PERP 0.55 7.1E-05 220.48 371.6 449.07 589.14 767.8 1099.68 
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PFN2 -0.91 2.5E-04 67.06 39.93 42.67 27.31 63.54 24.88 
PLAA -0.72 1.0E-04 93.43 68.49 110.54 65.05 121.97 64.03 
POMP -0.58 5.3E-05 403.97 262.89 300 231.55 366.69 217.52 
PPP1R15A -0.54 6.6E-05 5569.81 3395.73 3351.14 2634.6 2096.46 1410.87 
PPP1R3C -1.16 1.1E-04 58.22 21.57 36.05 18.55 19.08 8.84 
PROM1 0.76 4.1E-07 82.28 149.81 206.82 293.89 278.75 527.34 
PSAT1 1.28 3.8E-07 19.29 43.43 42.87 85.44 17.9 57.91 
PSMA1 -0.60 2.9E-04 120.86 90.93 150.31 99.13 162.49 94.62 
PSMA3 -0.63 3.9E-04 222.78 167.59 174.17 135.28 292.72 135.4 
PSMA4 -0.60 2.0E-05 290.2 192.65 246.69 155.58 319.67 219.96 
PSMC1 -0.59 1.1E-04 194.11 136.4 162.81 99.05 195.54 135.4 
PSMC3 -0.54 2.1E-04 231.98 170.79 205.06 143.8 334.23 213.17 
PSMD12 -0.69 3.3E-05 208.98 105.21 165.6 107.81 140.07 101.83 
PSMD14 -0.63 1.9E-04 378.14 322.64 372.93 248.03 502.62 240.08 
PXDN 0.81 5.6E-04 21.41 68.2 112.81 144.04 111.93 160.83 
PYGB 0.67 2.6E-04 53.44 96.47 131.82 148.5 214.03 431.36 
RGS2 -0.87 5.2E-09 634.71 319.72 168.18 87.98 93.64 58.87 
RIT1 -0.60 1.9E-04 155.18 123.58 170.56 98.26 221.9 140.98 
RMRP -0.75 4.3E-07 1431.87 686.96 962.09 690.34 438.88 265.64 
RPLP1 -0.62 2.0E-04 241.53 145.14 148.35 120.07 132.59 75.04 
RPPH1 -0.62 3.6E-05 2316.43 1493.12 1275.83 1029.1 709.38 377.12 
S100A8 -0.74 8.9E-05 272.32 133.19 45.04 31.45 38.75 24.47 
SACS 0.57 8.0E-05 282.59 507.13 439.67 597.73 583.28 780.34 
SCD 2.12 1.3E-11 9.91 112.79 127.48 289.35 225.84 835.67 
SCRIB 0.81 1.3E-04 35.57 73.45 45.66 80.34 45.64 68.11 
SDC1 1.09 8.5E-07 17.16 60.04 71.28 119.83 96.79 172.52 
SELK -0.56 4.0E-04 566.41 459.62 353.93 261.32 280.13 146.28 
SEMA3E -1.43 3.5E-04 50.96 12.82 19.94 14.65 20.66 5.44 
SERPINH1 -0.64 6.0E-04 427.51 184.49 175.21 134.25 143.8 114.06 
SLC1A5 0.69 1.2E-05 91.13 127.66 135.54 248.11 105.44 171.16 
SLC38A1 0.75 1.5E-05 202.08 491.39 405.89 556.73 281.9 406.08 
SLC43A3 0.61 5.0E-04 97.68 196.44 138.84 210.76 144 168.98 
SLC44A2 0.84 4.9E-04 6.72 16.32 41.84 65.45 60.2 101.28 
SLC6A14 0.62 2.3E-05 69.19 111.63 170.45 223.58 497.31 863.68 
SLC6A9 2.69 1.4E-05 0 5.54 3.31 17.52 6.69 22.84 
SLC7A5 0.78 9.2E-07 112.89 173.12 119.83 198.5 83.61 166.54 
SLU7 -0.50 4.4E-04 526.07 338.96 252.58 204.79 281.51 189.92 
SMARCA1 1.29 1.9E-05 12.03 45.76 16.43 39.33 34.03 56.83 
SNRPF -0.76 1.2E-04 115.72 68.78 60.74 36.07 68.46 40.24 
SOD1 -0.64 2.2E-06 1213.34 842.3 764.88 507.84 1023.74 592.46 
SORBS2 1.01 1.6E-04 10.97 25.07 24.59 44.11 32.66 66.34 
SQLE 0.85 9.0E-06 23.53 44.3 50.21 75.32 102.69 214.66 
SQSTM1 -0.67 3.3E-05 2126.92 1706.17 2167.46 1431.2 4024.32 1900.42 
SRXN1 -1.30 1.6E-18 339.92 162.34 362.4 141.25 441.25 159.06 
STC2 1.02 6.7E-08 57.33 101.43 69.11 128.19 49.57 127.52 
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TAF7 -0.55 4.2E-04 829.89 442.43 391.63 334.1 364.72 254.09 
TGFB2 0.91 2.8E-08 96.79 216.55 134.19 263.32 110.56 167.76 
TMEM123 0.62 7.4E-05 81.75 138.15 188.53 244.29 170.56 283.72 
TMEM184B 0.97 6.5E-04 14.16 42.84 26.65 43.63 33.05 52.48 
TNC 0.75 2.2E-04 233.04 255.9 126.24 221.99 83.02 204.74 
TPRKB -0.84 4.6E-05 91.66 40.22 81.1 46.74 90.1 60.5 
TRIB2 -1.04 3.3E-06 78.03 32.64 48.76 25.4 77.9 40.92 
TUBA1A 0.63 7.3E-05 111.65 157.68 190.7 253.44 245.11 479.35 
TUBB 0.54 6.1E-04 76.62 132.61 128 161.8 175.48 252.05 
UBB -1.10 8.7E-11 10406.87 3492.78 2556.3 1550.9 2549.7 1277.37 
UBC -1.10 2.4E-10 5944.94 1927.68 2413.02 1280.1 1993.77 1181.52 
VIM 0.53 6.4E-05 580.39 895.93 486.57 720.59 406.62 539.31 
VTRNA1-3 -1.42 3.5E-04 70.6 19.53 16.84 12.58 12.79 2.99 
ZFAND2A -1.12 6.4E-08 380.26 118.04 112.81 76.2 95.8 44.32 
ZNF222 -1.33 6.4E-05 92.72 55.96 61.67 34.32 38.16 6.25 
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Table 4.3. The 10 most enriched Gene Ontology biological processes in curcumin vs 
DMSO treated ALDH+ cells. 
Name #Genes OddsRatio P-Value FDR 
response to unfolded protein 61 0.26 4.97E-14 1.31E-10 
response to protein stimulus 96 0.31 1.76E-13 2.33E-10 
ectoderm development 143 2.71 2.15E-11 1.89E-08 
protein folding 147 0.42 7.20E-11 4.22E-08 
positive regulation of ligase 
activity 73 0.38 1.09E-10 4.22E-08 
anaphase-promoting 
complex-dependent 
proteasomal ubiquitin-
dependent protein catabolic 
process 
62 0.37 1.16E-10 4.22E-08 
negative regulation of 
ubiquitin-protein ligase 
activity involved in mitotic cell 
cycle 
61 0.37 1.42E-10 4.22E-08 
negative regulation of ligase 
activity 65 0.37 1.44E-10 4.22E-08 
negative regulation of 
ubiquitin-protein ligase 
activity 
65 0.37 1.44E-10 4.22E-08 
regulation of ubiquitin-protein 
ligase activity involved in 
mitotic cell cycle 
66 0.38 1.94E-10 4.57E-08 
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Table 4.4. The 247 genes identified as differentially expressed by curcumin treatment, with the estimated counts per million 
(CPMs) in each sample tested, in ALDH-/CD44+/CD24- normal breast cells. 
Gene logFC P Value Sample 1 CPMs Sample 2 CPMs Sample 3 CPMs 
      Curcumin DMSO Curcumin DMSO Curcumin DMSO 
ABCB1 -0.82 6.0E-06 451.14 188.47 260.01 190.3 115.16 68.56 
ADSL 0.81 2.2E-04 53.09 152.5 76.77 116.41 189.84 240.75 
AFG3L2 0.64 7.5E-04 134.59 305.78 171.64 228.55 209.58 262.07 
AGXT 0.93 1.4E-05 43.93 127.08 43.97 69.61 118.48 182.33 
AHSA1 -0.77 1.3E-05 1654.44 692.3 1057.16 760.12 763.82 507.33 
AHSA2 -0.92 3.7E-05 92.78 52.2 50.9 22.33 50.61 29.77 
AKAP1 0.75 7.0E-04 42.87 97.75 48.78 60.82 59.95 99.96 
ALAS1 -0.83 3.8E-06 282.97 116.52 231.03 151.33 174.06 113.5 
ALDH1A2 -1.51 2.3E-05 98.09 22.29 29.97 24.35 33.36 8.05 
ANKRD1 -1.51 9.1E-08 94.5 21.7 37.61 13.78 35.66 17.99 
ANO1 0.78 8.8E-06 68.62 130.8 69.99 116.89 88.66 140.92 
ANXA1 -0.75 5.7E-06 2676.31 1207.86 3763.32 2571.63 1277.75 864.2 
AP4B1 -1.14 2.1E-05 87.07 26.59 32.24 17.7 39.48 21.85 
ARID5B -0.67 1.7E-05 612.53 326.31 560.18 423.83 327.22 199.27 
ARL4A -0.71 5.3E-04 242.36 115.74 147.47 76.86 121.93 112 
AXIN2 -0.97 1.0E-04 86.94 31.67 55.99 33.14 25.31 15.37 
B4GALNT1 -1.69 2.7E-05 13.54 4.69 18.8 6.89 21.85 5.23 
BAG3 -1.41 3.7E-13 983.51 299.52 563.29 321.68 575.82 176.7 
BCL10 -0.81 5.5E-05 115.61 59.43 66.88 36.94 75.92 49.39 
BEX1 -0.78 6.4E-05 127.95 56.5 182.81 127.34 40.77 25.84 
BIRC3 0.65 1.6E-04 210.37 448.69 285.32 391.05 574.21 760.32 
BPHL 2.35 4.5E-04 1.46 10.95 0.85 5.94 2.85 8.18 
C1orf116 -0.81 5.6E-04 54.42 29.52 70.27 46.09 27.19 14.07 
C4orf26 -7.35 2.0E-04 5.57 0 2.69 0 0.46 0 
CABLES1 -0.96 4.8E-06 126.09 58.26 133.89 57.14 35.98 24.6 
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CACYBP -0.93 9.8E-07 1983.47 699.34 1095.9 736.72 907.64 554.24 
CARD10 0.84 4.1E-04 48.31 137.05 57.12 67 68.83 119.78 
CASP4 -0.71 6.7E-05 268.24 123.17 193.7 146.7 164.16 106.64 
CBR3 -1.09 1.1E-05 64.51 25.42 46.94 21.74 41.64 23.49 
CCDC121 -1.22 2.0E-05 50.57 19.94 28.98 11.76 24.66 12.04 
CCDC84 -0.89 2.4E-04 71.41 29.52 53.73 38.61 46.38 24.14 
CCND2 0.86 8.7E-05 115.61 342.73 185.22 222.61 115.07 195.02 
CD109 1.40 4.3E-04 4.51 31.87 15.41 30.41 26.59 40.76 
CD83 -0.60 3.1E-04 218.34 145.07 198.51 112.25 135.41 103.69 
CDC42EP3 -0.93 4.3E-05 131.13 42.43 121.17 80.66 108.91 71.57 
CDK6 0.69 3.4E-04 57.74 119.85 72.39 110.47 82.27 110.56 
CDKN2C -1.51 4.6E-04 20.71 6.84 12.72 3.44 12.56 5.82 
CDR2 -0.62 6.3E-04 145.07 84.66 114.24 81.25 75.64 50.57 
CHORDC1 -1.14 4.0E-09 998.5 297.17 676.4 393.54 460.65 246.37 
CITED2 -0.86 6.5E-06 196.57 82.31 145.21 97.64 86.41 51.22 
CLU -1.19 2.2E-11 1111.72 374.01 859.92 515.66 612.03 253.9 
CNN3 -0.59 1.2E-04 620.23 351.72 384.72 278.91 273.3 196 
COL2A1 -0.96 2.2E-07 142.81 67.26 115.37 71.51 110.52 51.55 
CREM -0.68 6.7E-04 118.26 55.13 122.44 94.67 88.52 58.94 
CRYAB -0.86 2.7E-07 1850.35 932.19 1431.13 1036.3 1341.48 617.57 
CSRP2 -0.84 5.5E-06 595.94 231.09 499.52 355.53 240.22 151.91 
CTGF -0.76 4.5E-06 364.87 185.34 186.63 127.58 73.66 44.16 
CYP1B1 2.45 1.2E-09 17.25 44.58 4.52 33.38 2.81 24.86 
DAZAP1 0.84 4.8E-04 48.31 157.39 103.21 133.87 116.96 164.53 
DEDD2 -0.78 1.1E-06 284.3 148.59 190.31 128.17 200.51 111.74 
DKC1 0.72 6.7E-04 75.26 199.62 154.4 212.51 167.16 207.06 
DNAJA1 -0.87 1.0E-04 3627.29 1118.71 2465.66 1855.1 1940.9 1344.26 
DNAJA4 -0.89 3.0E-09 472.11 240.67 354.74 210.97 223.2 114.94 
DNAJB1 -1.18 9.3E-14 5087.95 2006.32 2925.03 1588.54 3464.94 1402.68 
DNAJB4 -1.18 1.9E-10 1880.61 582.81 817.93 475.98 876.63 420.78 
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DOK5 -0.73 5.5E-04 114.28 62.95 66.31 40.63 27.05 17.53 
DST 0.60 1.5E-04 1534.06 2855.22 2672.93 3468.83 1952.68 2805.16 
DUSP1 -0.71 2.0E-05 356.77 176.94 261 159.77 153.31 114.16 
DUSP2 -0.80 7.1E-06 275.54 120.43 156.23 102.87 164.03 108.01 
DUSP7 0.99 1.5E-07 32.92 68.62 49.91 103.82 81.62 148.18 
EBNA1BP2 0.55 7.7E-04 189 354.07 364.92 475.86 399.92 513.16 
EGR1 -0.63 1.9E-05 828.22 521.42 384.86 277.01 594.36 352.68 
EGR2 -0.72 5.9E-04 134.98 62.56 71.12 45.02 61.79 46.38 
EGR3 -0.83 1.5E-04 101.01 47.31 53.87 33.74 47.44 28.65 
EHD3 0.82 4.7E-04 39.42 109.49 35.63 49.65 78.49 113.18 
ENDOD1 0.87 3.6E-04 25.35 73.71 52.45 87.43 69.43 90.21 
EPHB4 1.00 4.2E-05 28.93 80.16 30.12 61.06 41.92 60.91 
FABP4 -1.51 1.3E-04 58.27 16.42 9.33 2.26 7.27 4.38 
FAM110C 0.90 1.3E-05 28.54 44.97 27.85 55.95 76.24 155.24 
FAM129B 0.60 5.5E-04 60.39 106.55 83.42 121.88 148.2 200.97 
FAM210A -0.83 1.7E-04 144.54 52.79 167.97 100.49 81.44 65.29 
FAM210B 0.97 1.7E-04 17.39 32.45 15.98 32.79 30.23 59.01 
FAM43A -1.29 2.9E-04 39.15 13.49 20.36 11.52 10.72 3.73 
FBXL14 -1.44 6.4E-12 160.47 43.21 119.19 47.16 85.21 39.19 
FBXO30 -0.77 8.9E-06 264.52 178.11 226.93 150.74 169.82 76.41 
FEM1C -0.73 3.1E-04 111.89 59.63 95.15 67.83 45.96 26.56 
FLNC -0.73 6.5E-04 152.9 81.33 51.89 37.18 18.96 10.99 
FOS -0.70 1.9E-05 717.12 341.95 384.43 266.56 221.03 154.78 
FOSB -0.85 3.0E-06 503.17 200.98 232.02 165.59 186.99 111.54 
GABARAPL1 -0.75 5.2E-06 326.24 162.66 218.59 153.12 169.46 102.58 
GBP3 -1.25 3.9E-05 67.43 24.05 15.27 5.23 24.98 14.52 
GFM2 -0.77 1.5E-04 280.19 107.53 219.01 150.03 96.25 73.34 
GLA -0.88 4.5E-05 74.99 31.48 119.61 88.02 81.02 41.54 
GNG12 0.59 1.2E-04 138.43 197.86 128.8 202.77 177.37 269.34 
GNL3L 1.04 1.8E-04 19.51 76.05 37.18 61.65 61.93 88.19 
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GPATCH4 0.57 5.5E-04 88.26 145.46 99.82 161.08 188.27 235.91 
GPX1 0.88 1.1E-04 23.63 55.52 32.1 60.23 59.68 87.21 
GTF3A 0.70 6.7E-04 39.42 72.53 38.03 62.13 60 87.07 
HES1 -0.93 5.6E-05 491.89 145.07 309.5 242.09 302.79 187.69 
HIST1H4E 1.44 2.0E-05 6.77 30.7 12.02 29.22 17.48 33.82 
HLA-F-AS1 -1.18 3.9E-05 47.78 14.27 53.73 22.69 37.77 24.66 
HLA-G -1.13 8.8E-05 159.41 34.8 104.34 79.59 94.55 51.75 
HMGA2 1.06 1.0E-06 28.67 69.6 33.51 69.61 46.01 83.35 
HMOX1 -2.17 2.7E-12 1853.8 586.14 2398.36 865.01 2371.74 218.96 
HSP90AA1 -0.80 4.4E-07 11212.5 5298.9 10838.92 7430.38 8273.98 4820.37 
HSP90AB1 -0.78 1.1E-05 26939.85 11425.78 18681.84 13563.72 15235.33 9843.08 
HSPA1A -1.23 1.5E-12 4989.34 1774.64 3052.56 1772.9 2375.19 895.41 
HSPA1B -1.17 3.5E-13 8112.27 3253.48 4774.66 2660.24 4337.29 1700.8 
HSPA1L -1.49 1.9E-08 173.61 34.41 78.33 41.46 70.86 29.96 
HSPA2 -0.95 7.4E-06 402.96 127.67 236.54 148.6 133.61 91.46 
HSPA4 -0.74 5.0E-05 2102.26 874.91 1407.09 1055.66 1343.36 922.49 
HSPA4L -0.88 1.5E-05 946.74 319.07 685.87 498.79 575.13 369.36 
HSPA6 -1.20 8.6E-15 12009.53 4512.17 8307.23 4228 6227.9 2668.56 
HSPA7 -1.13 4.5E-14 7223.4 2950.04 1301.61 609.74 1178.97 593.36 
HSPA8 -0.79 3.5E-06 10952.89 4701.42 12143.36 8408.95 8163.69 5260.84 
HSPB1 -1.05 5.8E-09 310.45 121.41 167.83 107.03 170.7 77.2 
HSPB2 -4.89 1.1E-04 5.31 0 9.9 2.61 5.8 0 
HSPB8 -1.21 1.1E-09 174.27 52.59 199.07 110.47 171.02 81.64 
HSPD1 -0.84 4.7E-06 4937.71 1917.75 3488.6 2335.95 2278.66 1536.85 
HSPH1 -1.00 9.3E-09 3715.69 1383.62 2489.98 1585.45 1915.27 1015.98 
HTRA1 0.99 1.6E-04 22.3 71.95 62.49 87.43 22.82 40.43 
HTRA3 -2.64 1.2E-04 20.84 0.78 8.06 3.8 9.11 1.5 
IER5 -0.77 6.3E-07 1694.66 843.23 912.52 548.32 667.93 454.15 
IGFBP3 1.28 2.1E-06 149.19 650.85 409.32 500.21 278.45 744.42 
IL6 -0.87 4.0E-05 160.47 73.51 56.84 35.04 25.63 14.92 
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IMPDH2 0.65 1.5E-04 83.62 164.23 148.6 200.99 150.73 218.96 
IRAK1 0.91 2.9E-04 27.08 88.17 49.91 78.52 85.07 113.7 
ITGA3 0.66 5.1E-04 80.03 179.48 104.06 131.85 153.49 215.76 
ITGA6 0.76 1.8E-04 300.49 804.13 398.29 475.51 575.68 884.09 
JAG1 0.76 9.0E-07 251.52 370.69 238.52 391.52 339.6 678.08 
JMJD1C -0.60 3.9E-04 1004.08 506.96 746.24 620.66 652.06 447.21 
KANK1 0.75 2.9E-04 109.5 296.78 217.6 296.85 166.56 217.46 
KBTBD4 -1.59 2.0E-04 49.11 5.08 28.84 16.39 36.12 18.51 
KIAA0895 -0.95 4.8E-05 64.37 27.76 61.22 39.32 49.51 24.6 
KIF1A 1.27 1.6E-04 76.98 502.46 211.94 363.13 259.08 344.57 
KITLG -0.80 3.8E-04 110.3 45.36 90.35 54.52 53.1 40.1 
KLF13 0.78 4.5E-04 44.99 108.7 52.88 74 47.67 71.7 
LAD1 1.14 1.0E-04 16.19 75.47 44.25 72.82 71.91 107.94 
LIN54 -1.00 3.6E-05 42.61 19.94 55.42 28.15 45.55 23.55 
LINC00152 -0.80 1.4E-06 232.67 122.19 146.76 90.16 115.07 67.32 
LINC00568 -5.32 9.8E-05 4.91 0.2 3.82 0.12 2.16 0 
LMNB2 0.70 2.8E-04 82.03 186.91 88.08 130.07 147.14 188.67 
LOC100130899 1.08 6.1E-04 11.15 30.89 14.14 33.14 18.36 27.54 
LOC100506305 -0.89 1.5E-04 43 22.48 78.47 53.81 65.89 29.05 
LOC400680 -5.58 2.8E-04 5.44 0 3.82 0 1.56 0.13 
LRIF1 -0.92 1.8E-06 309.12 113.4 367.61 272.74 262.63 139.87 
MAP2 -0.77 1.7E-04 122.24 93.06 125.27 76.74 84.93 37.03 
MAP3K8 -0.80 4.9E-04 140.16 59.04 69.28 37.42 57.7 47.69 
MBNL2 -0.77 9.7E-06 208.91 103.23 178.71 125.56 117.51 68.63 
MCCC2 0.83 6.2E-04 33.71 96.97 49.2 76.86 66.16 85.44 
MEX3B -0.99 6.9E-04 53.62 19.55 33.65 20.31 18.82 10.79 
MICB -1.66 3.5E-05 51.63 6.45 26.16 12 27.38 13.61 
MIR22HG -0.68 6.1E-05 444.37 237.35 336.08 278.91 244.04 132.87 
MME -0.74 3.8E-04 164.98 67.45 160.05 104.3 77.8 61.95 
MMP3 -0.51 7.3E-04 617.58 397.47 756.14 504.73 652.7 529.97 
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MORC4 -0.62 3.2E-04 190.2 100.69 181.82 126.86 126.57 93.81 
MRPL18 -1.03 1.3E-06 763.58 223.08 570.5 386.65 393.8 229.17 
MRPS26 0.93 5.7E-05 20.44 47.31 34.92 63.91 40.54 66.93 
NAP1L2 -1.07 2.9E-07 201.48 73.9 128.66 89.45 88.62 37.16 
NEFM -0.60 2.9E-04 245.28 135.88 228.34 162.98 101.82 73.86 
NFKB1 0.55 4.3E-04 142.15 240.09 184.65 239.83 273.62 391.67 
NKIRAS2 -0.86 2.4E-04 94.63 42.03 58.25 43.24 45.6 23.29 
NOP14 0.63 1.0E-04 91.45 169.12 155.24 223.08 162.74 229.56 
NOV -1.66 4.6E-04 12.61 1.76 22.76 12.59 12.19 4.06 
NR4A1 -0.92 3.4E-06 159.27 86.42 86.81 38.37 48.63 29.77 
NUAK1 -1.59 3.6E-05 37.56 14.27 12.3 4.75 11.04 2.75 
NXT2 -1.14 4.5E-06 137.51 36.36 94.02 56.54 73.52 41.93 
PAPD5 -0.78 1.2E-04 167.5 69.41 127.53 95.74 91.51 57.96 
PDCD11 0.65 7.0E-04 107.51 251.03 204.73 259.55 184.13 243.1 
PDCD2L 1.46 6.1E-04 5.18 35.78 8.91 19.01 17.35 26.89 
PDHB 0.82 2.6E-04 29.2 48.1 25.87 43.12 45.92 90.35 
PDIA4 0.75 1.0E-04 96.36 241.65 208.55 261.09 325.2 496.28 
PDK4 -0.66 2.6E-04 276.6 136.86 135.59 91.23 81.44 61.95 
PEG10 -0.88 3.4E-06 211.04 84.66 168.25 110.23 90.27 54.17 
PELO -0.75 4.8E-05 97.55 63.74 113.25 59.75 120.64 73.99 
PES1 0.64 7.6E-04 125.16 288.57 196.39 267.03 237.46 290.07 
PF4V1 -7.25 4.1E-04 4.91 0 0.99 0 1.2 0 
PGF -0.89 2.2E-04 96.09 34.02 82.85 59.87 53.97 32.51 
PIP5K1A -0.59 5.2E-04 191.52 113.59 172.63 131.14 101.77 66.66 
PLEC 0.89 4.3E-05 337.13 1062.79 379.77 516.84 384.14 571.32 
PLK2 -0.65 1.1E-04 1022.4 492.1 891.31 664.97 484.99 349.87 
PNLDC1 -1.32 2.3E-04 63.05 11.54 33.37 24.23 33.77 15.31 
POGK 0.77 4.5E-04 58.53 155.43 71.97 111.07 101.5 125.08 
PPP1R14B 0.73 4.4E-04 66.23 168.92 107.03 129.36 143.37 215.23 
PPP1R3C -1.43 1.3E-04 48.31 8.41 42.42 15.32 33.91 25.64 
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PPP4R4 1.12 1.2E-05 12.87 49.27 25.17 42.53 94.41 160.48 
PRKAR1B 1.22 7.1E-04 6.64 29.91 14.28 32.55 24.66 32.97 
PRKD2 -1.14 7.6E-06 67.82 28.94 37.89 21.86 42.33 16.16 
PRRX1 0.76 7.5E-04 31.59 59.43 28.28 42.41 42.61 72.55 
PTGES3 -0.83 6.7E-06 465.47 194.92 290.13 226.88 322.62 177.03 
PWP2 1.07 6.0E-05 19.51 75.27 49.49 87.66 66.85 95.84 
PYGB 0.67 4.1E-04 36.37 65.89 47.22 68.07 99.8 155.57 
RAPGEF2 -0.63 1.3E-04 228.82 160.71 172.78 117.6 126.62 72.16 
RASD1 -1.12 1.0E-04 140.16 32.45 82.57 59.04 49.65 28.33 
RASSF9 -0.72 1.5E-04 143.48 73.9 97.84 64.98 65.15 42.59 
RBPJ 0.67 4.2E-04 38.62 82.51 93.88 134.7 115.3 156.68 
RGS2 -1.09 1.2E-05 506.62 122 273.16 166.18 179.3 122.73 
RGS4 -1.42 1.5E-04 35.44 13.29 15.13 4.16 13.16 6.48 
RRAD -0.57 2.0E-04 417.56 246.54 299.18 217.62 271.05 194.23 
RRP12 0.54 5.6E-04 130.47 216.43 155.67 225.81 260.51 333.84 
RRP9 0.93 8.6E-05 34.24 107.73 60.23 83.51 71.78 117.49 
S100A2 0.93 5.2E-05 21.63 40.67 38.74 50.84 86.04 235.58 
S100A6 0.71 3.4E-06 240.5 358.17 328.3 498.07 779.32 1502.05 
SAA1 -0.82 4.3E-05 472.38 172.44 213.07 150.27 136.56 95.51 
SCD 0.98 2.7E-05 24.55 68.43 51.18 69.97 57.83 118.8 
SCML1 -0.87 4.0E-04 45.92 20.92 57.83 34.09 37.22 22.31 
SDCCAG3 0.83 1.1E-04 36.37 95.21 67.44 107.15 93.26 129.07 
SDPR -1.17 1.9E-05 108.44 35.39 44.82 17.46 18.4 12.69 
SEC22C 0.81 7.5E-04 30.93 73.9 33.51 57.14 43.2 57.83 
SEPP1 -1.11 5.3E-04 44.86 12.12 50.76 38.01 19.42 9.03 
SERPINH1 -0.96 2.8E-07 604.17 208.8 564.84 359.09 482.05 293.08 
SH2D5 0.89 5.5E-05 66.23 196.29 86.53 129.24 69.15 100.68 
SH3BGR -1.01 2.2E-06 115.21 49.85 69.85 41.81 47.62 22.37 
SMO -1.36 6.9E-04 29.6 6.84 25.03 17.58 12.42 4.32 
SNAP23 -0.96 1.4E-05 383.98 119.26 152.27 115.7 238.89 136.6 
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SNX3 -0.62 2.2E-04 402.43 203.72 282.21 221.18 243.03 168.59 
SOD1 -0.53 4.4E-04 1190.03 704.03 801.81 601.18 792.53 592.38 
SOGA3 -2.51 2.9E-04 13.67 1.37 11.03 4.51 2.99 0.33 
SOX9 -0.99 2.1E-04 165.78 43.21 133.05 108.22 93.54 54.69 
SPP1 -0.76 5.3E-05 43.4 24.05 267.22 167.97 20.01 11.64 
SPRY2 1.13 1.4E-06 33.05 52.4 22.48 59.39 42.97 107.16 
SPTY2D1 -0.61 5.1E-04 285.76 142.92 247.71 204.55 164.26 111.54 
SREBF1 0.88 7.2E-04 16.33 41.25 29.13 49.42 33.17 49.2 
ST13 -0.62 2.1E-04 847.06 414.87 733.94 583.48 740.12 517.8 
STIP1 -0.85 2.9E-06 1761.95 686.63 1264.29 879.62 1189.14 751.61 
STK11 0.86 2.4E-04 45.39 131.77 53.3 82.2 67.36 91.2 
STK17B -0.64 3.2E-04 134.05 74.88 139.13 88.02 99.75 73.66 
SYNE1 -0.53 2.3E-04 1408.63 967.97 2559.68 1805.21 492.13 339.07 
SYNPO2 -0.90 5.0E-05 93.31 58.07 64.9 32.43 32.94 16.22 
SYP 1.23 1.9E-04 5.97 29.72 23.75 39.32 34.37 59.99 
TAOK3 -1.32 1.6E-11 144.01 46.53 132.2 60.46 85.9 37.22 
TCP1 -0.70 2.6E-04 2586.32 1052.23 1907.6 1425.45 1528.51 1171.74 
TGFBI 1.64 2.5E-04 1.59 17.79 14.7 22.69 21.26 51.55 
THOP1 0.73 7.2E-04 28.14 55.52 45.53 71.87 50.15 74.45 
TINAGL1 0.92 1.0E-04 107.38 378.51 413.28 595.12 290.92 395.53 
TP63 0.97 3.9E-06 36.63 106.55 70.27 102.75 113.19 203.92 
TRAF1 0.92 6.2E-04 61.85 248.88 211.52 296.26 420.99 525.78 
TSPYL2 -0.65 1.3E-04 2148.98 1024.27 1721.82 1375.32 1509.87 1021.41 
TTC28-AS1 -1.60 1.7E-04 28.14 4.5 17.39 7.01 17.12 8.7 
TXNIP 1.08 3.8E-09 44.33 104.01 41.71 89.68 91.79 174.48 
TXNL1 -0.55 6.8E-04 341.24 188.28 314.73 260.62 376.18 260.77 
UBB -0.98 1.6E-10 9995.13 4432.59 7484.5 3752.01 5609.25 3297.18 
UBC -1.19 2.0E-14 6809.95 2489.81 5701.03 2840.68 4185.46 1924.34 
ULBP1 -1.19 1.4E-05 70.48 27.76 49.34 30.41 19.97 6.87 
USPL1 -1.02 2.6E-06 229.62 73.51 127.11 69.85 92.02 61.76 
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VEGFA 0.81 1.3E-07 315.36 616.83 360.4 530.74 442.16 831.56 
VTRNA1-2 -1.49 3.3E-07 63.71 15.05 68.71 34.33 12.33 4.58 
VTRNA1-3 -1.70 2.2E-05 141.75 12.51 233.15 112.97 76.7 44.49 
WBP5 -0.62 4.0E-04 1385.8 643.81 903.61 690.87 638.76 490.46 
WDR3 0.85 6.8E-05 126.36 384.18 267.79 362.3 327.78 474.43 
WDR77 0.93 4.6E-04 15 45.94 31.53 55.24 50.06 67.91 
ZFAND2A -1.06 1.6E-09 421.94 150.74 234.14 126.75 196.79 111.08 
ZFP106 -0.62 1.4E-04 344.69 182.41 309.5 230.09 191.82 134.9 
ZNF131 -0.71 1.1E-05 488.7 240.09 338.48 217.26 319.59 230.67 
ZNF184 -0.82 5.3E-04 63.84 26.59 68.43 42.88 54.8 37.49 
ZNF701 -0.79 5.3E-04 79.77 33.04 80.59 50.37 59.72 43.5 
ZP4 1.60 3.7E-05 3.98 17.01 6.22 14.97 9.8 27.48 
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Table 4.5. The 10 most enriched Gene Ontology biological processes in curcumin vs 
DMSO treated ALDH-/CD44+/CD24- cells. 
Name #Genes Odds Ratio P-Value FDR 
response to protein stimulus 101 0.22 1.3E-31 3.5E-28 
response to unfolded protein 61 0.20 1.3E-29 1.7E-26 
response to biotic stimulus 333 0.41 1.7E-20 1.5E-17 
ribonucleoprotein complex biogenesis 187 4.12 8.2E-19 5.7E-16 
protein refolding 11 0.20 1.5E-18 8.5E-16 
protein folding 150 0.38 1.2E-17 5.4E-15 
ribosome biogenesis 126 4.54 8.7E-17 3.4E-14 
response to organic substance 723 0.53 4.0E-16 1.4E-13 
ncRNA metabolic process 221 3.25 3.0E-14 9.1E-12 
response to heat 51 0.34 6.5E-14 1.8E-11 
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Table 4.6. The top 10 most enriched Gene Ontology Biological processes enriched in ALDH+ and ALDH-CD44+CD24- 
breast cells following 5 µM  piperine treatment. 
Gene Ontology Biological Processes enriched in piperine treated ALDH+ cells    
Name #Genes OddsRatio P-Value FDR 
non-recombinational repair 14 0.02 1.5E-06 2.4E-03 
positive regulation of transcription from RNA polymerase II promoter 295 3.25 1.8E-06 2.4E-03 
regulation of transcription from RNA polymerase II promoter 593 2.19 1.7E-05 1.5E-02 
mesoderm development 51 8.92 2.2E-05 1.5E-02 
V(D)J recombination 10 0.02 3.9E-05 2.1E-02 
transcription from RNA polymerase II promoter 733 1.95 6.0E-05 2.6E-02 
regulation of tissue remodeling 12 30.46 7.5E-05 2.6E-02 
positive regulation of transcription, DNA-dependent 393 2.38 7.9E-05 2.6E-02 
positive regulation of gene expression 474 2.20 9.5E-05 2.8E-02 
positive regulation of RNA metabolic process 399 2.33 1.1E-04 2.8E-02 
Gene Ontology Biological Processes enriched in piperine treated ALDH-/CD44+/CD24- cells  
Name #Genes OddsRatio P-Value FDR 
translational elongation 99 14.51 1.9E-11 5.3E-08 
ribonucleoprotein complex biogenesis 186 5.13 4.2E-07 5.7E-04 
ribosome biogenesis 126 6.62 7.4E-07 6.8E-04 
response to amino acid stimulus 18 42.95 1.2E-06 7.9E-04 
ncRNA processing 182 4.84 1.5E-06 8.2E-04 
ncRNA metabolic process 222 3.90 6.4E-06 2.9E-03 
translation 377 2.84 1.1E-05 4.4E-03 
response to amine stimulus 34 16.80 1.4E-05 4.8E-03 
generation of precursor metabolites and energy 281 3.15 2.5E-05 7.7E-03 
response to organic nitrogen 62 8.88 3.0E-05 8.2E-03 
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Table 4.7. Genes identified as differentially expressed (FDR<0.05) in curucmin and piperine co-treated ALDH+ cells, 
compared to DMSO controls. 
Gene logFC P Value Sample 1 CPMs Sample 2 CPMs Sample 3 CPMs 
  
    Curcumin+Piperine DMSO 
Curcumi
n+Piperi
ne 
DMSO 
Curcumi
n+Piperi
ne 
DMSO 
ACAT2 1.00 2.4E-06 29.58 78.26 44.45 72.68 82.83 177.19 
ACOT13 -1.07 1.0E-04 19.72 10.04 41 21.21 66.15 28.09 
ACSL1 0.70 1.6E-04 74.94 143.82 224.26 314.01 289.89 495.09 
ACTN1 0.79 1.8E-05 128.19 274.36 417.59 597.28 326.09 583.28 
AGRN 0.93 5.9E-05 29.58 49.91 32.65 62.2 34.83 70.77 
AHNAK 0.63 2.5E-05 767.16 1260.44 1914.76 2712.26 1378.88 2223.06 
AHSA1 -0.70 1.4E-05 1601.38 903.4 639.11 439.92 430.01 258.76 
AKAP12 0.94 1.7E-04 25.64 84.17 45.31 68.79 31.54 57.26 
AKR1C1 -0.99 3.8E-04 141.99 137.92 226.99 113.2 636.63 183.94 
ALDH1A3 0.75 1.7E-06 370.76 587.1 777.35 1216.88 2106.05 3982.08 
ARHGAP29 0.66 4.4E-04 80.86 164.5 243.53 375.33 187.21 257.41 
ASNS 0.95 1.3E-04 51.28 93.03 63.44 89.52 29.27 81.03 
BAG3 -1.07 7.8E-07 1214.84 395.73 338.9 234.1 200.26 95.08 
BTN2A3P -2.76 3.0E-04 33.53 4.73 6.76 2.62 5.45 0.14 
C11orf73 -1.07 4.8E-05 69.03 25.4 45.6 21.37 38.35 22.55 
C20orf111 -0.75 1.3E-05 591.64 360.89 327.11 214.08 300.56 157.6 
C2CD2 1.12 3.9E-04 5.92 20.97 25.17 38.92 23.83 63.61 
C6orf15 1.62 4.6E-04 0 5.91 19.71 37.18 5.22 22.69 
CACYBP -0.79 5.6E-06 1946.51 904.28 697.8 488.45 503.08 299.54 
CALD1 0.67 5.2E-04 151.86 289.42 634.66 760.68 291.93 534.8 
CBR3 -1.34 4.2E-06 138.05 70.88 35.53 18.67 52.65 11.88 
CBS 1.36 4.6E-04 7.89 20.67 19.56 30.9 11.35 47.67 
CCL2 -1.07 8.7E-06 347.1 113.4 57.68 38.45 13.62 6.62 
CD24 0.69 3.8E-05 268.21 453.62 834.46 1136.09 1088.43 2007.38 
CDH1 0.85 1.1E-04 114.38 349.07 478.87 650.98 556.75 872.29 
CDH3 0.91 4.3E-04 3.94 34.85 55.24 77.05 97.01 174.62 
CDK2AP1 0.83 1.2E-04 21.69 61.43 80.41 113.59 108.81 202.57 
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CDK6 0.85 1.4E-05 49.3 97.16 130.47 194.78 117.89 245.25 
CDKN2AIP -0.71 2.0E-04 147.91 75.9 101.41 67.6 95.99 61.99 
CEP170B 0.79 3.8E-04 35.5 102.77 84.15 125.59 64.9 97.24 
CEP85 -1.07 1.4E-04 82.83 26.58 29.63 19.62 48.9 22.82 
CHORDC1 -0.62 4.9E-04 522.62 313.04 403.92 313.22 210.92 124.38 
CLDN1 0.99 5.4E-06 23.67 78.85 80.99 150.45 64.67 109.39 
CLMN 1.02 1.8E-05 9.86 38.39 50.06 82.69 56.05 116.28 
CLSTN1 0.85 1.6E-05 47.33 107.5 120.4 178.1 111.08 215.54 
CLU -0.65 5.0E-05 1534.33 854.08 948.24 686.64 1051.66 671.74 
CLUH 0.82 1.4E-04 33.53 78.85 59.27 95.4 36.53 61.31 
CNN2 0.89 1.3E-05 43.39 97.16 80.55 123.28 71.48 145.58 
COL12A1 0.84 3.4E-05 69.03 98.93 121.26 208.04 28.71 61.99 
CREM -1.05 6.8E-07 102.55 52.27 56.96 26.21 66.03 32.01 
CRYAB -0.88 2.3E-06 1396.28 568.5 452.83 273.02 338.68 220.94 
CSRP2 -1.29 2.5E-08 512.76 130.53 86.31 45.99 69.66 34.3 
CYP1B1 1.77 3.9E-05 23.67 34.26 8.49 27.8 4.31 29.71 
CYP51A1 0.90 6.7E-05 51.28 172.17 206.85 281.12 473.13 831.91 
DAG1 0.79 3.7E-04 25.64 58.18 64.01 89.13 63.99 121 
DEPDC5 -1.33 3.9E-04 33.53 10.93 18.41 8.98 19.63 7.29 
DNAJA1 -0.58 1.9E-04 3577.47 2040.69 1664.17 1284.08 1366.97 922.39 
DNAJB1 -1.13 2.4E-09 4459.02 1420.21 1414.88 805.64 1000.83 524.8 
DNAJB4 -1.02 7.2E-08 1416 691.65 475.42 307.42 468.82 177.73 
EIF4EBP1 1.19 1.6E-07 27.61 55.23 30.35 72.6 35.74 82.92 
F3 0.65 3.9E-04 67.05 115.77 172.33 275.72 154.31 224.32 
FADS2 1.40 1.3E-04 0 10.63 21 33.84 24.51 84 
FAM53C -0.78 7.5E-05 106.5 57 75.23 45.76 72.73 42.81 
FBXO30 -0.91 1.7E-04 201.16 142.05 164.99 111.29 151.58 48.75 
FLNA 0.76 1.1E-04 495.01 1266.94 1460.2 1931 1202.11 1784.41 
FTL -0.99 4.0E-08 790.83 504.71 534.25 268.33 1396.13 563.29 
GAA 1.97 2.5E-04 1.97 17.42 3.45 11.12 2.04 7.56 
GABARAPL1 -0.76 2.9E-04 254.41 217.65 206.42 116.85 250.75 110.07 
GADD45G -1.42 2.5E-08 143.97 56.7 39.99 19.46 49.7 13.37 
GARS 0.86 1.8E-05 80.86 207.32 173.19 252.61 112.89 201.49 
GLA -1.42 8.1E-08 104.52 28.06 43.01 24.39 98.6 32.01 
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GLIPR1 0.67 2.2E-04 104.52 202.59 252.6 376.92 207.18 306.7 
GLRX -1.09 1.4E-04 63.11 11.52 77.39 55.29 311.56 174.75 
GNB4 1.46 3.6E-05 0 25.99 21 41.23 20.2 50.64 
GNE 1.21 4.3E-05 9.86 42.82 17.55 31.77 24.17 56.05 
GSR -0.99 1.0E-06 100.58 68.52 101.12 44.48 187.89 87.78 
GUCY1A3 1.00 3.3E-05 15.78 51.09 52.94 79.2 59.45 132.75 
HIP1R 0.68 6.8E-04 57.19 71.47 82.71 127.97 93.83 178.94 
HMOX1 -2.27 2.1E-13 1416 620.18 1067.78 203.04 1698.16 183.26 
HSP90AA1 -0.68 9.7E-06 9056.09 4610.01 6381.51 4890.86 5118.77 3217.43 
HSP90AB1 -0.58 1.3E-05 20476.78 12166.18 9580.68 7299.27 8245.28 5463.71 
HSPA1A -1.35 5.8E-13 3346.73 1032.45 978.02 523.01 603.5 222.29 
HSPA1B -1.41 5.2E-15 5251.82 1495.52 1921.52 944.73 1422.34 542.77 
HSPA1L -1.61 3.5E-10 126.22 35.73 32.65 11.12 29.61 10.53 
HSPA4L -0.80 9.6E-05 445.7 189.01 208.58 160.06 107.11 61.45 
HSPA6 -1.41 2.0E-17 8683.35 2579.07 2883.57 1354.46 2206.01 841.9 
HSPA7 -1.32 3.5E-16 2510.54 942.68 296.04 130.43 355.58 139.51 
HSPA8 -0.54 4.0E-04 10939.49 6100.81 6129.2 5252.29 4736.97 3196.22 
HSPD1 -0.73 1.5E-06 3358.56 1905.14 1612.96 1099.07 1015.02 571.4 
HSPH1 -0.83 3.5E-07 2583.51 1406.04 1442.22 972.37 894.18 436.35 
HYOU1 0.72 5.8E-04 368.79 952.42 727.44 945.13 508.3 703.34 
ID2 -1.05 1.6E-04 254.41 67.04 46.75 32.57 43.57 25.79 
IER5 -0.74 3.3E-05 2001.73 921.71 852.01 635.96 737.61 458.09 
IGFBP3 0.98 8.1E-06 136.08 434.13 425.93 564.31 1273.82 2525.97 
IGSF3 0.79 2.0E-04 19.72 39.87 53.37 84.04 76.02 136.4 
INTS1 1.32 3.5E-05 15.78 52.86 29.92 46.63 14.98 51.72 
ITGB4 1.16 3.6E-07 13.81 35.14 67.03 116.37 113.23 312.64 
ITGB8 0.70 4.4E-04 65.08 160.36 273.74 380.82 462.92 676.6 
JAM3 2.69 1.3E-04 0 16.83 1.01 7.15 1.25 4.59 
KCNN4 1.28 2.5E-04 1.97 64.38 85.88 121.38 88.39 175.02 
KDR 1.79 1.0E-04 3.94 2.36 7.34 25.9 7.15 32.55 
KIAA1644 3.37 3.7E-06 3.94 8.56 0.43 6.59 0.91 14.32 
KIFC3 1.08 2.3E-04 11.83 40.75 37.4 57.75 15.66 37.68 
KLF6 0.68 2.6E-04 76.91 158.29 140.25 218.45 104.72 147.61 
KLK10 1.01 1.1E-05 1.97 22.44 77.1 122.09 161 338.16 
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KLK5 0.79 2.7E-04 21.69 58.18 120.54 158.47 148.86 281.98 
KLK7 1.01 4.7E-06 5.92 29.53 79.26 148.78 70.23 129.24 
KRT15 1.38 2.4E-10 136.08 470.16 801.23 1334.28 874.21 2836.32 
KRT16 0.91 3.6E-07 112.41 189.3 402.92 703.17 374.42 821.37 
KRT17 0.89 1.4E-06 408.23 624.32 1541.9 2522.88 380.21 959.66 
KRT5 0.92 9.3E-07 224.82 440.33 504.04 751.07 268.56 627.17 
KRT6A 1.14 6.4E-08 21.69 44 162.4 304.16 66.26 178.67 
KRT7 0.59 2.8E-04 1173.43 2035.67 3246.93 3763.83 4664.02 7904.2 
KRT81 1.23 3.9E-04 3.94 52.27 123.71 149.9 19.97 50.78 
LOXL4 1.79 3.2E-04 5.92 5.02 6.04 15.97 8.28 57.26 
LPAR6 -2.37 1.4E-04 63.11 9.75 16.97 9.85 6.69 0.27 
LPP 0.72 3.6E-04 23.67 35.73 92.64 147.75 83.28 146.53 
LRIF1 -0.80 1.4E-05 451.62 212.63 235.48 160.78 124.58 72.66 
LYPD3 -0.99 1.6E-04 47.33 21.56 39.41 18.27 46.86 27.15 
MACC1 0.85 9.0E-06 106.5 269.63 530.8 871.17 306.57 472.54 
ME1 -1.11 3.4E-04 13.81 3.84 40.28 19.86 51.51 26.33 
MED6 -0.77 1.3E-04 220.88 108.09 110.19 85.23 108.92 56.18 
MIR22HG -0.69 4.0E-04 684.33 501.17 357.17 258.33 332.44 149.77 
MRPL18 -0.73 2.0E-05 534.45 305.66 331.28 221.23 218.3 124.38 
MTHFD1L 0.83 3.1E-04 33.53 59.36 35.67 65.69 28.93 50.1 
MTHFD2 0.74 4.1E-04 112.41 288.24 221.09 290.34 134.56 206.09 
MVD 1.16 2.2E-05 11.83 32.49 19.56 37.57 28.14 67.93 
MYH9 0.82 2.0E-04 532.48 1546.02 2198.71 2574.83 1414.28 2364.18 
NBEAL2 1.31 3.8E-05 5.92 12.11 24.89 49.09 20.2 65.5 
NRIP3 -1.43 5.0E-04 55.22 18.9 21.86 14.54 18.38 3.78 
NT5E 0.72 3.3E-04 23.67 56.7 121.26 190.33 116.86 174.62 
OSBPL5 1.15 3.0E-04 11.83 31.9 13.09 33.28 17.47 31.47 
PDIA4 0.88 3.8E-05 163.69 491.42 476.85 712.78 490.94 740.88 
PFDN4 -0.74 1.9E-04 102.55 78.26 95.08 50.6 121.29 68.88 
PFN2 -1.22 1.3E-06 65.08 40.46 63.72 27.25 75.34 24.71 
PHGDH 1.06 9.5E-06 25.64 47.55 25.6 56.88 30.97 64.28 
PIP4K2B 1.17 6.7E-04 7.89 31.9 12.95 19.94 18.49 47.4 
PKP3 1.05 1.2E-04 3.94 43.12 47.76 81.74 75.68 124.92 
PLEC 0.85 1.2E-04 485.15 1448.86 1486.95 1854.59 939 1519.85 
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PLXNA1 0.89 1.9E-04 27.61 88.6 80.7 106.6 62.86 123.03 
PPL 0.97 2.2E-04 29.58 139.69 311.14 400.36 388.83 684.57 
PPP1R3C -1.19 5.3E-05 61.14 21.85 37.11 18.51 19.63 8.78 
PROM1 0.73 2.7E-04 94.66 151.8 221.53 293.2 244.51 523.86 
PRSS12 1.15 1.6E-04 7.89 20.67 24.31 43.45 20.2 52.8 
PSAT1 1.34 1.1E-06 25.64 44 38.55 85.23 16.11 57.53 
PSMA2 -0.70 6.2E-05 234.69 157.41 215.77 136.47 278.77 155.44 
PSMA3 -0.74 5.2E-04 191.3 169.81 234.62 134.96 300.67 134.51 
PSMA4 -0.76 3.2E-05 280.04 195.21 250.73 155.22 451.57 218.51 
PSMA6 -0.57 4.5E-04 709.97 519.77 544.61 370.57 703.68 434.05 
PSMB1 -0.65 1.3E-04 508.81 326.33 324.38 225.28 395.64 229.45 
PSMC1 -0.71 1.0E-04 183.41 138.21 167.58 98.82 252.34 134.51 
PSMC3 -0.73 5.9E-05 230.74 173.06 254.03 143.46 398.02 211.76 
PSMD12 -0.62 4.2E-04 159.74 106.61 156.94 107.56 167.24 101.15 
PSMD13 -0.62 3.0E-04 301.74 197.28 221.09 151.56 353.66 219.05 
PSMD14 -0.78 2.9E-04 374.71 326.92 438.3 247.44 578.31 238.5 
RASD1 -0.83 9.0E-05 153.83 83.87 41.43 25.82 39.26 20.53 
RGS2 -1.14 3.9E-11 765.19 323.97 176.64 87.78 132.41 58.48 
RNASE4 1.93 2.6E-04 0 9.16 1.87 7.23 7.83 22.96 
RPL39 -0.83 5.1E-05 126.22 96.28 90.77 44.8 107.79 54.29 
RPS6KA2 1.14 2.1E-04 5.92 16.24 36.97 60.77 19.52 54.97 
S100A8 -0.86 4.3E-05 315.54 134.96 43.87 31.38 44.93 24.31 
SACS 0.71 2.6E-04 216.94 513.86 444.63 596.32 529.52 775.19 
SCD 1.59 4.1E-10 21.69 114.29 155.21 288.67 225.11 830.15 
SCNN1A 1.46 2.5E-06 3.94 21.56 17.55 34.87 27.23 88.32 
SDC1 0.94 1.2E-05 35.5 60.84 73.07 119.55 71.59 171.38 
SGPL1 0.82 2.1E-04 21.69 55.52 74.08 106.29 61.84 115.06 
SHFM1 -0.65 1.6E-04 297.79 210.27 239.94 142.59 290.8 181.24 
SHMT2 0.98 5.3E-06 45.36 134.37 86.16 134.64 63.42 123.44 
SLC38A1 0.78 1.5E-05 252.43 497.92 394.57 555.41 215.35 403.39 
SLC43A3 0.63 6.5E-04 102.55 199.05 143.42 210.27 120.95 167.87 
SLC44A2 1.05 4.7E-04 3.94 16.54 46.75 65.3 37.56 100.61 
SLC7A1 0.99 1.0E-06 37.47 83.58 68.62 129.64 33.58 66.85 
SLC7A5 0.75 4.1E-05 98.61 175.42 134.93 198.03 89.18 165.44 
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SNIP1 -0.60 6.1E-04 201.16 134.37 152.62 98.82 92.81 62.12 
SOD1 -0.85 7.1E-08 1500.8 853.49 840.21 506.64 1181.46 588.55 
SQLE 0.85 1.6E-04 23.67 44.89 52.65 75.15 96.78 213.24 
SQSTM1 -0.64 4.4E-04 1993.84 1728.83 2205.62 1427.86 4008.56 1887.86 
SREBF1 1.24 5.3E-06 17.75 45.48 43.3 72.37 31.77 103.18 
SRXN1 -1.34 2.2E-10 305.68 164.5 335.45 140.92 559.59 158.01 
STC2 1.25 3.4E-09 31.55 102.77 65.16 127.89 50.72 126.68 
TAGLN 1.16 4.7E-04 7.89 14.47 27.91 46.95 16.79 53.61 
TGFB2 0.97 4.7E-07 82.83 219.43 150.75 262.69 92.92 166.65 
THAP9-AS1 -0.72 4.0E-04 323.43 137.33 284.96 218.61 121.18 79.41 
THSD4 0.93 2.5E-04 13.81 31.01 24.89 45.76 35.63 66.98 
TMA7 -0.70 6.0E-04 187.35 160.36 141.69 86.19 181.31 84.95 
TMEM132A 0.97 6.8E-04 21.69 54.04 27.91 39 19.74 48.08 
TNC 0.95 1.6E-04 199.19 259.29 136.94 221.47 60.81 203.39 
TP53INP1 1.38 6.2E-04 7.89 12.11 6.47 24.55 14.41 32.14 
TRIM16L -0.98 3.6E-04 43.39 43.12 86.45 35.67 86.68 33.9 
TUBA1A 0.67 3.9E-04 106.5 159.77 183.69 252.84 249.95 476.19 
TXN -0.67 3.9E-04 481.2 371.52 411.98 281.12 576.83 275.23 
TXNIP 0.93 9.3E-05 74.94 85.05 76.96 145.37 86.68 240.93 
UBB -1.33 5.6E-14 11966.97 3539.17 2888.17 1547.25 3215.58 1268.93 
UBC -1.10 3.1E-10 5727.11 1953.28 2401.39 1277.09 2120.92 1173.72 
VGLL3 1.10 2.0E-05 19.72 46.07 27.62 58.94 18.38 38.08 
VIM 0.59 2.6E-04 546.28 907.83 503.18 718.89 369.09 535.74 
VTRNA1-3 -1.73 4.6E-05 65.08 19.79 22.44 12.55 20.54 2.97 
ZFAND2A -1.58 2.4E-10 571.92 119.61 141.26 76.02 134.34 44.03 
ZNF462 0.72 4.2E-04 86.77 153.86 111.05 145.05 38.12 76.3 
ZNF701 -0.79 6.1E-04 86.77 38.69 59.7 35.98 48.9 32.68 
ZPLD1 2.08 3.6E-04 0 3.25 7.05 18.83 2.16 13.5 
 
  
153 
 
Table 4.8. Genes identified as differentially expressed (FDR<0.05) in curucmin and piperine co-treated ALDH-
CD44+CD24- cells, compared to DMSO controls. 
Gene logFC P Value Sample 1 CPMs Sample 2 CPMs Sample 3 CPMs 
  
  Curcumin+Piperine DMSO 
Curcumi
n+Piperi
ne 
DMSO 
Curcumi
n+Piperi
ne 
DMSO 
ABCB1 -0.94 1.2E-06 483.29 188.74 283.11 190.49 127.05 68.59 
ABHD3 -0.95 5.1E-04 86.08 28 60.26 44 42.42 24.15 
ACTBL2 -1.61 1.9E-04 39.24 8.22 21.86 8.68 4.47 1.9 
AFAP1 -0.73 6.4E-04 87.09 43.86 95.81 58.74 66.03 46.47 
AFG3L2 0.72 5.2E-04 122.53 306.21 157.65 228.78 207.42 262.19 
AGXT 1.01 7.4E-04 28.1 127.26 50.52 69.68 130.37 182.41 
AHSA1 -0.85 1.3E-05 1793.67 693.27 996.73 760.88 878.95 507.56 
AHSA2 -0.80 5.5E-04 99.49 52.27 35.75 22.35 51.21 29.78 
AKAP1 0.95 2.0E-04 31.65 97.89 45.49 60.88 55.88 100.01 
AKT1 1.06 1.9E-04 20 80.47 42.64 77.05 73.13 98.37 
ALAS1 -0.94 2.2E-06 315.7 116.69 233.87 151.49 194.1 113.56 
ALDH1A2 -1.52 9.3E-06 70.38 22.32 37.52 24.38 39.51 8.05 
ANKRD1 -1.64 2.8E-08 112.4 21.73 36.24 13.79 41.13 18 
ANO1 1.23 3.2E-06 29.37 130.98 72.28 117 73.94 140.98 
ANXA1 -0.80 1.6E-05 3025.56 1209.55 3604.26 2574.2 1299.41 864.59 
AP4B1 -1.16 8.1E-05 96.2 26.63 26.88 17.72 45.19 21.86 
ARFRP1 0.95 6.5E-04 19.75 66.96 34.96 53.51 49.12 72.65 
ARID5B -0.71 1.6E-05 622.28 326.76 619.98 424.26 314.65 199.36 
ARL4D -1.83 2.8E-05 32.4 7.24 18.81 4.04 13.19 5.96 
ATP1B1 -1.38 4.6E-04 63.04 9.2 44.9 25.33 28.14 17.28 
AXIN2 -0.90 8.7E-04 85.32 31.72 53.47 33.17 23.27 15.38 
B4GALNT1 -1.55 4.8E-04 13.16 4.7 17.23 6.9 18.67 5.24 
BAG3 -1.40 1.2E-14 994.93 299.94 656.71 322 477.5 176.78 
BCL10 -0.75 4.2E-04 109.87 59.52 66.17 36.98 71.31 49.41 
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BEX1 -0.89 6.8E-05 154.68 56.58 172.03 127.47 45.6 25.85 
BIRC3 0.58 5.0E-04 246.33 449.32 288.13 391.44 558.54 760.66 
BMP4 -1.09 6.9E-04 36.71 11.75 40.57 21.76 23.41 13.55 
BPGM -0.84 2.3E-04 82.28 35.44 70.51 45.3 65.01 40.19 
C2orf44 -0.93 8.1E-04 65.32 22.91 43.82 26.63 41 26.83 
C7orf50 1.10 8.0E-04 17.97 85.75 28.26 51.72 65.35 79.72 
CABLES1 -1.08 2.4E-07 151.14 58.34 116.2 57.19 44.38 24.61 
CACYBP -1.03 3.6E-07 2186.58 700.32 1119.03 737.46 999.44 554.49 
CAMK2N1 0.66 6.8E-04 40.25 77.33 78.09 117.36 104.66 147.39 
CASP4 -0.80 3.7E-05 294.43 123.34 206.49 146.85 170.76 106.68 
CBR3 -1.07 4.3E-05 66.84 25.45 42.34 21.76 43.3 23.5 
CCDC121 -1.54 2.8E-07 77.97 19.97 33.68 11.77 26.93 12.04 
CCK -0.96 2.4E-04 55.7 20.95 68.93 49.46 50.13 24.28 
CCND2 0.84 2.2E-04 116.96 343.21 173.8 222.83 126.78 195.11 
CD83 -0.68 1.2E-04 256.71 145.27 190.84 112.37 143.29 103.74 
CDC42EP3 -0.97 7.7E-04 173.92 42.48 117.38 80.74 93.83 71.6 
CDK6 0.68 7.7E-04 60 120.02 86.46 110.58 67.79 110.61 
CDR2 -0.68 6.4E-04 166.84 84.77 107.24 81.33 80.03 50.59 
CHORDC1 -1.12 1.1E-07 1024.05 297.59 681.03 393.94 427.7 246.48 
CITED2 -0.75 1.5E-04 182.02 82.42 149.68 97.74 72.86 51.25 
CKAP5 0.80 2.9E-04 54.43 149.77 112.55 162.07 131.45 179.92 
CLU -1.19 2.0E-10 1130.88 374.53 877.09 516.17 583.51 254.01 
CNN3 -0.57 4.2E-04 574.43 352.21 400.98 279.19 274.47 196.09 
COL2A1 -1.05 1.1E-07 167.09 67.35 120.23 71.58 109.94 51.57 
CRYAB -0.83 4.4E-07 1956.45 933.49 1506.42 1037.34 1131.63 617.85 
CSRP2 -0.91 6.4E-06 625.31 231.42 483.59 355.89 274.33 151.97 
CTGF -0.86 2.1E-06 393.42 185.6 192.31 127.71 82.81 44.18 
CYB5D2 -1.42 1.9E-05 25.06 9.98 35.15 16.77 38.36 10.6 
CYP1B1 2.11 2.2E-05 22.28 44.64 10.83 33.41 1.62 24.87 
DEDD2 -0.86 1.2E-06 281.01 148.8 197.73 128.3 227.11 111.79 
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DKC1 0.84 3.9E-04 64.56 199.89 158.93 212.72 145.93 207.15 
DNAJA1 -0.93 4.9E-05 3826.07 1120.27 2639.43 1856.96 1946.38 1344.86 
DNAJA4 -0.87 1.3E-07 410.13 241.01 393.3 211.18 223.19 115 
DNAJB1 -1.21 3.8E-15 5138.21 2009.13 3130.51 1590.13 3482.24 1403.31 
DNAJB4 -1.20 8.2E-10 1893.92 583.63 792.2 476.46 941.8 420.97 
DOK5 -0.77 8.6E-04 128.1 63.04 75.63 40.67 22.73 17.54 
DST 0.61 3.6E-05 1769.11 2859.22 2376.32 3472.29 1882.11 2806.42 
DUSP1 -0.90 2.7E-07 390.89 177.18 271.68 159.93 197.41 114.21 
DUSP2 -0.93 4.9E-06 324.05 120.6 147.81 102.97 195.52 108.06 
DUSP4 0.57 5.6E-04 267.09 422.5 382.17 600 182.19 237.84 
DUSP7 1.03 3.2E-07 32.15 68.72 57.8 103.92 66.98 148.24 
EBNA1BP2 0.64 2.8E-04 176.2 354.56 321.21 476.34 397.94 513.39 
ECHS1 1.09 1.4E-04 20.76 80.08 31.61 57.43 48.51 70.75 
EDN1 -0.73 7.0E-04 201.77 84.77 121.32 83.47 60.82 46.14 
EGR1 -0.67 1.7E-05 849.87 522.15 452.97 277.29 539.87 352.84 
EGR2 -0.88 3.8E-04 177.21 62.65 84.69 45.07 55.2 46.4 
EHD3 1.03 6.5E-04 25.32 109.64 38.01 49.7 71.1 113.23 
FADD 1.26 7.7E-05 12.41 59.52 19.01 37.69 44.25 70.1 
FAM210A -0.98 2.6E-04 197.21 52.86 172.52 100.59 80.37 65.32 
FAM210B 1.04 2.1E-04 18.48 32.5 15.26 32.82 26.32 59.04 
FAM60A 0.64 7.7E-04 126.33 267.44 157.85 215.93 148.84 197.72 
FAM83D -1.31 1.5E-05 70.63 21.54 52.88 32.58 17.66 6.02 
FBXL14 -1.47 2.5E-12 153.67 43.27 127.03 47.21 89.1 39.2 
FBXL5 0.87 8.5E-04 25.06 78.12 53.17 66.94 69.28 112.64 
FBXO30 -0.72 9.4E-05 250.38 178.36 229.83 150.89 160.41 76.45 
FEM1C -0.98 9.4E-07 121.27 59.71 122.4 67.9 56.02 26.57 
FLNC -0.90 3.3E-05 150.89 81.45 61.84 37.22 23.61 11 
FOS -0.80 8.1E-06 779.49 342.42 420.08 266.83 227.86 154.85 
FOSB -0.94 1.8E-07 487.85 201.27 296.3 165.76 182.87 111.59 
GABARAPL1 -0.74 7.4E-05 265.32 162.89 206 153.27 217.84 102.63 
156 
 
GADD45G -0.77 9.3E-05 170.13 102.79 112.45 55.41 58.52 39.86 
GATA3 -1.25 7.4E-04 36.96 10.96 25.7 13.08 10.96 5.3 
GBP3 -1.19 5.1E-04 58.99 24.08 17.53 5.23 22.12 14.53 
GCLM -0.66 6.1E-04 224.81 184.04 275.62 181.33 250.32 117.48 
GEMIN8P4 -1.64 1.8E-04 36.2 5.48 19.4 8.2 16.24 7.72 
GFM2 -0.85 6.1E-05 293.67 107.68 207.09 150.18 116.7 73.37 
GJA5 -2.95 8.6E-04 11.9 0 11.82 2.62 4.87 1.51 
GLA -1.01 4.2E-06 69.62 31.52 132.44 88.11 102.36 41.56 
GLOD4 1.00 2.5E-04 18.73 63.43 42.15 60.64 40.32 71.08 
GNG12 0.74 1.2E-05 118.73 198.13 124.76 202.97 156.28 269.46 
GPATCH4 0.64 2.6E-04 85.82 145.66 105.46 161.24 160.88 236.01 
GPM6B 1.28 1.7E-04 7.59 34.65 34.17 50.18 16.24 39.07 
GPRC5C -1.01 7.4E-04 160.51 39.74 174 169.92 94.51 46.21 
H1F0 1.03 1.3E-04 18.99 68.13 62.33 87.4 41.94 76.64 
HBEGF -0.72 3.6E-04 317.72 132.74 247.95 183.12 168.12 120.69 
HES1 -1.02 4.1E-04 644.81 145.27 311.96 242.33 282.38 187.78 
HIST1H1D 2.34 1.2E-04 0 8.22 6.5 22.83 6.29 17.67 
HIST1H1E 0.87 7.6E-04 24.56 56.39 41.56 57.31 24.76 48.96 
HIST1H4E 1.17 3.2E-04 9.87 30.74 14.48 29.25 17.73 33.84 
HLA-F-AS1 -1.37 7.8E-07 52.15 14.29 46.18 22.71 59.53 24.67 
HLA-G -1.03 1.7E-06 95.19 34.85 125.75 79.67 105.61 51.77 
HMGA2 1.01 1.3E-05 29.37 69.7 44.8 69.68 36.87 83.38 
HMGCS1 -0.76 7.7E-04 428.1 150.95 333.62 254.22 224.27 169.65 
HMOX1 -2.10 9.7E-10 1423.03 586.96 2581.63 865.87 2547 219.06 
HSP90AA1 -0.78 9.8E-08 10653.14 5306.31 
12275.2
7 7437.81 7417.89 4822.53 
HSP90AB1 -0.83 6.2E-07 27881.19 11441.77 
19161.0
9 
13577.2
9 
16278.1
4 9847.5 
HSPA1A -1.40 1.6E-17 5350.87 1777.12 3694.36 1774.67 2651.32 895.81 
HSPA1B -1.31 3.5E-17 9036.43 3258.03 5445.18 2662.9 4599.87 1701.56 
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HSPA1L -1.71 1.5E-09 214.68 34.46 84.59 41.5 84.7 29.98 
HSPA2 -0.92 3.3E-06 335.7 127.85 263.02 148.75 134.9 91.5 
HSPA4 -0.75 1.1E-04 2181.01 876.13 1343.74 1056.72 1396.36 922.91 
HSPA4L -0.95 7.6E-06 989.62 319.52 708.11 499.29 616.66 369.53 
HSPA6 -1.35 2.1E-17 13755.91 4518.48 8603.46 4232.22 7185.97 2669.76 
HSPA7 -1.22 2.7E-14 8378.71 2954.17 1208.94 610.34 1340.75 593.63 
HSPA8 -0.81 2.0E-06 11210.1 4708 
11747.4
6 8417.36 8476.66 5263.21 
HSPB1 -1.11 2.1E-09 331.9 121.58 204.13 107.13 151.14 77.23 
HSPB8 -1.22 7.4E-08 194.43 52.67 183.94 110.58 171.7 81.68 
HSPD1 -0.92 2.7E-06 5596.95 1920.44 3526.56 2338.29 2379.63 1537.54 
HSPH1 -1.02 1.3E-07 4227.58 1385.56 2533.77 1587.04 1756.54 1016.43 
HTRA1 1.36 2.0E-05 13.42 72.05 56.52 87.51 18 40.45 
HTRA3 -2.77 4.8E-05 22.03 0.78 11.72 3.8 8.19 1.51 
IARS2 0.77 4.1E-04 49.37 123.74 57.31 83 102.09 143.79 
ICMT 1.30 8.5E-04 6.33 32.3 16.44 47.92 38.16 42.74 
IER5 -0.96 8.9E-09 2037.72 844.41 981.37 548.87 773.07 454.35 
IGFBP3 1.37 8.0E-06 139.49 651.76 441.74 500.71 233 744.75 
IL6 -0.75 5.6E-04 131.9 73.61 60.46 35.08 23.14 14.92 
IL8 0.56 7.3E-04 2014.68 3612.59 3816.07 4258.74 6572.77 10532.37 
IMP3 0.86 3.2E-04 32.66 61.28 26.98 54.34 38.63 61.2 
IMPDH2 0.61 8.7E-04 86.33 164.46 148 201.19 157.36 219.06 
IRAK1 1.12 4.1E-05 21.27 88.3 51.4 78.6 64.81 113.75 
ITGA3 0.82 1.7E-04 64.56 179.73 94.04 131.99 147.82 215.85 
ITGA6 0.77 7.0E-05 345.82 805.26 390.83 475.98 506.32 884.49 
ITPA 0.98 4.8E-04 20.51 54.23 17.04 29.96 28.41 47.84 
JAG1 0.84 4.6E-07 202.28 371.21 254.16 391.91 335.36 678.39 
JUND -0.58 6.2E-04 509.87 301.31 276.41 212.37 230.16 152.83 
KANK1 0.84 1.6E-04 101.52 297.2 190.25 297.15 168.12 217.55 
KCNJ2 -1.14 1.1E-04 44.05 20.17 46.48 23.66 19.35 7.66 
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KCNMA1 0.87 3.2E-04 17.47 45.81 48.05 70.87 57.44 95.43 
KIAA1644 2.21 2.0E-04 0 2.35 2.86 9.16 6.56 27.62 
KIF1A 1.38 1.3E-04 66.84 503.16 207.18 363.5 238.95 344.72 
KITLG -0.78 3.8E-04 94.43 45.42 96.11 54.58 55.88 40.12 
LAD1 1.07 7.1E-05 19.49 75.57 44.02 72.89 68.74 107.99 
LDHA 0.72 2.7E-04 151.9 362.59 348.49 432.58 384.61 585.51 
LGALS7B 5.86 8.4E-04 0 4.11 0.1 2.73 0 1.44 
LIMD1-AS1 -1.85 1.7E-04 24.81 7.05 19.89 10.58 13.4 1.77 
LIN54 -1.16 6.0E-05 73.92 19.97 52.58 28.18 39.71 23.56 
LINC00152 -0.82 9.0E-06 253.16 122.36 133.23 90.25 120.96 67.35 
LINC00472 -0.95 3.3E-04 91.65 32.5 51.11 35.2 39.51 22.19 
LINC00568 -5.10 7.9E-04 5.57 0.2 2.46 0.12 1.89 0 
LOC100128239 -1.06 4.8E-04 52.4 25.84 25.01 12.13 21.72 10.01 
LOC100130899 1.45 3.9E-04 4.56 30.93 14.97 33.17 16.71 27.55 
LOC100506305 -1.03 8.7E-05 59.49 22.52 71.79 53.86 71.92 29.06 
LRIF1 -0.98 5.8E-05 399.75 113.55 361.39 273.01 234.08 139.93 
MAK16 0.85 5.0E-05 80 214.58 148.89 202.73 145.32 237.58 
MAP2 -0.72 5.8E-04 115.19 93.19 131.46 76.81 77.94 37.04 
MAP3K8 -0.81 7.7E-04 141.01 59.13 72.18 37.46 56.29 47.71 
MBNL2 -0.87 2.3E-05 272.4 103.37 184.24 125.68 110.14 68.66 
MCCC2 0.80 8.1E-04 35.95 97.11 54.75 76.93 58.93 85.48 
MEX3B -1.12 2.6E-04 57.97 19.58 45.1 20.33 17.05 10.8 
MGC16275 -2.67 4.4E-04 22.78 0.2 33.68 24.02 11.64 1.96 
MICB -1.87 3.1E-06 58.48 6.46 30.72 12.01 32.34 13.61 
MIR22HG -0.92 5.4E-06 616.2 237.68 367.2 279.19 265.67 132.93 
MME -0.87 9.2E-05 192.4 67.55 159.03 104.4 89.23 61.98 
MORC4 -0.74 2.5E-04 234.68 100.83 168.09 126.99 142.41 93.85 
MRPL18 -1.10 1.5E-06 824.81 223.39 606.49 387.04 396.18 229.27 
MRPS26 0.96 1.4E-04 18.99 47.38 32.3 63.97 43.7 66.96 
MSX1 -1.31 4.6E-04 44.56 13.51 14.38 7.25 14.75 6.35 
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MSX2 -1.88 2.1E-04 28.1 3.33 25.7 16.53 10.62 2.49 
MYBBP1A 0.84 7.8E-04 24.81 68.33 50.12 86.8 61.09 77.17 
MYCN -3.31 6.4E-04 6.08 0.59 7.88 1.66 2.44 0.07 
NAP1L2 -1.30 1.5E-09 233.67 74.01 152.04 89.54 105 37.18 
NBN 0.95 5.9E-04 19.75 67.35 27.47 39.48 60.21 94.57 
NCAPG -1.55 3.4E-04 36.2 8.03 13.79 7.25 12.38 4.12 
NFKB1 0.70 5.3E-05 126.84 240.42 154.3 240.07 268.99 391.85 
NKIRAS2 -1.02 4.2E-06 95.95 42.09 80.35 43.28 46 23.3 
NOL6 0.98 5.1E-04 22.53 85.75 46.28 65.76 53.65 82.27 
NPPC -1.11 4.1E-04 48.86 17.62 38.4 18.91 14 7.72 
NPY1R -1.64 4.6E-04 43.54 4.89 31.51 21.64 15.02 5.56 
NR1D1 1.04 1.0E-04 28.86 55.6 17.82 35.08 18.81 42.94 
NR4A1 -0.77 6.9E-04 121.01 86.54 91.78 38.41 44.58 29.78 
NUDC -0.56 6.7E-04 530.13 353.39 610.23 370.15 319.12 247.86 
NXT2 -1.33 4.2E-06 189.11 36.42 102.41 56.6 74.42 41.95 
OGFOD1 0.69 7.1E-04 59.24 119.62 90.99 111.53 73.07 126.32 
PAPD5 -0.71 6.4E-04 158.99 69.5 130.57 95.84 82.88 57.99 
PDHB 0.79 8.5E-04 31.65 48.16 20.58 43.16 55.81 90.39 
PDIA4 0.68 2.8E-04 112.15 241.99 193.99 261.36 349.02 496.5 
PDK4 -0.60 7.4E-04 229.11 137.05 135.6 91.32 87.48 61.98 
PEG10 -0.85 1.3E-04 228.35 84.77 141.9 110.34 91.87 54.19 
PELO -0.67 5.2E-04 98.48 63.83 87.84 59.81 130.16 74.02 
PLEC 0.72 4.4E-04 418.48 1064.28 395.46 517.36 424.12 571.57 
PLK2 -0.69 2.2E-04 1126.33 492.79 863.5 665.64 500.16 350.03 
PM20D2 0.98 1.5E-04 40.76 137.64 50.81 71.82 41.4 69.05 
PNLDC1 -1.55 5.7E-05 86.58 11.55 40.37 24.26 33.62 15.32 
PNMAL1 -1.10 7.8E-04 40.51 18.99 29.64 12.84 14.27 7.07 
POGK 0.95 8.6E-04 37.72 155.65 79.47 111.18 93.5 125.14 
POLR2F 0.91 3.0E-04 25.57 72.44 46.08 72.65 38.22 59.3 
PPP4R4 0.93 1.5E-04 17.47 49.34 31.12 42.57 85.92 160.55 
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PRKD2 -1.28 9.3E-07 86.84 28.98 43.62 21.88 38.83 16.17 
PROM1 0.82 5.7E-04 14.18 24.47 34.47 56.48 53.45 102.3 
PRRX1 0.89 2.9E-04 26.08 59.52 26.78 42.45 40.86 72.58 
PTGES3 -0.68 4.7E-05 342.28 195.2 331.26 227.11 284.95 177.11 
PWP2 0.93 5.6E-05 28.1 75.38 48.74 87.75 64.47 95.88 
PYGB 1.03 1.9E-06 24.3 65.98 37.22 68.13 86.6 155.64 
RASD1 -1.00 6.6E-04 128.1 32.5 77.1 59.1 45.87 28.34 
RASL11A -1.35 1.7E-04 41.77 10.77 34.37 21.52 17.59 6.35 
RASSF9 -0.73 2.4E-04 140.25 74.01 108.42 65.04 61.36 42.61 
RBPJ 1.01 5.0E-06 26.58 82.62 82.42 134.84 91.2 156.75 
RCAN1 -0.62 2.9E-04 440.51 244.34 198.42 142.93 233.06 159.57 
RGS2 -1.22 2.2E-06 548.86 122.17 281.63 166.35 209.52 122.78 
RRAD -0.73 5.7E-05 527.59 246.88 299.94 217.84 300.24 194.32 
RRP9 0.96 5.8E-04 28.1 107.88 53.17 83.59 90.66 117.55 
RUVBL1 0.85 4.0E-05 63.8 167.39 111.27 157.79 144.3 232.8 
S100A16 0.80 4.2E-04 24.3 68.33 55.44 82.05 151.75 207.8 
S100A2 1.07 2.4E-06 18.99 40.72 32.59 50.89 86.53 235.68 
S100A6 0.69 4.0E-05 276.96 358.67 265.18 498.57 868.53 1502.73 
SCD 0.69 6.7E-04 44.3 68.52 44.31 70.04 69.21 118.86 
SCML1 -1.06 1.5E-04 66.84 20.95 54.26 34.13 40.93 22.32 
SDPR -1.34 1.3E-06 126.33 35.44 45.79 17.48 22.05 12.7 
SEPP1 -1.22 2.7E-04 45.06 12.14 52.49 38.05 23.14 9.03 
SEPT11 0.84 7.7E-04 25.06 69.7 51.7 75.98 47.09 69.25 
SERPINB4 -2.35 6.7E-04 18.73 2.55 3.94 0.24 13.67 7.46 
SERPINH1 -1.09 4.8E-08 671.64 209.1 628.84 359.45 513.35 293.21 
SH2D5 0.99 6.4E-04 47.09 196.57 77.99 129.37 85.04 100.73 
SH3BGR -1.25 1.8E-07 152.15 49.92 68.83 41.85 59.94 22.38 
SH3BP5L -0.71 4.5E-04 204.56 94.95 95.12 73.96 92.14 58.05 
SLC6A15 1.24 3.0E-04 11.9 38.37 26.78 39.12 7.64 22.32 
SMYD2 1.04 1.4E-05 20.76 43.27 25.5 48.87 41.94 90.39 
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SNAP23 -1.02 5.7E-07 347.34 119.43 181.19 115.81 250.32 136.66 
SNX16 -0.94 1.4E-04 82.03 35.44 53.27 34.36 44.04 22.38 
SOCS3 -0.64 7.2E-04 265.57 133.33 163.76 114.98 127.8 95.95 
SOD1 -0.60 1.5E-04 1165.31 705.02 802.54 601.78 934.22 592.65 
SOX9 -1.03 4.8E-05 157.97 43.27 186.7 108.32 76.18 54.72 
SPP1 -0.82 5.7E-05 39.49 24.08 265.58 168.13 25.1 11.65 
SPRY2 1.08 1.5E-05 34.68 52.47 28.16 59.45 37.48 107.21 
ST13 -0.67 5.9E-04 958.48 415.45 702.79 584.07 750.95 518.03 
ST18 -3.99 1.0E-04 10.63 0 7.98 1.19 2.3 0.2 
STIP1 -0.80 1.2E-05 1657.46 687.59 1190.92 880.5 1230.07 751.95 
SYNE1 -0.62 6.9E-05 1646.83 969.32 2444.66 1807.02 531.48 339.23 
SYP 1.15 3.2E-04 7.09 29.76 20.48 39.36 38.29 60.02 
SYT2 -4.44 4.9E-04 8.1 1.37 2.17 0 3.86 0.07 
TAOK3 -1.35 3.3E-08 176.46 46.6 98.27 60.52 100.33 37.24 
TCP1 -0.80 3.8E-05 2771.13 1053.71 2032.26 1426.87 1660.07 1172.27 
TFRC 0.72 2.7E-04 171.9 425.83 464.29 634.84 559.76 752.8 
TGFBI 1.80 1.2E-04 1.01 17.82 10.93 22.71 22.33 51.57 
TINAGL1 1.06 9.6E-05 87.59 379.04 364.15 595.72 297.4 395.71 
TM4SF1 -0.57 7.2E-04 371.14 211.25 283.8 209.39 342.8 246.61 
TNIP2 0.63 5.4E-04 82.78 157.02 87.15 132.22 264.73 345.71 
TP63 0.78 1.9E-04 60.25 106.7 81.53 102.85 90.18 204.01 
TRAF1 1.12 2.5E-04 49.11 249.23 165.53 296.55 436.02 526.02 
TRIM26 -0.82 5.8E-04 103.04 37.98 79.66 57.43 84.84 56.55 
TSPYL2 -0.71 2.1E-04 2495.18 1025.71 1759.98 1376.69 1449.4 1021.87 
TTLL12 1.10 5.1E-04 19.75 96.33 48.84 84.42 68.4 87.57 
TUBB 0.64 7.2E-04 63.29 110.42 58.39 92.27 113.72 156.49 
TXNIP 0.96 6.6E-07 61.77 104.16 41.06 89.77 87.68 174.55 
TXNL4A 1.04 3.9E-04 15.7 68.13 51.7 76.34 67.18 101.51 
TYMP 0.84 3.5E-04 33.67 93.78 34.47 49.94 107.91 158.19 
UBB -1.04 2.8E-13 9580.23 4438.8 7471.73 3755.77 6624.18 3298.67 
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UBC -1.23 1.1E-15 6832.89 2493.3 5797.51 2843.52 4436.08 1925.2 
USPL1 -1.05 2.6E-06 226.58 73.61 138.65 69.92 90.72 61.78 
VEGFA 0.84 2.3E-06 283.29 617.7 386.01 531.27 436.09 831.93 
VTRNA1-2 -1.49 2.1E-06 58.48 15.08 63.12 34.36 14.75 4.58 
WBP5 -0.69 2.0E-04 1462.78 644.71 936.96 691.56 671.46 490.68 
WDR3 0.83 3.6E-05 146.58 384.71 253.56 362.66 315.06 474.64 
WDR75 0.59 7.4E-04 94.18 146.45 121.71 190.96 135.44 189.94 
XPC 0.75 3.4E-04 56.96 137.05 86.36 134.84 113.79 148.51 
ZFAND2A -1.26 6.4E-10 531.9 150.95 258.29 126.87 216.29 111.13 
ZFP106 -0.64 8.4E-04 394.94 182.67 296.6 230.32 185.71 134.96 
ZMYND11 0.64 2.0E-04 150.13 278.8 217.43 326.63 193.89 267.62 
ZNF131 -0.76 6.7E-05 568.61 240.42 313.53 217.48 331.43 230.78 
ZNF184 -0.84 6.7E-04 66.84 26.63 71 42.93 53.78 37.5 
ZNF259 0.80 1.5E-04 79.75 209.29 153.91 241.02 189.7 248.12 
ZP4 1.34 6.9E-04 7.85 17.03 6.11 14.98 9.2 27.49 
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Table 4.9. The most differentially expressed genes (q<0.05) between curcumin and piperine treated vs. curcumin only 
treated ALDH+ or ALDH-CD44+CD24- cells. 
Genes differentially expressed in ALDH+ 
Gene logFC P Value Sample 1 CPMs Sample 2 CPMs Sample 3 CPMs 
      Curcumin 
Curcumin 
+ 
Piperine Curcumin 
Curcumin 
+ Piperine Curcumin 
Curcumin + 
Piperine 
RPL26 0.27 1.6E-07 5662.93 7132.06 3326.19 3839.2 3127.85 3779.93 
UBB 0.24 1.8E-06 10310 11863.31 2557.14 2872.6 2526.8 3197.72 
CALHM2 7.93 3.4E-05 0 9.78 0 2.43 0 5.19 
TPT1 0.27 3.5E-05 3989.86 5071.43 2544.94 2777.75 2599.52 3290.92 
RPL32 0.44 8.5E-05 660.89 977.53 420.49 498.46 346.04 497.47 
PLEKHG4 -1.85 1.1E-04 28.75 9.78 17.77 6.72 10.92 1.81 
DMD -0.81 1.2E-04 81.87 44.97 57.77 35.05 58.1 31.71 
RPL31 0.36 1.4E-04 1232.89 1640.3 638.02 746.84 632.63 854.24 
Genes differentially expressed in ALDH-CD44+CD24- 
HSPA6 0.15 9.5E-12 11720.74 13469.66 8051.91 8361.56 6086.89 7010.39 
HSPA1B 0.14 1.9E-08 7917.2 8848.39 4627.91 5292.08 4239.09 4487.47 
HSP90AB1 0.06 1.6E-07 26292.03 27301.01 18107.64 18622.34 14890.38 15880.39 
HSPA1A 0.18 8.4E-06 4869.36 5239.52 2958.74 3590.48 2321.41 2586.54 
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Table 4.10. The most significantly enriched Gene Ontology Biological Processes identified comparing expression 
between curcumin and piperine co-treated and curcumin only treated ALDH+ and ALDH-/CD44+/CD24- cells.  
Concepts enriched in ALDH+     
Name #Genes OddsRatio P-Value FDR 
translational elongation 98 70.47 4.3E-39      1.1E-35 
translation 372 6.69 3.1E-19 4.1E-16 
ribosomal small subunit biogenesis 13 50.46 4.2E-09 3.7E-06 
hydrogen transport 46 9.73 9.1E-06 4.1E-03 
ribosomal large subunit biogenesis 10 33.24 1.2E-05 4.1E-03 
oxidative phosphorylation 84 6.18 1.2E-05 4.1E-03 
ATP synthesis coupled proton transport 34 11.85 1.4E-05 4.1E-03 
energy coupled proton transport, down 
electrochemical gradient 34 11.85 1.4E-05 4.1E-03 
proton transport 44 9.71 1.4E-05 4.1E-03 
Concepts enriched in ALDH-CD44+CD24- 
Name #Genes OddsRatio P-Value FDR 
protein refolding 11 18.00   3.3E-08          9.0E-05 
negative regulation of proteolysis 21 10.01 8.8E-07 1.2E-03 
response to unfolded protein 61 6.52 1.4E-06 1.3E-03 
response to protein stimulus 102 4.93 4.1E-06 2.9E-03 
calcium ion transport 131 3.69 9.3E-05 4.2E-02 
regulation of cytokine-mediated signaling pathway 22 7.10 1.0E-04 4.2E-02 
di-, tri-valent inorganic cation transport 168 3.32 1.1E-04 4.2E-02 
negative regulation of growth 120 3.75 1.3E-04 4.4E-02 
cellular amino acid catabolic process 53 5.08 1.5E-04 4.5E-02 
divalent metal ion transport 138 3.37 2.8E-04 7.3E-02 
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CHAPTER 5. CONCLUSION 
5.1 Overview. 
The epidemiological distribution of many cancers, including head and neck 
and breast, is shifting worldwide. In the United States, the epidemiology of head 
and neck cancer has undergone a radical shift in the past decade, with a rapid 
increase in the incidence of oropharangeal cancers associated with HPV 
infection. With respect to breast cancer, incidence rates have more than doubled 
between 1980 and 2010 in many developing countries. Due to the stable nature 
of the human genome over this time period, these changing cancer rates likely 
reflect the strong environmental role in these diseases. How environmental 
factors influence carcinogenesis for many types of cancer, however, remains 
poorly understood. Additionally, mechanisms by which dietary factors influence 
cancer development and pathogenesis remain poorly understood. 
Many epidemiological studies of environmental carcinogenesis or 
characterizing the role of diet in cancer prognosis poorly quantify previous 
exposures. With respect to environmental epigenetic epidemiology, many studies 
often either poorly characterize environmental exposures or focus on a limited 
number of epigenetic target sites. Studies designed to characterize the 
mechanisms of cancer chemopreventive compounds utilize immortalized or 
cancer cell lines, which may not recapitulate the effects of these compounds in 
normal human cells. Developing novel methodology to study the role of nutrition 
and the environment in carcinogenesis at relevant time stages provides essential 
insight towards the prevention, early identification, and treatment of cancer. 
Incorporating novel culture methods, including primary tissue culture, will allow 
for the study of environmental and nutritional factors in specific normal cell 
populations that may be at increased risk for cancer development, including stem 
cells. 
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Epigenetic changes are now recognized as an important mechanism in 
carcinogenic progression. These modifications are environmentally labile, vary 
over the lifetime, and are potentially reversible, making them an attractive target 
for cancer prevention and treatment. Additionally, epigenetic modifications 
control the gene expression required to establish and maintain each of the cell 
types in the body, establishing cellular identity during and throughout 
development, as cells progress from pluripotent, to multipotent, to fully 
differentiated.  
The overarching goal of this dissertation was to develop and apply novel 
statistical and experimental methods to characterize the roles of nutrition and the 
environment in carcinogenesis and cancer exposure, with a focus on epigenetic 
change. In Chapter 2, comprehensive epidemiological and clinical information 
was paired with comprehensive DNA methylation profiling of head and neck 
tumors to identify significant differences in tumor DNA methylation in chemically 
induced or HPV induced tumors. In Chapter 3, comprehensive data on average 
dietary intake was paired with tumor epigenetic measurements to identify that a 
patient’s diet in the year before diagnosis can significantly affect tumor epigenetic 
profiles, providing a potential mechanism by which diet affects disease 
prognosis. In Chapter 4, we treated normal human breast stem cells from 
reduction mammoplasty tissue with the cancer prevention compounds curcumin 
and piperine, and conducted a genome-wide screen to identify the stem cell 
specific changes induced by these compounds. The results and methods 
presented here reflect the utility of these methods, from cancer molecular 
epidemiology to normal human in vitro stem cell culture, to understanding the 
role of the environment in cancer.    
5.2. Chapter 2 - Comprehensive analysis of DNA methylation in head and 
neck squamous cell carcinoma indicates differences by survival and 
clinicopathologic characteristics. 
Head and neck squamous cell carcinoma (HNSCC) is the eighth most 
commonly diagnosed cancer in the United States. The risk of developing HNSCC 
increases with exposure to tobacco, alcohol and infection with human papilloma 
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virus (HPV). HPV-associated HNSCCs have a distinct risk profile and improved 
prognosis compared to cancers associated with tobacco and alcohol exposure 
(Fakhry et al. 2008; Gillison et al. 2008). Epigenetic changes are an important 
mechanism in carcinogenic progression, but how these changes differ between 
viral- and chemical-induced cancers remains unknown. We previously reported 
an epigenome-wide analysis of concurrently measured DNA methylation and 
gene expression in HPV(+) and HPV(-) squamous cell carcinoma cell lines, 
noting that HPV(+) cell lines have higher amounts of genic methylation (Sartor et 
al. 2011). In Chapter 2, to translate and extend the findings in cell lines to 
patients, we conducted an epigenetic epidemiology study in a well-characterized 
cohort of 68 patient samples.  
Unsupervised hierarchical clustering based on methylation identified 6 
distinct tumor clusters, which significantly differed by age, HPV status, and three 
year survival. Weighted linear modeling was used to identify differentially 
methylated genes based on epidemiological characteristics. Consistent with 
previous in vitro findings by our group, methylation of sites in the CCNA1 
promoter was higher in HPV(+) tumors, which was validated in an additional 
sample set of 128 tumors. After adjusting for cancer site, stage, age, gender, 
alcohol consumption, and smoking status, HPV status was a significant predictor 
for DNA methylation at an additional 11 genes, including CASP8 and SYBL1. 
In this study we investigated the likelihood of identifying a clinically 
relevant subset of head and neck tumors defined by CpG methylation, taking 
advantage of a well-established patient cohort at the University of Michigan with 
well-annotated survival and epidemiologic data. Our sample was representative 
of the overall cohort regarding age, gender, smoking history, and alcohol 
consumption. We examined the epigenetic differences between HPV(+) and 
HPV(-) tumors, following from our recent work in cell lines showing evidence for 
divergent pathways of carcinogenesis and the well-described epidemiologic 
differences between individuals with differential HPV tumor status (Sartor et al. 
2011). Further, we were able to evaluate survival in this cohort in light of their 
epigenetic profile (as defined by cluster status), HPV status and other 
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epidemiologic characteristics. These findings provide insight into the epigenetic 
regulation of viral vs. chemical carcinogenesis and could provide novel targets for 
development of individualized therapeutic and prevention regimens based on 
environmental exposures and epigenetic profiles of tumor DNA. 
5.3 Chapter 3 - Pretreatment dietary intake is associated with tumor 
suppressor DNA methylation in head and neck squamous cell carcinomas. 
Epidemiologic evidence supports the hypothesis that diet modulates risk, 
progression and prognosis of head and neck cancer (Duffy et al. 2009; 
Lucenteforte et al. 2009; Sandoval et al. 2009). The molecular mechanisms by 
which dietary compounds exert their effects are not entirely understood. 
Epigenetic dysregulation is a key mechanism in tumorigenesis that may be 
influenced by dietary intake by determining the availability of functional groups 
involved in the covalent modification of DNA and histone proteins (Burdge et al. 
2007; Oommen et al. 2005). The objective of the study reported in Chapter 4, 
was to test the hypothesis that pretreatment dietary intake of methyl donors, 
antioxidants, and foods abundant with these micronutrients is associated with 
tumor DNA methylation in head and neck tumors isolated from 49 individuals. 
We found that individuals reporting in the highest quartile of folate, vitamin 
B12, and vitamin A intake, compared to those in the lowest quartile, had 
significantly less tumor suppressor gene methylation, as did patients reporting 
the highest cruciferous vegetable intake. Gene specific analyses, identified 
differential associations between DNA methylation and vitamin B12 and vitamin 
A intake when stratifying by HPV status.  
To our knowledge, this was the first study to comprehensively examine the 
association between dietary intake and promoter methylation of genes related to 
head and neck cancer. These novel findings suggest diet is significantly 
associated with epigenetic events that occur in head and neck cancer and may 
provide a mechanism by which dietary micronutrient intake influences cancer 
prognosis. These findings have potential clinical implications for the treatment of 
head and neck cancer. The idea that dietary interventions could potentially 
reprogram the epigenome in such a way as to optimize the likelihood of positive 
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disease outcomes is appealing. Such studies could give rise to highly specific 
randomized controlled trials and ultimately to the development of individualized 
medical nutrition therapy regimens that may improve prognosis in the head and 
neck cancer population.  
5.4 Chapter 4 - Transcriptomic effects of curcumin and piperine in normal 
human breast stem cells. 
Curcumin is a dietary polyphenol derived from the rhizomes of turmeric 
(curcuma longa) which has been implicated as a potential agent for both the 
prevention and treatment of cancers. Recently, we showed that curcumin 
treatment alone, or in combination with piperine, limited breast stem cell self-
renewal while remaining non-toxic to normal differentiated cells (Kakarala et al., 
2010). In Chapter 4, to extend these findings and identify the stem cell specific 
mechanisms of action of these compounds, we characterized the genome-wide 
changes induced specifically in normal breast stem cells following treatment with 
these compounds by pairing fluorescence activated cell sorting (FACS) with low 
input high throughput RNA sequencing (RNA-seq). 
We generated genome-wide maps of the transcriptional changes that 
occur in luminal (ALDH+) and basal (ALDH-/CD44+/CD24-) normal breast stem 
cells following treatment with curcumin and piperine. Our results confirm that 
these compounds target breast stem cell self-renewal in both stem cell 
populations by down-regulating expression of breast “stemness” genes including 
ITGA6, PROM1, ALDH1A3, and TP63. Curcumin treatment was also found to 
significantly increase unfolded protein response, heat shock, and oxidative stress 
response genes in both stem cell fractions. Additionally, we identified novel 
genes and pathways targeted by curcumin in these cells, including mechanisms 
by which curcumin may target Wnt signaling in breast stem cells that have not 
been previously described, including downregulation of SCD and upregulation of 
CACYBP.  
These findings help clarify the mechanisms by which curcumin and 
piperine function as cancer preventive compounds, providing novel targets for 
cancer chemoprevention and treatment efforts. The use of primary tissues 
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provides novel information about stem cell regulation in the normal human breast 
that may not be available from studies utilizing cell lines or model animals. This 
experimental technique can thus be applied to understand the effects of 
carcinogens or cancer preventive compounds in specific cell populations. Here, 
we identify the pathways and individual genes differentially expressed by 
curcumin treatment, pointing to novel mechanisms of inhibiting stem cell self-
renewal and potential biomarkers of curcumin efficacy in clinical trials. 
5.5. Public health implications and future research needs. 
The public health burden of cancer is estimated to increase worldwide 
throughout the 21st century, with the majority of the burden in the developing 
world. As populations age and the rates of mortality from infectious disease 
decrease, rates of chronic diseases, including cancer, will concurrently increase. 
Thus, the identification of novel methods of prevention, early detection, and 
treatment of cancer will become imperative. Of particular importance will be the 
characterization of environmental and dietary risk factors for cancer and 
understanding how these interact with genotype to influence disease risk. 
With respect to epigenetic differences between HPV(+) and HPV(-) 
tumors, a growing body of research, including the research presented here, 
shows dramatic differences between these tumor types. Interestingly, the 
hypermethylation profile observed in HPV(+) tumors is also generally, but not 
always, associated with a decreased somatic mutation rate.  Future research that 
combines high throughput epigenomic profiling and genomic mutation analysis 
across tumors, paired with comprehensive epidemiological data, will identify 
biomarkers that predict whether tumors are more or less responsive to treatment. 
The field of nutritional epigenetics, particularly with respect to cancer prognosis, 
is still in its infancy. Mechanisms by which dietary intake influence epigenetic 
profiles in people are still poorly understood. For example, in Chapter 3, we 
identified that increased intake of dietary micronutrients associated with one 
carbon metabolism is associated with a decrease in tumor suppressor DNA 
methylation. These findings suggest that epigenetic regulation based on 
micronutrient availability is a complex process involving a number of feedback 
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loops. How these pathways differ in tumors and normal cells is not understood, 
but could provide insight into dietary prevention of cancer and modulation of 
tumor epigenetic profiles by diet.  
Finally, characterizing how environmental and dietary factors specifically 
affect breast stem cells will be essential to understand the molecular origins of 
breast cancer. We also know, however, that mammary stroma also plays an 
essential role in the maintenance of the stem cell niche. Future work could 
investigate the role of toxicant exposed stroma, including adipose and fibroblasts, 
on stem cell self-renewal in an effort to build an organ level model of disease. 
Integrating molecular toxicology and epidemiology by culturing tissues isolated 
from epidemiologically and clinically characterized individuals will allow us to 
define the molecular basis for known breast cancer risk factors with respect to 
stem cell regulation. Additionally, isolating and exposing tissues from women with 
known breast cancer risk factors to carcinogens will allow us to better 
characterize factors that govern environmental susceptibility. We will also be able 
to study the interplay of environmental exposures, diet, and stem cell regulation 
by incorporating nutritional epidemiology and exposure assessment 
methodologies. These studies will define new markers for the screening of at risk 
populations and will provide mechanistic insight for the early detection, 
chemoprevention, and treatment of breast cancers. 
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